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 1. Introduction 
 
1.1. The pituitary gland
 
The pituitary gland, 
turcica, in the sphenoid bone at the base of the brain. The mammalian pituitar
constituted by two lobes 
neurohypophysis or posterior pituitary
base of the developing diencephalon
developed from Rathke’s pouch, an embr
(1, 2) (Figure 1).  
Figure 1. Pituitary anatomy.
an extension of the hypothalamus that descends into the 
adenohypophysis, which is composed of hormone
from (3). 
 
 
The neurohypophysis comprises the infundibulum, the pituitary stalk, and the 
pars nervosa or posterior lobe of the gland; it is composed of pituicytes, modified glial 
cells, and the axonal processes of neurons, whose cell bodies are located in the 
hypothalamus. Thus, neurons from different hypothalamic nuclei release regulatory 
factors to the hypothalamic
which branch again into another series of capillaries to establish a direct functional 
interplay between hypothalamic nuclei and endocrine cells within the adenohypophysis 
(4); among these factors 
hormones directly released from the posterior lobe to the general circulation, 
hypophysiotropic hormones
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or hypophysis, is an endocrine gland located at the 
which are anatomically and functionally distinct: the 
, generated from neural ectoderm from the 
; and the adenohypophysis or anterior pituitary
yonic structure that arises from oral ectoderm
 The pituitary is composed by the neurohypophysis, 
sella turcica, and the 
-secreting epithelial cells.
-pituitary portal veins located in the infundibular stalk
stand out oxytocin and arginine-vasopressin (AVP)
 that regulate the production of various hormones of 
sella 
y is 
, 
 
 
 Adapted 
, 
, two 
and key 
the 
 adenohypophysis by exerting stimulatory effects, such 
hormone-releasing hormone (GHRH), corticotropin
gonadotropin releasing hormone (GnRH) and thyrotropin
by inducing inhibitory actions, like somatostatin (SST) and the monoamine Dopamine 
(DA) (1).  
On the other hand, the anterior pituitary gland is 
physiological processes as
immune system, etc. (2), 
granular cells are composed of five type of endocrine cells
lactotropes, corticotropes, gonadotropes and thyrotropes
the following pituitary hormones: 
muscle growth, and maintains lean body mass in adults
regulates gonadal function and stimulates breast milk production during and after 
pregnancy; adrenocorticotropin 
by the adrenal gland; follicle
which coordinately regulate germ
release by the gonads; and thyrot
produce thyroid hormones, respectively
endocrine sustentacular-like 
of the anterior pituitary 
communications (6, 7).  
Figure 2. Anterior pituitary cell types
cell types that produce
Adapted from (3). 
 
10 
as the neuropeptides 
 releasing hormone (CRH), 
 releasing hormone (TRH)
associated with a variety of 
 metabolism, growth, reproduction, stress response
and it is composed by granular and agranular cells. T
 (Figure 2)
, which synthesize 
growth hormone (GH), which regulates bone and 
; prolactin (PRL), 
(ACTH), which stimulates glucocorticoids
-stimulating hormone (FSH) and luteinizing hormone (LH), 
 cell development and sexual hormone
ropin (TSH), which stimulates the thyroid gland to 
 (1, 3, 5). Finally, folliculostellate cells, a non
agranular population, are located in the parenchymal tissue 
supporting additional control allowing inter
. The adenohypophysis is composed of six 
 hormones, supported in acini by folliculostellate cells
growth 
, or 
, the 
he 
: somatotropes, 
and secrete 
which 
 production 
 production and 
-
-cellular 
 
. 
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1.2. Control of pituitary hormone release 
 
Complex control of pituitary hormone synthesis and release involves 
hypothalamic, intrapituitary and peripheral signals, and the integration of these 
stimulatory and/or inhibitory mechanisms results in a coordinated regulation of 
differentiated hormone synthesis and secretion, and cell proliferation (8). Hypothalamic 
releasing hormones, such as GHRH, CRH, GnRH and TRH, frequently activate the 
secretion of a specific pituitary hormone (i.e. GH, ACTH, FSH/LH and TSH release, 
respectively), but this regulation is normally not exclusive and, for instance, GHRH and 
TRH can also stimulate PRL secretion (3). In addition, other releasing factors must be 
considered in the complex regulation of the secretion of a specific pituitary hormone 
such as AVP, mainly produced in the in hypothalamus and accumulated in the 
neurohypophysis, which may stimulate ACTH release (9); peripheral hormones, such as 
ghrelin, which is highly expressed in stomach and can exert stimulatory effects on 
somatotrope, lactotrope and corticotrope cells (10); or central hormones, like melatonin, 
a hormone mainly produced and secreted in the pineal gland (11, 12), which can 
regulate the function of several pituitary cell types. 
On the other hand, central inhibitory hormones, like SST and DA, which bind to 
their own family of receptors (sst1-5 and D1-5, respectively), have been shown to inhibit 
hormone synthesis and/or release of the main types of pituitary cells under normal 
physiological conditions (13, 14). Importantly, SST and DA receptors are encoded by 5 
separate genes, which are highly conserved across species, and exhibit a wide 
expression pattern in normal, but also in tumoral, pituitary tissues (14, 15). 
Additionally, intrapituitary autocrine or paracrine growth factors and peripheral 
endocrine hormones can also exert mainly negative feedback control of pituitary 
hormone synthesis and cell proliferation (8).  
Finally, the regulation of hormone release of different types of pituitary cells has 
also been shown to be sex-dependent and present circadian rhythm oscillations related 
to light/dark, sleep/wake cycles (16).  
In sum, the final concentration of pituitary hormones into the bloodstream is 
defined by a precise and complex interplay between releasing and inhibiting factors 
arriving not only from different hypothalamic nuclei but also from other, central and 
systemic, endocrine tissues (i.e. stomach, liver, pancreas, etc.) (17-19). 
 1.2.1. Somatostatin and somatostatin receptors 
 
Somatostatin (SST)
to inhibit GH secretion (20
nervous system and also in peripheral tissues, where it
actions including regulation of neurotransmission
gastrointestinal hormones, 
SST is also able to inhibit cell proliferation of normal and tumoral cells 
SST gene is transcribed to pre
is subsequently translated and proteolytically 
active peptide of 28 amino
processed into a shorter active variant of 14 amino
simply SST (23, 30) (Figure 3). 
somatostatin can give rise to an additional 
neuronostatin (31).  
Figure 3. Somatostatin gene derived peptides
binds with similar affinity to the five 
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 was discovered in 1973 in ovine hypothalamus by its ability 
). SST is widely distributed throughout the human central
 has a broad range of biological 
, inhibition of 
pancreatic enzymes and neuropeptides (21-23
-pro-somatostatin encoding mRNA 
processed to give rise to somatostatin, 
-acids (SST-28) (28, 29), which is commonly further 
-acids, generally named SST
More recently, it has been discovered 
peptide of 13 amino
, including neuronostatin, SST-14 and SST
classical somatostatin receptors. 
 
 
pituitary and 
). In addition, 
(24). 
(25-27), which 
an 
-14 or 
that pre-pro-
-acids, named 
 
-28. SST-14 
 SST binds with similar
which belong to a seven transmembrane
Each sst subtype has been shown to
actions and, since most tissues co
that the precise actions of SST depend on the 
subtypes expressed in each 
in each cell in response to SST
In addition to the canonical, full length sst1
sst5 have been recently identified and
sst5TMD4, based on the number of transmembrane domains (TMDs) 
Subsequent studies have demonstrate
distribution in normal tissues
and subcellular distribution
and very low in normal tissues
pituitary adenomas, sst5TMD4 is frequently present in pituitary tumors 
 
Figure 4. Schematic representation of the full
variants splicing diagram. 
similar in both sst5 variants (full
same start codon but have a different length (specific of specie), while the CDS 2 of 
each truncated sst5 variant (
sequences originated by the splicing of the 3’
rise to a new stop codon in the truncated sst5
length sst5 variant is removed by splicing. 
structure of translated full
sst5TMD4 are indicated in the right part of the figure
 
More interestingly, and in line with that mentioned above, the expression of 
sst5TMD4 was negatively linked to poorer clinical response in a series of 
13 
 affinity to all its 5 receptor subtypes, named sst1
, G protein-coupled receptor superfamily
 preferentially trigger one or more specific SST 
-express several sst subtypes, it has 
amount and interaction of the 
cell, as well as the specific set of signaling routes activated 
   (Figure 3) 
-sst5, two novel truncated variants of 
 characterized, which were termed sst5TMD5 and 
d that these receptors are functional, show
 and, present unique ligand-selective signali
. Specifically, the expression of both receptors is 
, and, while sst5TMD5 is present only 
-length sst5 variant and truncated sst5 
The N-terminal regions of the CDS 1 (red boxes) are 
-length and both truncated variants) and share the 
brown and black boxes) is constituted by unique
-UTR of the full-length sst5, giving 
 variants. The stop codon of the full
Predicted transmembrane
-length and truncated sst5 variants, sst5TMD5 and 
. Adapted from (34). 
-sst5, 
 (13). 
been suggested 
specific sst 
(32) (Figure 4). 
 distinct 
ng properties 
infrequent 
in a subset of 
(32, 33). 
 
 
-
 domain 
acromegalic 
 patients with partial resistance to SSA
demonstrated that sst5TMD4 presence is associated with poor prognosis
cancer, and its expression in a germane cell model (MCF
malignancy features (proliferation, invasiveness and migration) 
presence has been associated with poor prognosis in thyroid cancer 
 
1.2.2. Ghrelin system in pituitary (patho) physiology
 
Ghrelin is a 28-amino acid hormone identified by reverse pharmacology 
Although initial observations demonstrate
it has subsequently been found to be involved in the 
(patho)physiological functions
processes, food intake, body weight gain, insulin release, 
energy homeostasis, inflammatory processes, as well as in the development and 
progression of several types of cancers 
GHRL gene, which is located in chromosome 3 and encompasses six exons, four of 
them corresponding to coding region 
processes to generate several mRNAs: some of them, after translation, generate prepro
peptides which are subsequently processed to originate biologically active peptides 
and some of them follow nonsense
attention has been dedicated to ghrelin itself, including its acyla
forms, obestatin and, more recently, to their splicing variants, such as In1
41) (Figure 5).  
 
Figure 5. Overview of the human ghrelin gene structure and two of the functionally 
relevant ghrelin gene
sequence that is shared between In1
while the unique sequence of the In1
intron 1 is shown in grey
 
14 
-therapy (33). On a different scenario, 
-7 cell line) increases 
(35); and si
(36).
 
d that ghrelin is highly expressed in stomach, 
regulation 
, including hormone secretion, memory and learning 
β-cell survival, adiposity, 
(10, 38). In humans, ghrelin is encoded by
(39), that alternatively combine through splicing 
-mediated decay pathway. Among them, special 
ted and unacylated 
-derived variants (transcripts and putative peptides). The 
-ghrelin variants and ghrelin is shown in black
-ghrelin variants generated by the retention of 
. Adapted from (10)  
it has been 
 in breast 
milarly, its 
 
(37). 
of multiple 
 
-
(40), 
-ghrelin (10, 
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In contrast to the growing number of biologically active GHRL derived peptides, 
only a single receptor, transcribed from GHSR gene (42), named GHSR1a, has hitherto 
been identified as unequivocal endogenous functional binding target for ghrelin. It is a 7 
TMD, G-protein coupled receptor detected for the first time in the pituitary gland (43-
45). GHSR encodes another receptor, GHSR1b, an intron-retaining variant with 5 
TMDs, and to date, its functional activity remains to be fully elucidated (42). On the 
other hand, the receptors mediating the actions of unacylated-ghrelin, obestatin, In1-
ghrelin and other variants remain elusive, if not controversial (46). Ghrelin can be post-
translationally modified at its Ser3 by MBOAT4, an enzyme that belongs to the 
superfamily of membrane bound O-acyltransferases (47). MBOAT4 or GOAT (ghrelin 
o-acyl transferase) acylates ghrelin, and essential step for its binding to GHSR1a, and, 
in fact, the interaction of GHSR1a and acylated ghrelin is fundamentally determined by 
the high conformational flexibility introduced by ghrelin when it is modified (48). 
Similarly, ghrelin and derived transcripts/peptides were also found to be 
produced and released in the pituitary itself (41, 49-51), where they could be 
presumably involved in secretory pattern regulation (10, 37, 52, 53). Moreover, the first 
evidence indicating that ghrelin system could be involved in tumor development and/or 
progression was the finding that GHSR1a was expressed not only in normal, but in 
tumoral pituitaries (45). Thereafter, ghrelin was also found in different types of pituitary 
tumors (49, 51, 54), thus suggesting a complex autocrine/paracrine role of the ghrelin 
system in pituitary tumor pathogenesis. In addition, other ghrelin system components, 
including obestatin, In1-ghrelin, GHSR1b and MBOAT4 are expressed in a wide 
variety of endocrine-related tumors, including pituitary and neuroendocrine tumors (55), 
breast (41, 56) and prostate (57) cancers. Nevertheless, although the ghrelin system 
seems to play an autocrine/paracrine regulatory role in pituitary adenomas, which could 
provide diagnostic, prognostic biomarkers and therapeutic tools, its exact role in tumor 
development and progression of pituitary tumors is still uncertain.  
 
1.3. Pituitary adenomas 
 
Pituitary adenomas have been commonly considered a rare tumoral pathology 
due to an underestimated diagnosis, and, consequently, low incidence; however, 
autopsy and imaging studies have revealed that these tumors present an overall 
 estimated prevalence of 14
neoplasms; which are often accompanied by serious comorbidities through mass effects 
and inappropriate secretion of pituitary hormones, e.g. amenorrhea,
dysfunction, infertility, hypogonadism, hypopituitarism, emotional disturbances, growth 
abnormalities, etc. (3). Although 
benign due to their virtual 
and may be lethal due to either infiltration of local structures or the complications of the 
metabolic effects of the hormone excess syndromes they can cause 
 
1.3.1. Pituitary tumorigenesis
 
Clonal analysis has demonstrated that almost all pituitary adenomas are 
unicellular in origin, arising from a monoclonal expansion of a genetically mutated cell 
(60-62).  
 
Figure 6. Cas
Nevertheless, the primary initiating cause for pituitar
elusive. Several studies on 
inactivating or overexpressing
tumorigenesis (63-65) (Figure 
(66), but a growing set of pituitary
associated with pituitary tumorigenesis 
adenomas occur sporadically, and only in 5% a familial genetic background may be 
assumed, such as Multiple Endocrine Neoplasia Type 1, Carney’s Complex, or Familial 
Isolated Pituitary Adenomas 
16 
-22% (58, 59), representing the most common intracranial 
 galactorrhea, sexual 
pituitary tumors have been classically regarded 
inability to metastasize, these lesions can be highly invasive 
(1). 
 
cade of pituitary tumorigenesis. Adapted from (8) 
 
y tumorigenesis remains 
transgenic mouse models have demonstrated that both 
 cell cycle regulators are required to initiate pituitary 
6). In this case, classic oncogenes are rarely mutated 
-specific cellular disruptors is being found 
(Table 1). Importantly, in 95% of cases
(59, 67). 
as 
 
to be 
 pituitary 
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Gene Function Mode of activation 
or inactivation Clinical context 
GNAS Oncogene Activating, imprinting 
Nonfamilial, 
syndromic or sporadic 
H-Ras Oncogene Activating Invasive or malignant 
HMGA2 Oncogene Overexpression Sporadic 
FGFR4 Oncogene Alternative 
transcription Sporadic 
CCND1 Oncogene Overexpression Sporadic 
AIP Tumor suppressor Inactivating Familial, syndromic 
MEN1 Tumor suppressor Inactivating Familial, syndromic 
PRKAR1A Tumor suppressor Inactivating Familial, syndromic 
Rb Tumor suppressor Epigenetic 
silencing Sporadic 
BRG1 Tumor suppressor Glucocorticoid 
receptor function Sporadic 
CREB Transcription factor Constitutive phosphorylation Sporadic 
CCNB2 Cyclin Induced by HMGA Sporadic 
CDKN1B Cyclin-dependent kinase inhibitor Inactivating Sporadic, syndromic 
CDKN2A Cyclin-dependent kinase inhibitor 
Epigenetic 
silencing Sporadic 
PTTG Securin Overexpression Sporadic 
GADD45G Proliferation inhibitor Epigenetic 
silencing Sporadic 
MEG3 Proliferation inhibitor Epigenetic 
silencing Sporadic 
Table 1. Main cellular disruptors in pituitary adenomas. Adapted from previous studies (8) 
 
1.3.2. Classification of pituitary adenomas 
 
Pituitary adenomas have been classically classified according to 
immunohistochemistry data into GH, PRL, FSH/LH, ACTH, TSH, plurihormonal and 
null cell adenomas, as well as by ultrastructural characteristics (densely or sparsely 
granulated) (1, 68, 69). More recent and complete studies on large series of pituitary 
adenomas have enabled to propose a novel classification, which incorporates magnetic 
resonance imaging for diagnosis of cavernous and/or sphenoid sinus invasion, 
immunocytochemistry, Ki67 and p53 analysis, and classified tumours according to size 
[microadenoma (<1 cm), macroadenoma (1-4 cm) and giant (>4 cm)], type (GH, PRL, 
ACTH, FSH/LH and TSH), and grade (1a: non-invasive, 1b: non-invasive and 
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proliferative, 2a: invasive, 2b: invasive and proliferative, and 3: metastatic), thereby 
contributing to a more complex classification, and predicting the probability of post-
operative remission or tumour progression, which could help clinicians to choose the 
best post-operative therapy (70).  
According to clinical phenotype, pituitary adenomas evoke a wide variety of 
manifestations depending of the hormone that is over-secreted. Specifically, about 40-
50% of all pituitary adenomas do not show a specific pattern of hormone secretion, and 
are named non-functioning pituitary adenomas (NFPA), most of them derive from 
gonadotrope cells that produce, but do not release, FSH and/of LH (71), and can 
oversecrete non-functional α subunit. For this reason, NFPA often present at diagnostic 
as macroadenomas that cause neurological symptoms due to mass effects (i.e. visual 
defects, headache and hypogonadism) (72). Nevertheless, a small proportion of these 
gonadotrope-derived tumors are functional, and secrete FSH and/or LH, which are 
generally named gonadotropinomas, and may cause ovarian hyperstimulation, 
testicular enlargement, and precocious puberty (71). Prolactinomas comprise 25-41% 
of all pituitary adenomas, which produces clinical symptoms such as weight gain, 
infertility, galactorrhea, gonadal dysfunction, headache, hypopituitarism, and visual 
field defects (73). About 10-15% are somatotropinomas causing acromegaly, a 
syndrome caused by GH hypersecretion, and subsequent increase in IGF1 production by 
the liver, and the main consequences of chronic exposure to GH and IGF1 are skeletal, 
tissue, and organ growth, including acral changes, gigantism, arthritis, heart disorders, 
diabetes, insulin resistance, hypogonadism, etc. (74). Cushing’s disease with 
production of ACTH accounts for 10%, and is characterized by central obesity, diabetes 
mellitus, dyslipidemia, hypertension, hirsutism, muscle weakness, and emotional 
disturbances (75). Thyrotropinomas account for less than 2% of all pituitary 
adenomas, and are characterized not only by the typical pituitary adenoma symptoms 
(headache, visual defects, and hypopituitarism), but also by thyroid dysfunction (76). 
Finally, pituitary carcinomas, defined as pituitary tumors displaying metastatic spread 
are extremely rare (1, 4, 8). 
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1.3.3. Diagnosis of pituitary adenomas 
 
Although pituitary adenomas are in fact frequent, their detection and diagnosis is 
still complicated due to their multiple clinical symptoms. Specifically: 
Non functioning pituitary adenomas are frequently diagnosed at a late stage or 
incidentally, presenting in magnetic resonance imaging as a large mass, which produces 
vision alteration and/or headache (72, 77).  
Prolactinomas in women are frequently detected after amenorrhea and/or 
galactorrhea episodes, and in men are normally fast-growing tumors which provoke 
compression symptoms (73), but just serum prolactin evaluation and magnetic 
resonance imaging of the sella are required for its diagnosis (73, 78). Interestingly, in 
most patients, serum prolactin levels correlates with tumor size (79).  
In acromegaly, typical appearance includes acral and facial changes, observing 
gigantism features only in untreated or late-diagnosed patients (74, 80). Diagnosis can 
be confirmed by elevated GH and IGF1 serum levels and by a lack of suppression of 
GH after an oral glucose tolerance test (80, 81).  
Thyrotropinomas are infrequent and there are not well-established guidelines to 
perform their diagnosis. 
Finally, Cushing’s disease (caused by an ACTH-secreting pituitary adenoma) is 
frequently diagnosed by typical clinical symptoms including abdominal fat distribution, 
red striae, muscle weakness and emotional disturbances. However, these symptoms can 
lead to the suspicion of other cortisol or stress related diseases including Cushing’s 
syndromes (due to an ectopic ACTH-secreting tumor, or to an adrenal cortisol-secreting 
tumor) (82), or pseudo-Cushing states (provoked by depression, alcoholism, polycystic 
ovary syndrome, and excess visceral body fat) (83), and therefore, it is often necessary 
to perform additional test (24-hour urinary cortisol assay, dexamethasone suppression 
test, CRH or desmopressin stimulation test, magnetic resonance imaging, etc.) to verify 
that the disease is due to an ACTH-secreting pituitary adenoma (84).  
Consequently, excessive cortisol levels may lead to severe health problems and 
even death (84); and the first crucial step in the management of the Cushing’s syndrome 
is the correct diagnosis, and to establish its particular features by means of obtaining 
conclusive clinical and biochemical data. The second step is the differential diagnosis in 
order to determine if the syndrome is caused by an ACTH-releasing pituitary tumor, 
known as Cushing’s disease, by an ACTH-releasing ectopic tumor, frequently a benign 
20 
 
carcinoid lung tumor, or by an adrenal tumor that over-secrete cortisol (84). To date, the 
tests used to diagnose Cushing’s disease or to determine the efficacy of the surgery are 
often inconclusive. Consequently, it is frequently necessary to perform various tests 
(CRH stimulation, 24-h urinary cortisol, late-evening serum, midnight salivary cortisol 
dexamethasone suppression, brain MRI, etc.) to obtain a reliable diagnosis and 
differential diagnosis of the Cushing’s disease, which is not always definitive (85). One 
of those tests is based on ACTH stimulation by treatment with desmopressin, a 
synthetic analogue of the endogenous neuropeptide AVP that binds with high affinity to 
the different vasopressin receptors, which belong to the same family that oxytocin 
receptor. These receptors are named AVPR1a, AVPR1b and AVPR2 and are encoded 
by 3 different genes and have different tissue distribution (9). In has been demonstrated 
that desmopressin stimulates ACTH secretion and cortisol levels in patients with 
Cushing’s disease (86, 87). Based on these and other results, desmopressin test, either as 
an intravenous injection to evaluate ACTH and cortisol levels or by bilateral inferior 
petrosal sinus sampling, has been proposed as a reliable test for the differential 
diagnosis and post-surgery prognosis of Cushing’s disease (86, 88-94). However, some 
studies have questioned the use of the desmopressin test based, in part, on the limited 
and often conflicting information available regarding the cellular and molecular 
mechanisms underlying the response of ACTH-producing tumoral cells to desmopressin 
(95).  
 
1.3.4. Treatment of pituitary adenomas with somatostatin and 
dopamine receptor agonist 
 
Surgical resection is normally the first line treatment for a patient with a 
pituitary adenoma, while several medical therapeutic approaches are possible. Most 
pituitary adenomas express SST receptors (sst1-sst5) together with DA receptors (D1-5, 
respectively), specially D2 (96). Consequently, these tumors would be susceptible to be 
responsive to SST and DA, and to SST and DA receptor agonists, which can decrease 
hormone release and/or cell proliferation (13, 14). Therefore, single- o multiple-receptor 
agonists have been designed for pharmacological treatment of these tumors (97-100).  
Specifically, the potent and broad anti-secretory properties of SST have made it 
an important pharmacological target; however, its clinical usefulness was limited by its 
short half-life (less than 3 min) (101). Therefore, to overcome this obstacle, synthetic 
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somatostatin analogs (SSA) were developed (Table 2). Specifically, octreotide and 
lanreotide, which bind selectively to sst2, have been largely used in the treatment of 
pituitary adenomas and other neuroendocrine tumors (102-104). Nevertheless, some 
patients are, at least, resistant to these compounds, and therefore, additional novel set of 
multi-receptor targeted SSA, such as pasireotide (105), which binds with high affinity to 
sst5, sst2, sst3 and sst1, were then developed based on the idea that the simultaneous 
targeting of more than one sst may be more effective in the treatment of patients who 
are non-responsive or who escape from response (e.g. acromegalic patients resistant to 
octreotide/lanreotide and patients with Cushing’s disease). Interestingly, initial 
approaches in clinical trials using pasireotide demonstrate its tolerability in healthy and 
efficacy in tumoral subjects, but there are some key concerns related to glucose 
metabolism side effects that have to be fully elucidated (106, 107). Beside SSA, it is 
important to mention that certain most prolactinomas are fairly responsive to DA 
agonists (e.g. cabergoline) (1), while patients with Cushing’s disease are frequently 
treated using cortisol inhibitors, like ketoconazole (75), as octreotide is frequently 
ineffective, probably due to the ability of glucocorticoids to decrease sst2 levels (108).  
Although specific subsets of sst1-sst5 and D1-5 are abundantly present in 
pituitary adenomas, and the efficacy of individual selective sst2, sst5 or D2 compounds 
has been proven in the treatment of pituitary adenomas, an appreciable proportion of 
patients are poorly responsive or totally resistant to conventional therapy with SSA or 
DA-agonists (13, 78, 109, 110). In line with this, several studies revealed that certain 
SST and DA receptors can form heterodimers (e.g. sst2 and sst5 with D2), which results 
in changes in the functional, pharmacological and signaling properties of the receptors 
(111, 112). These results led to the idea of using chimeric compounds that can bind both 
ssts and D2 to treat pituitary tumors. One of these compounds, BIM-23A760 
(Dopastatin; designed by IPSEN (99, 113), binds with high affinity to sst2, sst5 as well 
as to D2 (114). However, clinical trials using BIM-23A760 in acromegalic patients 
unveil a problem with prolonged administration with the compound, since it produces a 
metabolite with potent dopaminergic activity that interferes with the activity of the 
parent molecule, and the metabolite accumulates in the circulation (115). Thus, current 
efforts have led to the generation of novel compounds of this class able to overcome this 
problem. 
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Compound sst1 sst2 sst3 sst4 sst5 D2S D2L 
SST-14 0.93 0.15 0.56 1.50 0.29 ND ND 
Octreotide 280 0.38 7.10 >1000 6.30 ND ND 
Lanreotide 2129 0.75 98 1826 12.70 ND ND 
Pasireotide 9.30 1 1.50 >100 0.16 ND ND 
Cabergoline ND ND ND ND ND 0.53 0.41 
BIM-23A760 622 0.03 160 >1000 3.70 15* 
Table 2 Binding affinities (IC50) of SST analogs and DA agonists. Data summarized in previous works 
(116, 117) *IC50 for both D2 isoforms 
 
1.4. Non-human primate as a model to study pituitary physiology 
 
In spite of the wealth of knowledge gathered about regulation of pituitary 
hormone release from normal cells derived from rodent models, there are still a number 
of aspects of the regulation of pituitary physiology, particularly in normal human gland, 
that remain unclear. In this context, non-human primate models can provide normal 
pituitaries to ascertain investigate direct actions of regulators of pituitary cell function. 
These samples may reproduce physiological conditions or indicate specific regulation of 
primate lineage that could not be determined with the use of other models. Accordingly, 
results obtained with the use of non-human primate models are actually being used for 
translational research to humans (118-120). However, the choice of a good primate 
model needs validation of the presence and composition of regulatory systems in the 
pituitary. In this regard, comparison of sequences of mRNA and predicted proteins of 
primate with that of humans would indicate the similarity between these two models. 
Furthermore, it is important to keep in mind that an experimental approach using 
pituitary cells (primary pituitary cell culture conditions vs. in vivo conditions) should 
not alter expression of the regulatory system present in these pituitary cells. A non-
human primate model that fulfills all these features is the olive baboon (Papio anubis), 
which has been used in previous reports to analyze pituitary physiology (121, 122). 
Therefore, the high similarities at the genomic, proteomic and physiological levels 
shared by this model with humans, makes the baboon a suitable model to study the 
effects of different peptides/hormones on specific pituitary hormone function, which 
cannot be evaluated in healthy human subjects. (118, 121-123). 
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2. Aims of the study 
 
The general aim of this study was to further our knowledge of the molecular 
and cellular features defining pituitary tumors, in order to improve our understanding of 
pituitary patho-physiology, and to facilitate the identification of novel markers to 
improve diagnosis and prognosis of pituitary tumors, and the development of clinical 
tools and therapeutic approaches to treat these pathologies. This general aim was 
developed into the following specific objectives: 
 
Objective 1: To investigate to role of ghrelin system in pituitary adenomas, 
particularly the novel In1-ghrelin splicing variant, including its presence, function and 
potential use as diagnostic or prognostic tool in pituitary adenomas. 
 
Objective 2: To study and compare the effect of classical (octreotide) and novel 
(pasireotide) somatostatin analogs, as well as SST/DA chimeric drugs (BIM-23A760) 
in normal and tumoral pituitaries, by evaluating different functional parameters 
(hormone secretion, signaling, cell viability) in a large series of pituitary adenomas as 
well as in normal pituitary cells. 
 
Objective 3: To explore the functional effect of the novel truncated splicing 
variants of somatostatin receptor 5, sst5TMD4 and sst5TMD5, in somatotropinomas, 
particularly in their aggressive features (invasion, pharmacological response and cell 
viability) of these pituitary adenomas. 
 
Objective 4: To elucidate the cellular and molecular mechanisms involved in 
desmopressin response in human ACTH secreting adenomas, to validate and support 
its use as a reliable and specific test for Cushing’s disease diagnosis. 
 
Objective 5: To establish the precise relationship between melatonin and 
pituitary cell function, by determining the direct, in vitro impact of melatonin on the 
functioning of all pituitary cell types, particularly in hormone secretion and in the 
precise cellular signaling pathways activated by melatonin in normal primate pituitary 
cell cultures.  
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3. Results and general discussion 
 
3.1. In1-ghrelin role in pituitary adenomas (Article I) 
 
Ghrelin system seems to play an autocrine/paracrine regulatory role in pituitary 
adenomas, which could provide diagnostic, prognostic or therapeutic uses, although its 
exact role in tumor development and progression is still uncertain. Therefore, the aim of 
this study was to systematically analyze the presence of different components of the 
ghrelin system: native ghrelin, In1-ghrelin, MBOAT4, GHSR1a and GHSR1b, in 
normal pituitaries (n=11), and in a set of 169 pituitary tumors, including 76 
somatotropinomas, 57 NFPAs, 29 corticotropinomas and 7 prolactinomas. In addition, 
we used pituitary adenoma primary cell cultures and cell lines to compare the direct 
effects of native-ghrelin and In1-ghrelin variant administration on selected functional 
parameters to better define the (patho)physiological significance of this regulatory 
system in pituitary tumors. 
Expression profile analysis revealed that ghrelin system is dramatically altered 
in pituitary adenomas compared to normal pituitary. Specifically, native ghrelin is 
significantly upregulated only in somatotropinomas compared with normal pituitary; 
while MBOAT4 tended to be over-expressed in somatotropinomas, while it was 
markedly downregulated in corticotropinomas and NFPAs. GHSR1a and GHSR1b are 
over-expressed in GH secreting adenomas, GHSR1b in corticotropinomas, whereas both 
GHSR1a and GHSR1b were under-expressed in NFPA compared with normal pituitary 
samples. Notably, In1-ghrelin variant is the only component of the ghrelin system that 
was significantly over-expressed in all types of pituitary adenomas, while its expression 
in normal pituitaries was very low. Interestingly, comparison between the expression 
levels of the two ghrelin gene derived transcripts in corticotropinomas, and in AtT-20 
cell line (a mouse corticotropinoma cell line), revealed that the expression of the human 
In1-ghrelin and the mouse In2-ghrelin variant were significantly higher than that of 
native ghrelin, which further supports a relevant role of this variant in 
corticotropinomas. Indeed, our study offered additional clues to unveil the role of 
ghrelin system in pituitary adenomas by demonstrating, for the first time, that In1-
ghrelin is the only component of ghrelin system consistently and unanimously 
overexpressed in all pituitary adenoma subtypes,  
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Furthermore, we also had the opportunity to demonstrate that In1-ghrelin variant 
can exert functional responses in all the main classes of pituitary adenomas. In 
particular, somatotropinomas responded to acylated-ghrelin and In1-ghrelin increasing 
[Ca2+]i kinetics and GH release, which is consistent with previous studies showing 
similar effects using ghrelin-analogs (124). Remarkably, In1-ghrelin also influenced 
other key, clinically relevant process, such as cell viability, since treatment with In1-
ghrelin peptides significantly increased cell viability in somatotropinomas and this 
effect was higher than that observed with acylated-ghrelin. Moreover, In1-ghrelin, but 
not native ghrelin, reduced apoptotic rate compared with vehicle-treated controls in 
somatotropinomas. In line with this, a differential signaling pathway was observed, 
between both ghrelin-gene derived variants since the treatment with both peptides 
(acylated ghrelin and In1-ghrelin) evoked ERK1/2 phosphorylation but only acylated 
ghrelin activate Akt signaling. Finally, In1-ghrelin overexpression also increased cell 
viability, while the use of a specific siRNA for this ghrelin variant reduced cell 
viability, which, again, strongly suggests a relevant role of In1-ghrelin variant in 
somatotropinomas.  
In1-ghrelin or In2-ghrelin treatment also increased [Ca2+]i and ACTH release 
from human corticotropinomas or AtT-20 cell line, respectively. Likewise, [Ca2+]i 
kinetics (51), and ACTH release (125) were stimulated after acylated-ghrelin treatment 
in ACTH-secreting adenomas. In addition, In1-ghrelin overexpression also stimulated 
corticotropinoma cell viability, and treatment with In1-ghrelin or In2-ghrelin revealed 
similar effects in human ACTH secreting adenomas and AtT-20 cell line, respectively.  
To the best of our knowledge, no functional studies with the ghrelin system 
components had been implemented in NFPAs to date (10).  Our study demonstrated, for 
the first time, that a subset of NFPA cells is responsive to both acylated ghrelin and In1-
ghrelin in terms of [Ca2+]i kinetics and cell viability. Moreover, overexpression of In1-
ghrelin variant also increased cell viability in NFPA cells, while silencing of In1-ghrelin 
expression significantly reduced NFPA cell viability. These latter results are particularly 
relevant in this type of pituitary adenomas, because the main comorbidities of NFPAs 
are derived from tumor overgrowth and mass effects (126).  
Finally, prolactinomas presented a weak response in terms of [Ca2+]i 
mobilization to acylated ghrelin and In1-ghrelin, which is in line with absence of 
response of In1-ghrelin in PRL secretion. Interestingly, In1-ghrelin treatment was as 
potent as acylated ghrelin in stimulating cell viability from human prolactinomas. 
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In sum, the data presented herein demonstrate, for the first time, a consistent 
upregulation of In1-ghrelin expression in the most predominant pituitary adenoma 
subtypes compared to normal pituitary. Moreover, the functional data collected strongly 
support the concept that In1-ghrelin substantially influences intracellular signaling, 
hormone secretion, and cell viability in pituitary adenoma cells. Hence, it seems 
reasonable to propose that the In1-ghrelin variant could play a relevant functional role 
in the regulation of pituitary adenoma pathology. As such, these results pave the way 
for using In1-ghrelin variant as a new tool to explore novel and more general diagnostic, 
prognostic and/or therapeutic targets in these human pathologies, where additional 
studies are warranted to determine the clinical implications of the alteration of specific 
components of the ghrelin family. 
 
3.2. Effect of octreotide and pasireotide in normal and tumoral 
pituitary (Article II) 
 
In spite of the recent advances achieved in the clinical development of SSA, 
there are still relevant aspects on the mechanisms mediating the effects of different SSA 
on pituitary tumors that remain incompletely understood. In particular, for instance, few 
studies have addressed what are the actual differences and similarities of the direct 
actions of sst2-preferring (e.g. octreotide) and multi-sst (e.g. pasireotide) SSA on the 
different classes of pituitary tumors, which are not exclusively dependent on their 
distinct sst-binding profile. Indeed, there is ample evidence that a number of different 
factors, besides receptor affinity, substantially influence the functional capacities of a 
given analog, from dynamics of receptor internalization, recycling and degradation, to 
selectivity in signaling pathway activation, or receptor-receptor interaction, thereby 
defining precisely their actions, which would also depend on the target cell type (127). 
Accordingly, in the present study we have carried out a systematic analysis of the direct 
in vitro actions of octreotide and pasireotide in a representative series of 85 pituitary 
samples, that includes the main classes of adenomas (32 somatotropinomas, 15 
corticotropinomas, 28 NFPAs and 4 prolactinomas), as well as samples from 6 normal, 
non-tumoral human pituitary. 
Assessment of sst1-sst5 expression profiles in the present tumor series revealed 
that they compare well, by and large, with those described in previous studies for each 
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of the tumor types examined (96, 128, 129), thereby supporting the contention that the 
samples investigated provide a representative picture of the tumors under study. On the 
other hand, it is important to note that the actual, precise sst1-sst5 profile in each tumor 
examined did not always match, necessarily, that observed, on average, for its 
corresponding tumor type. It is widely, and reasonably, assumed that the actions of a 
specific SSA in a given pituitary tumor would result from the functional correspondence 
between the sst1-sst5 binding profile of that SSA and the pattern of sst1-sst5 expression 
in the tumor. Accordingly, it has been suggested by different authors that, in the future, 
recommendations to select a specific SSA could be done on the basis of sst expression 
pattern, e.g. octreotide would be recommendable when sst2 is highly and predominantly 
expressed, whereas high expression of sst5, and sst2, sst3, or sst1 in pituitary adenomas 
would predict pasireotide responsiveness (130). In the present study, although 
somatotropinomas were characterized by sst5>>sst2 expression, as previously 
described (128, 129, 131), we observed that octreotide and pasireotide induced 
comparable levels of inhibition of both, GH release after 4- or 24-h of in vitro treatment, 
and of cell viability at 24, 48, and 72h. Moreover, it was noteworthy that pasireotide 
evoked less responses from tumor cells than octreotide in terms of [Ca2+]i kinetics, 
which would argue against the theoretical superiority of pasireotide predicted by the 
higher sst5 levels observed in these GH tumors. Analysis of corticotropinomas showed 
the typical sst5 predominant profile, yet, our results on [Ca2+]i kinetics, ACTH release 
and cell survival demonstrated that these tumors are significantly responsive, in vitro, to 
octreotide treatment, similar to that previously reported on primary cultures (132, 133) 
and in the mouse corticotropinoma AtT-20 cell line (132-134). Our data is also in 
keeping with (and extends) the accepted view that octreotide may exert strikingly 
divergent actions in vivo and in vitro on corticotropinomas. Indeed, it is well known that 
glucocorticoids downregulate sst2, affecting octreotide response in corticotropinomas 
(134, 135), which suggests that octreotide therapy in untreated Cushing’s disease 
patients presenting high levels of cortisol would be ineffective in vivo as previously 
reported in small series of Cushing’s disease untreated patients (136-139). The sst 
expression profile observed in NFPAs (sst3>>sst2>sst5) is similar to that reported 
previously (128), and suggested a possible responsiveness to pasireotide. However, our 
data demonstrate that only a small proportion of NFPA are responsive, in vitro, to both 
SSA, at least in the parameters evaluated. Moreover, some of the effects observed could 
be considered as paradoxical and, from a clinical perspective, undesirable. Indeed, cell 
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viability assay demonstrated that both SSA, and particularly pasireotide, might increase 
cell viability compared to vehicle-treated cells in the majority of responsive tumors. 
Similar stimulatory actions of pasireotide (140) and of a sst5 specific agonist (141) have 
been described previously in NFPAs, but the precise underlying mechanisms and the 
specific sst involved remain unclear. Prolactinomas are often responsive to dopamine 
agonists. However, 10% of patients fail to normalize PRL levels and tumor growth 
(142). SSA therapy has been proposed as an alternative, since prolactinomas express 
ssts and several works demonstrated that SSA are able to inhibit PRL release in 
prolactinoma primary cell cultures (143, 144) and germane cell lines (145). Our results 
showed that octreotide decreased cell viability in one prolactinoma after 48-72h 
treatment and only inhibited [Ca2+]i in a very low proportion of cells, pasireotide being 
even less effective despite the high levels of sst1 expression in these tumors. Finally, we 
were also able to evaluate the effect of octreotide and pasireotide on a limited set of 
normal pituitary cell cultures. This revealed that, similarly to in vivo analyses on 
healthy volunteers with octreotide (146, 147), and pasireotide (148-150), where both 
SSA were able to act on normal pituitary by decreasing hormone levels, particularly 
GH, in our studies both SSA directly acted on pituitary cells to evoke decreases in 
[Ca2+]i kinetics, and pasireotide, but not octreotide, also reduced cell viability after 24, 
48 and 72h treatment in cell cultures derived from a normal pituitary.  
In summary, our results indicate that both SSA act on the main types of pituitary 
adenomas by exerting both similar and distinct effects on [Ca2+]i kinetics, hormone 
release, gene expression and cell viability. However, we did not observe any evident 
correspondence between the effects observed and the specific sst1-sst5 profile of the 
target tumors. Hence, the picture that emerges is that there might not be a simple 
predictive correspondence between the presence of a sole receptor and the response to a 
given SSA with high affinity for this receptor, but that other factors may substantially 
influence the response of pituitary tumor cells, such as the proportion of other receptors 
for which the SSA may not have high affinity, the signaling status of the target cell, etc. 
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3.3. BIM-23A760 distinctly influences key functional endpoints in 
pituitary adenomas and normal pituitaries (Article III) 
 
As previously mentioned, SST and DA receptors have served as valuable targets 
for the pharmacological management of pituitary adenomas. In fact, the efficiency of 
the individual compounds selective for sst2/5 or D2 have been proven in the treatment of 
pituitary adenomas. However, an appreciable subset of patients is poorly responsive or 
totally resistant to conventional therapy with SST- or DA-analogs (13, 78, 109). For that 
reason, and based on the fact that pituitary adenomas often express, simultaneously, 
high levels of various ssts and Ds, new approaches are already being tested or are 
currently under clinical investigation to treat patients with pituitary adenomas, as is the 
case of the use of combined drug therapies (SST- plus DA-analogs), which have been 
shown to be more effective than treatment with the individual compounds (13). In this 
same context, and based on the well-known developing central interaction between the 
somatostatinergic- and dopaminergic-systems (111), and on the evidence on the ability 
of sst2 and sst5 to establish physical and functional interactions with D2 resulting in 
altered pharmacological or/and signaling properties (111, 112), an interesting new 
approach that is currently under basic and clinical investigation is the development and 
application of chimeric SST/DA compounds. As previously shown (151), these drugs 
can retain the ability to interact with ssts and D2, and can display greater effects in 
reducing pituitary secretions than individual compounds. One of these promising 
chimeric SST/DA compounds is BIM-23A760, an agonist for sst2/sst5/D2 receptors, 
which has been used in clinical trials (115, 152, 153). Specifically, the effect of BIM-
23A760 has been tested in pituitary cell lines (145) and, in limited series of primary 
pituitary adenoma cell cultures (142, 151, 154-158); however, to the best of our 
knowledge, the data collected to date on the direct in vitro effect of BIM-23A760 in 
pituitary adenomas is still incomplete, with some apparently contradictory results, 
which renders the available evidence somewhat inconclusive. Moreover, the studies 
reported so far have not been focused to specifically analyze and compare the distinct 
effects of BIM-23A760 on several functional parameters (i.e. contribution of signaling 
pathways, hormonal expression/secretion, cell viability and apoptosis) in parallel in the 
same samples and/or in a wide range of cell types from pituitary adenomas, nor the 
responses of these pituitary adenoma-cells have been compared with those observed in 
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normal pituitary cells in vitro. Therefore, the aim of this study was to analyze, for the 
first time, a set of key functional parameters (signaling pathways, hormonal expression 
and secretion, cell viability and apoptosis), in response to BIM-23A760 in the main 
types of human pituitary adenomas (22 somatotropinomas, 5 mixed GH/PRL-secreting 
adenomas, 11 corticotropinomas, 26 NFPAs, 6 prolactinomas, 1 FSH secreting 
gonadotropinoma and 3 thyrotropinomas) and, in 5 human normal pituitaries and 
pituitary samples derived from 3 female olive baboons (Papio anubis).  
It should be mentioned that, although BIM-23A760 has been withdrawn from 
clinical development after discovering a dopaminergic metabolite that accumulates and 
interferes with the activity of the parent compound in vivo (115, 159), BIM-23A760 is 
still considered a good prototype molecule for this class of compounds and therefore, 
the results generated in this study using primary pituitary cell cultures from pituitary 
adenomas and normal pituitaries may be really useful in predicting the response to 
members of this class of compounds (i.e. new generation of chimeric agonist for 
sst2/sst5/D2 receptors) that may be used for clinical purposes in the future.  
Specifically, the results of this study indicated that sst5, sst2 and D2 were highly, 
and similarly, expressed in both baboon and human normal pituitaries, which is 
consistent with previous reports (96, 160). [Ca2+]i kinetics assay unveiled that primary 
cultures of normal pituitary were especially sensitive to BIM-23A760, and in line with 
this, hormone secretion was also affected. In particular, we observed a decrease of GH 
and PRL release in response to BIM-23A760 in human and baboon primary pituitary 
cultures, as well as a GH, PRL, LH and a slight inhibition in ACTH release. These 
results extend and reinforce previous preliminary data, which indicated that 
administration of BIM-23A760 on healthy human male volunteers suppressed 
circulating PRL (152), and GH, IGF1 and PRL in cynomolgus monkeys in vivo (161). 
Additionally, hormone expression was evaluated by qPCR in primate primary cultures, 
showing a decrease in GH and PRL at mRNA levels, which was supported by a strong 
repression of POU1F1, a pituitary-specific transcription factor responsible for GH and 
PRL expression. Finally, BIM-23A760 treatment decreased viability of normal 
pituitaries cells after 48 and 72 h treatment compared to vehicle treated controls. In the 
case of somatotropinomas, mean expression levels of receptors revealed high 
expression of D2 followed by sst5 and sst2 as previously described (128, 129, 131). 
Functional studies demonstrated that all but one somatotropinoma cell culture 
responded to BIM-23760 treatment: 13/20 somatotropinomas decreased [Ca2+]i levels, 
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but surprisingly 6/20 samples increased [Ca2+]i in response to this compound. In the 
same line, BIM-23A760 inhibited GH release, as previously reported in primary 
cultures from somatotropinomas and the germane cell line GH3 (99, 145, 151, 158), but 
it also exerted paradoxical responses stimulating GH release in certain cases. 
Nonetheless, we observed a decrease in cell viability, and an induction of apoptosis in 
somatotropinomas. To ascertain the cause of paradoxical responses to BIM-23A760, we 
analyzed ssts/Ds mRNA expression profile, and observed a significant down-regulation 
of sst5 in paradoxical stimulatory responders, which might be used as a predictor of 
such response. GH-PRL secreting adenomas behaved in the same fashion as 
somatotropinomas in response to BIM-23A760, as previously observed (151, 158); 
however, we did not observe paradoxical responses in this pituitary adenoma type. 
Corticotropinomas presented high expression of D2 followed by sst5 and low 
expression of sst2. Interestingly, as previously found in somatotropinomas, we also 
observed in vitro paradoxical responses in some corticotropinomas in response to BIM-
23A760 in terms of [Ca2+]i kinetics and ACTH release. In contrast, mRNA expression 
profile in corticotropinomas revealed that the paradoxical, stimulatory responders 
presented very low expression of sst2 and sst5, and ROC curves demonstrated that sst5 
was also a key molecular marker of this differential response to this compound. In 
addition, we found that sst5TMD4 was only present in paradoxical, stimulatory 
responders, which may suggest a potential involvement of this truncated receptor in the 
unique stimulatory response of some corticotropinomas to BIM-23A760. A large set of 
NFPAs was also evaluated and, in this case, sst3 was the predominant sst-subtype, as 
previously reported (128). BIM-23760 treatment was often ineffective, yet, we also 
observed both inhibitory and stimulatory responses, although it generally decreased cell 
viability compared to vehicle-treated control cells. The effect of BIM-23A760 on 
[Ca2+]i kinetics was also evaluated in one functional case of gonadotropinoma, and 
where the chimeric compound was able to decrease of [Ca2+]i. In prolactinomas, sst1 
was the prevailing sst, followed by sst5, however BIM-23A760 were quite ineffective in 
decreasing [Ca2+]i,, while it was effective in decreasing PRL release/expression (after 
24h) and cell viability (after 72h). In rare thyrotropinomas, BIM-23A760 altered 
[Ca2+]i in 1 out of 2 cases studied, while it was unable to affect cell viability. 
When viewed together, the results of this study strongly suggest that sst5 
expression in GHomas and ACTHomas, and sst5TMD4 expression in ACTHomas 
might represent useful molecular markers to predict the ultimate, inhibitory or 
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stimulatory, response of these pituitary adenoma types to BIM-23A760. Nevertheless, it 
seems plausible that other factors, still to be identified, substantially contribute to the 
differential, inhibitory/stimulatory response of GHomas and ACTHomas to BIM-
23A760. One of these factors could be the precise number and proportion of receptors 
available on the tumor cells, i.e. the receptor expression profile of pituitary adenomas. 
In this scenario, it seems conceivable that a specific expression profile might be a key 
molecular determinant for the response to BIM-23A760, as it could dictate the possible 
interactions between receptor-subtypes (homo and/or heterodimerization). Obviously, 
further, specifically directed studies will be required to formally prove this notion with 
regard to the effect of BIM-23A760 in pituitary adenoma cells. However, this concept is 
supported by several studies demonstrating that the therapeutic response of pituitary 
tumors to different drugs is directly dependent on the relative expression pattern of both 
SST and DA receptor subtypes (128, 162). The existence of heterodimers between 
SST/DA receptors (e.g. sst5 and D2) that result in changes in the functional, 
pharmacological and signaling properties of the receptors is well established (111). In 
particular, this concept is supported by results from a recent report demonstrating that 
only the amount of dimers between sst5 and D2, and not between sst2 with D2, were 
directly and positively correlated with an enhanced antiproliferative effect of BIM-
23A760 in prostate and lung cancer cell lines (163), thereby reinforcing the main idea 
derived from our results, i.e. that chimeric compounds for the sst2/sst5/D2 system might 
represent valuable tools for the design and development of new therapeutic drugs for the 
management of certain pituitary adenomas and their associated comorbidities in the near 
future. 
 
3.4. Truncated somatostatin receptor, sst5TMD4, is associated with 
aggressive features in somatotropinomas (Article IV) 
 
Somatotrope adenomas present as large macroadenomas in 65% of the cases, 
wherein the invasion of intracranial structures becomes a crucial problem (74). As 
previously stated, SSA treatment has been successfully used to treat patients with 
somatotropinomas, although some patients are biochemically resistant, at least partially, 
to this therapy (13, 162). In previous studies, it has been observed that the expression of 
sst2 is directly correlated with the decrease of GH and IGF1 levels and tumor volume in 
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response to octreotide-LAR in a population of Brazilian acromegalic patients (128, 
131); conversely, sst5 is negatively correlated with the decrease of GH and IGF1 levels 
after octreotide-LAR treatment (128, 131). Soon thereafter, two studies on independent 
populations of Spanish (32) and French (33) acromegalic patients, demonstrated that 
novel truncated variant of sst5, sst5TMD4 and sst5TMD5, were present in pituitary 
tumors and, most interestingly, that the expression of truncated sst5TMD4 variant was 
negatively linked to poorer clinical response in partially resistant somatotropinomas 
(33). However, the possible influence of sst5TMD4 on aggressiveness features in 
somatotropinomas (i.e. invasion and proliferation abilities) has not been reported 
hitherto. In addition, the putative association between the levels of truncated sst5 
variants, especially sst5TMD4, and the response to octreotide-LAR therapy was not 
originally explored in the well-characterized, and previously reported, population of 
Brazilian acromegalic patients (96, 128, 131), as the truncated receptors were not yet 
discovered at that time.  
Accordingly, this study had three main goals: 1) To evaluate and compare 
truncated sst5 variants levels in somatotropinomas, normal pituitaries and non-
functioning pituitary adenomas (NFPA); 2) To assess potential correlations between 
truncated sst5 variants expression levels in somatotropinomas and the response to SSA-
therapy and/or presence of GNAS mutation (indicative of good response to SSA-
therapy) (164); and, 3) To investigate the potential role of the truncated sst5 variants in 
conferring aggressiveness features to GH secreting adenomas(i.e. invasion/proliferation 
abilities) in vivo and in vitro. 
Overall, the results of this study revealed that sst5TMD4 is expressed in 89% of 
somatotropinomas and 50% of NFPAs, while it was not relevantly expressed in normal 
pituitary samples. Additionally, we found a positive correlation between sst5TMD4 
mRNA expression levels (by quantitative real-time PCR) and protein levels (by 
immunohistochemistry) in somatotropinomas, suggesting that sst5TMD4 mRNA is 
appropriately translated to build a protein, and that sst5TMD4 expression levels may 
serve as a reliable indicator to perform further analyses. Interestingly, in acromegalic 
patients, expression levels of sst5TMD4 were inversely correlated with age (i.e. a higher 
expression was observed in younger patients in which the disease is frequently more 
aggressive (162, 165)). Moreover, we also found an inverse correlation between 
sst2/sst5TMD4 ratio and percent decrease of GH and IGF1 levels after 3 and 6 months 
postsurgical octreotide-LAR treatment, suggesting that patients with high sst2 levels 
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and low sst5TMD4 levels respond better to octreotide-LAR, which was also in line with 
the observed lower sst2/sst5TMD4 ratio in uncontrolled acromegalic patients. 
According to GNAS mutation (a predictor or good response), we had previously 
observed a high expression of sst2 in GNAS positive patients (166), and consistent with 
the previous results, a low expression of sst5TMD4 was observed in these patients. 
Most importantly, we found that sst5TMD4 expression was significantly higher in 
somatotropinomas presenting extension into sinus, both cavernous and sphenoid sinus, 
suggesting that the relative sst5TMD4 expression levels might represent a potential 
unique molecular signature contributing to invasion abilities of somatotropinomas. 
Finally, we had the opportunity to study the consequences of the in vitro overexpression 
of truncated sst5 variants in GH-secreting adenomas. These results revealed that a 
significant increase in cell viability is observed in cells transfected with both truncated 
sst5 variants, which suggest that the presence of these variants increase tumor 
proliferation and growth.  
In conclusion, our data demonstrate that presence of sst5TMD4 is associated 
with aggressiveness in somatotropinomas, thereby suggesting that sst5TMD4 could 
contribute to worsen acromegaly prognosis and may provide an attractive target for 
therapeutic research. Accordingly, it seems plausible that analysis of sst5TMD4 
expression, particularly in relation to sst2, could represent in the future a genuine, 
valuable diagnostic and/or prognostic tool to help in predicting aggressive properties of 
somatotropinomas (proliferative and invasive capacities), and outcome of clinical 
response to SSA-therapy in these patients. 
 
3.5. Cellular and molecular basis of desmopressin test in Cushing’s 
disease (Article V) 
 
Cushing’s syndrome is caused by prolonged exposure to excessive cortisol 
levels which may lead to severe health problems and even death (84). The first crucial 
step in the management of the Cushing’s syndrome is its correct diagnosis, and to 
establish its particular features by means of obtaining conclusive clinical and 
biochemical data. The second step is the differential diagnosis in order to determine if 
the syndrome is caused by an ACTH-releasing pituitary tumor, known as Cushing’s 
disease, by an ACTH-releasing ectopic tumor, frequently a benign carcinoid lung 
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tumor, or by an adrenal tumor that over-secretes cortisol (84). To date, the tests used for 
the diagnosis of Cushing’s disease, such as CRH stimulation, 24-h urinary cortisol, late-
evening serum, midnight salivary cortisol, dexamethasone suppression and brain MRI, 
are often inconclusive, and this is also the case when determining the efficacy of the 
surgery. Consequently, it is frequently necessary to perform various tests to obtain a 
reliable diagnosis and to determine the differential diagnosis of the Cushing’s disease, 
which is not always definitive (85).  
Desmopressin is a synthetic analogue of the endogenous neuropeptide arginine-
vasopressin (AVP) that binds with high affinity to the different vasopressin receptors, 
which belong to the same family that oxytocin receptor. They are named AVPR1a, 
AVPR1b and AVPR2, which have different tissue distribution, and are encoded by 3 
different genes (9). In has been demonstrated that desmopressin stimulates ACTH 
secretion and cortisol levels in patients with Cushing’s disease (86, 87). Based on these 
and other results, desmopressin test, either as an intravenous injection to evaluate 
ACTH and cortisol levels or, by bilateral inferior petrosal sinus sampling, has been 
proposed as a reliable test for the differential diagnosis and post-surgery prognosis of 
Cushing’s disease (86, 88-94). However, some studies have questioned the use of the 
desmopressin test based, in part, on the limited and often conflicting information 
available regarding the cellular and molecular mechanisms underlying the response of 
ACTH-producing tumoral cells to desmopressin (95).  
In this context, our study was aimed at elucidating whether desmopressin 
directly stimulates ACTH release and/or influences other functional parameters in 
human pituitary corticotropinomas, what types of receptor(s) and mechanisms would 
mediate such actions, and if these effects are exerted selectively on pituitary tumoral 
cells derived from patients with Cushing’s disease or, if are also found in normal 
pituitary cells or in cells derived from other types of pituitary adenomas. To that end, 
we used a set of 69 human pituitary samples in which we evaluated AVPRs expression 
profile and, assessed the direct effect of desmopressin on ACTH release, POMC and 
AVPRs expression, [Ca2+]i kinetics and cell proliferation. Additionally, we correlated 
the expression of AVPR receptors in the tumor sample with plasma ACTH/cortisol 
levels of the patients in which a desmopressin test was assessed in vivo. 
Our results indicate that corticotropinomas expressed all AVPR subtypes; 
however, the relative expression levels markedly varied between AVPR subtypes being 
AVPR1b the predominant subtype. Moreover, AVPR1b subtype were markedly more 
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expressed in human corticotropinomas samples than in normal pituitaries tissues and in 
other pituitary adenoma types, thus providing a possible basis for the well-known 
secretory hyperresponsiveness of corticotropinoma cells to vasopressin (167). 
Interestingly, we found a positive and strong correlation between POMC and AVPR1b 
expression in corticotropinoma samples, which was not found for the other AVPR 
subtypes.  
Functional studies revealed that desmopressin treatment only increase ACTH 
release in corticotropinomas but not in normal pituitary cell cultures. Indeed, 
desmopressin also exerted a slight but significant increase of POMC expression in 
corticotropinoma cultured cells. Importantly, the fact that desmopressin-induced ACTH 
increase is exclusive of corticotrope adenomas, but not normal corticotrope cells, and 
that AVPR1b is markedly over-expressed in corticotropinomas, might suggest the 
existence of a selective constitutive activation of the level of specific receptors and/or 
second messengers imparting higher sensitivity to desmopressin (and possibly to 
endogenous vasopressin in vivo) in patients with Cushing’s disease. Consistent with 
this, desmopressin treatment evoked a rapid and pronounced stimulatory effect in the 
kinetics of [Ca2+]i exclusively in corticotropinoma cell cultures. Moreover, use of 
selective antagonists for each AVPR subtype revealed that the stimulatory effect of 
desmopressin on [Ca2+]i kinetics and ACTH release is mainly exerted via AVPR1b. 
Finally, we also have the opportunity to evaluate plasma ACTH and cortisol levels in 
patients before surgery and during desmopressin test (0-120 min after 10 µg intravenous 
desmopressin injection), and found that basal ACTH plasma levels were positively 
correlated with AVPR1b expression in the tumor samples. 
Altogether, our study indicated that the effect of desmopressin on 
corticotropinoma cells is marked, as it strongly stimulates ACTH release and [Ca2+]i 
levels; prolonged, since it enhances both ACTH expression and/or release at short (4h) 
and long (24h) periods of time; and exclusive of corticotropinoma cells, because it was 
only observed in cell cultures from Cushing’s disease patients but not in normal 
pituitary cells or in other human pituitary tumor cell-types. Moreover, the results of the 
present study demonstrate that AVPR1b is overexpressed and is directly involved in the 
desmopressin-stimulated ACTH secretion observed in human pituitary 
corticotropinomas and, invite to suggest that future studies could be devised to explore 
the potential that AVPR1b antagonists may have to develop therapeutic approaches in 
patients with Cushing’s disease. 
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3.6. Melatonin regulates pituitary cell function (Article VI) 
 
Melatonin is an ancient molecule, unchanged in nature from plants to mammals 
across billions of years of evolution (168). In mammals, melatonin is mainly produced 
in the pineal gland wherein it is directly secreted to the blood and cerebrospinal fluid, a 
process that is under the precise control of the master circadian clock, the 
suprachiasmatic nucleus of the hypothalamus (11, 12, 169). Melatonin exhibits a 
striking circadian rhythm in its release and is involved in a high number of 
physiological processes and behaviors in humans and seasonally breeding animals 
(170). These main physiological actions of melatonin depend on the expression of three 
receptors to which melatonin binds with strong affinity, two GPCRs: MT1 and MT2 
(171), and the less-characterized cytosolic enzyme quinone reductase 2 (172). 
Surprisingly, the role of melatonin in some neuroendocrine organs has not been clearly 
defined in mammals, especially in humans and non-human primates and, therefore; it 
would be important to evaluate the direct actions of melatonin in some of these key 
neuroendocrine tissues, as is the case of the pituitary, which is considered the most 
important organ of the endocrine system for its capacity to produce several hormones 
that control many of the most important functions of the body (2). In fact, as melatonin, 
anterior pituitary hormones also show clear circadian patterns and rhythms of release. 
However, the precise relationship between melatonin and anterior pituitary function 
remains controversial, and the majority of the available data regarding the role of 
melatonin on pituitary function, derived from nocturnal laboratory rodents, suggest that 
melatonin contributes to the secretion of certain pituitary hormones (173-180). 
Therefore, the main goal of this study was to determine, for the first time, what are the 
precise effects of melatonin on the pituitary hormonal expression and release in a non-
human primate model (Papio anubis).  
In particular, we studied the effects of melatonin on the synthesis and release all 
anterior pituitary hormone types. These results indicated that melatonin stimulated GH 
and PRL expression and release in a dose- and time-dependent fashion while. We also 
studied the effect of melatonin on GH and PRL release in the presence of some of the 
main primary regulators of somatotrope and lactotrope function (GHRH, ghrelin and 
SST). Specifically, GHRH and ghrelin stimulatory actions on GH or PRL release were 
not altered by coadministration of melatonin, suggesting that melatonin might activate 
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similar intracellular signaling pathways as GHRH or ghrelin to induce GH and PRL 
secretion, respectively. Additionally, SST completely blocked melatonin stimulatory 
effect of GH and PRL. Finally, the use of a specific intracellular signaling inhibitors 
revealed that melatonin stimulates GH and PRL release through similar, but not 
identical, signaling pathways in baboon primary cultures in vitro. Specifically, the 
stimulatory effects of melatonin on somatotropes require AC/PKA and extra-/intra-
cellular Ca2+ influx, whereas AC/PKA/PLC activation and extracellular Ca2+ influx are 
necessary for the stimulatory actions of melatonin on lactotropes.  
In summary, our results unveil a clear, selective action of melatonin on 
somatotrope and lactotrope function in normal primary pituitary cell cultures from a 
primate model, which seems to involve both, common and distinct, signaling 
mechanisms, thereby lending support to the notion that the actions of melatonin on 
these cells might substantially contribute to the define daily patterns of GH and PRL 
observed in primates, and possibly also in humans. 
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4. General conclusions 
 
1. Ghrelin system expression is markedly altered in human pituitary adenomas; 
in particular, In1-ghrelin splicing variant was functional, and consistently elevated, in 
all human pituitary adenomas subtypes which, suggest that this novel variant could 
contribute to the pathogenesis of different pituitary adenomas types and, might be used 
as a new tool to identify novel, more general diagnostic, prognostic and potential 
therapeutic targets in pituitary tumors. 
 
2. Parallel comparison of the actions of two SSA, octreotide and pasireotide, 
with different sst1-sst5 binding profile, on key functional endpoints of pituitary 
adenomas showed that, although both SSA seem to exert, in general, comparable effects 
in vitro in the main types of pituitary adenomas, octreotide appears to be more effective 
in eliciting Ca2+ signaling responses, decreasing hormone secretion, and reducing cell 
viability in most pituitary adenomas. Unexpectedly, both SSA increased cell viability in 
a relevant proportion of non-functioning pituitary adenomas. Our data indicate that the 
mere presence of high levels of a given sst does not ensure a functional response to a 
SSA with high affinity for that receptor, thus suggesting that additional mechanisms 
operate to define the precise response of pituitary tumors to these drugs, which should 
be preferentially explored on primary cell cultures from these tumors. 
 
3. Chimeric compounds for the sst2/sst5/D2 system, such as BIM-23A760, affect 
multiple, clinically relevant parameters on pituitary adenomas and, may represent new 
therapeutic tools for the design and development of new therapeutic drugs for the 
management of certain pituitary adenomas and its associates comorbidities in the near 
future. Notably, the relative ssts/D2 expression profile, particularly sst5 and/or 
sst5TMD4 levels, might represent useful molecular markers to predict the ultimate 
response of pituitary adenomas to BIM-23A760. 
 
4. Presence of truncated sst5 variants, especially sst5TMD4, is associated with 
increased aggressiveness in GH secreting adenomas, thereby suggesting that sst5TMD4 
could contribute to worsen somatotropinoma prognosis and may provide an attractive 
target for therapeutic research in the future. 
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5. Desmopressin stimulation test as a reliable, specific test for the diagnosis and 
post-surgery prognosis of Cushing’s disease, and its direct effects are mainly mediated 
through the receptor AVPR1b which is markedly overexpressed in corticotropinomas, 
thus opening the possibility of exploring AVPR1b-antagonists as potential therapeutic 
tools for Cushing’s disease treatment. 
 
6. Melatonin directly regulates somatotrope and lactotrope function in a primate 
model, thereby lending support to the notion that the actions of melatonin on these cells 
might substantially contribute to finely tune the precise daily patterns of secretion of 
these pituitary cell types in primates and, open the possibility that melatonin, together 
with GHRH, ghrelin and somatostatin, might be an additional key factor involved in the 
regulation of somatotrope and lactotrope function in primates and, possibly also in 
humans.  
 
Altogether, the results of these studies indicate that the precise expression profile 
and number of receptors and/or their specific proportion available on normal and 
tumoral pituitary cells might be an key molecular feature to predict the ultimate, 
inhibitory or stimulatory, response of these pituitary cells to physiological (ghrelin/In1-
ghrelin and melatonin) or pharmacological (octreotide, pasireotide, BIM-23A760 and 
desmopressin) regulators of human pituitary function. Furthermore, an alteration of 
specific molecular markers, specially the In1-ghrelin variant and the truncated 
sst5TMD4 variant, could contribute to pathogenesis of different pituitary adenomas 
types, and suggest that these variants and its related components (ligands, receptors and 
enzymes) could provide new tools to identify novel, more general diagnostic, prognostic 
and potential therapeutic targets in pituitary tumors. 
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Abstract 
 Pituitary adenomas comprise a heterogeneous subset of pathologies causing 
serious comorbidities, which would benefit from identification of novel, common 
molecular/cellular biomarkers and therapeutic targets. The ghrelin system has been 
linked to development of certain endocrine-related cancers. Systematic analysis of the 
presence and functional implications of some components of the ghrelin system, 
including native ghrelin, receptors and the recently discovered splicing variant In1-
ghrelin, in human normal pituitaries (n=11) and pituitary adenomas (n=169) revealed 
that expression pattern of ghrelin system suffers a clear alteration in pituitary adenomas 
as compared with normal pituitary, where In1-ghrelin is markedly overexpressed. 
Interestingly, in cultured pituitary adenoma cells In1-ghrelin treatment (acylated 
peptides at 100nM; 24-72h) increased GH and ACTH secretion, Ca2+ and ERK1/2 
signaling and cell viability, whereas In1-ghrelin silencing (using a specific siRNA; 100nM) 
reduced cell viability. These results indicate that an alteration of the ghrelin system, 
specially its In1-ghrelin variant, could contribute to pathogenesis of different pituitary 
adenomas types, and suggest that this variant and its related ghrelin system could 
provide new tools to identify novel, more general diagnostic, prognostic and potential 
therapeutic targets in pituitary tumors. 
Introduction 
 Ghrelin gene (GHRL) products and associated receptors, proteins, and enzymes 
are emerging as an intricate and pleiotropic regulatory system involved in a plethora of 
physiological and pathological functions, including hormonal secretions and tumor 
development and progression1,2. GHRL gene encompasses four coding exons3 that 
alternatively combine, through splicing processes, to generate several mature and 
functional mRNAs, which, after translation, generate prepro-peptides that are further 
processed by the action of proteolytic enzymes to originate biologically active peptides4 
(e.g. native ghrelin, obestatin, etc.). Among them, special attention has been dedicated 
to ghrelin itself, a 28-aa peptide hormone, including its acylated (AG) and unacylated 
forms, obestatin5, and more recently, to their splicing variants1,4,6-9. Among these 
splicing variants is the In1-ghrelin variant, which is generated by retention of intron 1 
(In1) resulting in an alteration in the amino acids (aa) sequence of the C-terminal 
portion as compared with native-ghrelin. However, In1-ghrelin variant shares the signal 
peptide and an initial portion of 13 aa of its peptide sequence with native ghrelin, which 
includes the first 5-amino acids (aa) that comprises the minimum sequence required for 
ghrelin acylation by MBOAT4, the enzyme responsible for ghrelin acylation10,11, and for 
binding and activation of GHSR-1a1,4. Therefore, In1-ghrelin variant would encode a 
different prepro-peptide that conserves the initial aa of native ghrelin but presents a 
different C-terminal tail, and whose expression has been demonstrated in several human 
healthy tissues, and has been found to be overexpressed in breast cancer6. Moreover, 
the orthologous counterparts of the human In1-ghrelin variant have also been found in 
mice (named In2-ghrelin12) and in a non-human primate model6, which suggest that this 
new variant might exert an important physiological role that is conserved across 
mammalian species. 
GHRL gene-derived transcripts/peptides are produced by the pituitary gland6,13,14, 
and seem to be involved in the regulation of the normal pituitary secretory pattern1,15-17. 
In contrast to the growing number of biologically active ghrelin gene-derived peptides, 
only a single receptor, transcribed from GHSR gene, named GHSR1a, has hitherto been 
identified as unequivocal endogenous functional binding target for AG, while a 
physiological function has not been unequivocally ascribed to its shorter, truncated 
splicing isoform GHS-R1b18. On the other hand, the receptor(s) mediating the actions of 
unacylated-ghrelin, obestatin, In1-ghrelin and other splicing variants remain elusive, if 
not controversial18. The enzyme responsible for ghrelin acylation, MBOAT4, belongs to 
the superfamily of membrane bound O-acyltransferases, and is commonly referred to as 
ghrelin-O-acyltransferase (GOAT)10,11. This enzyme has been found to be expressed in a 
variety of human and rodent tissues19,20, including the pituitary, where it has been 
proposed that locally produced GOAT might possibly be active to convertlocally produced 
or circulating non-acylated forms of proghrelin or proIn1-ghrelin to their acylated forms 
to mediate tissue-specific effects20. 
The first evidence indicating that ghrelin system could be involved in tumor 
development and/or progression was the finding that GHSR1awas expressed in normal 
and tumoral pituitaries21. Thereafter, ghrelin was also found in various types of pituitary 
tumors13,22,23, thus suggesting a complex autocrine/paracrine role of the ghrelin system 
in pituitary pathogenesis. In fact, ghrelin, GHSR1a and the truncated GHSR1b have been 
found to be expressed in a wide variety of endocrine-related tumors, including pituitary 
adenomas, neuroendocrine tumors and breast and prostate tumors 6,13,21,24,25. 
Additionally, MBOAT4 and In1-ghrelin variant expression has been observed inbreast6,26 
and prostate27-29 cancers but their presence in pituitary adenomas is still to be 
determined. 
Although some of the components of the ghrelin system seems to exert 
autocrine/paracrine regulatory actions and could thus hold potential as a diagnostic, 
prognostic or therapeutic target in several tumoral pathologies, including pituitary 
adenomas, its exact role in tumor development and progression is still uncertain. 
Moreover, the presence of MBOAT4 and In1-ghrelin has not yet been determined in 
pituitary adenomas. Therefore, the aim of this study was to systematically analyze, for 
the first time, the side-by-side presence of different components of the ghrelin system: 
native ghrelin, In1-ghrelin variant, MBOAT4 enzyme, GHSR1a and GHSR1b, in normal 
pituitaries and in all major types of human pituitary tumors. In addition, we used 
pituitary adenoma primary cell cultures and a mouse corticotropinoma cell line (AtT-20) 
to compare the direct effects of native ghrelin and In1/In2-ghrelin variant administration 
on selected functional parameters to better define the pathophysiological significance of 
this regulatory system in pituitary tumors.  
Results 
 
 Ghrelin system is altered in pituitary adenomas compared to normal 
pituitary: All components of the ghrelin system examined (native ghrelin, In1-ghrelin 
variant, GHSR1a, GHSR1b and MBOAT4 enzyme) were expressed in normal pituitaries 
(Figure-1 and Supplemental Figure-1). Expression of MBOAT4 and that of ghrelin 
receptors were also found at appreciable levels in normal pituitaries (Figure-1). 
Interestingly, the expression pattern of ghrelin system components was markedly 
altered in pituitary adenomas compared with normal pituitaries. Specifically, median 
expression levels of native ghrelin were significantly elevated in GH-omas, while no 
significant changes were observed in ACTH-omas, NFPAs or PRL-omas compared with 
normal pituitaries (Figure-1 and Supplemental Figure-1). In contrast, the expression of 
In1-ghrelin was significantly elevated in all types of pituitary adenomas analyzed 
(Figure-1 and Supplemental Figure-1), suggesting a potential common relevant role in 
pituitary tumors pathogenesis. Expression of MBOAT4 was slightly, but significantly, 
reduced in ACTH-omas and NFPAs compared to normal pituitaries, while no significant 
changes were observed in GH-omas and PRL-omas (Figure-1 and Supplemental-1). In 
the case of ghrelin receptors, a pronounced overexpression of GHSR1a and GHSR1b was 
observed in GH-omas and, similarly, an elevation in the expression of both receptors 
was also observed in ACTH-omas, which was only statistically significant for GHSR1b. In 
contrast, median expression levels of both receptors were reduced in NFPAs, and no 
changes were observed in PRL-omas (Figure-1 and Supplemental Figure-1). Although 
caution should be exerted when comparing normal pituitary tissues (which contain a 
mixture of pituitary cell subtypes) and pituitary adenomas (though to be 
mono/oligoclonal in origin), it should be noted that the careful use of this type of 
comparison has been generally accepted13,30 as it provides potentially valuable and 
informative insights, and may help to set the stage for future investigations to elucidate 
the putative physiological role(s) for the ghrelin system in normal pituitaries and 
pituitary adenomas. In1-ghrelin expression levels correlated with those of MBOAT4 in 
GH-omas, ACTH-omas, and NFPAs, but not in normal pituitaries (no correlation analysis 
were performed in PRL-omas due to insufficient number of samples), which may suggest 
that In1-ghrelin could be functionally linked with MBOAT4 in pituitary adenomas. 
Expression levels of ghrelin and MBOAT4 correlated in GH-omas and NFPAs but not in 
ACTH-omas and normal pituitaries (Supplemental Table-2). Inasmuch as In1-ghrelin 
expression was consistently elevated in all pituitary adenomas, and its expression 
correlated with that of MBOAT4 in pituitary adenomas (and not in normal pituitaries), we 
considered of foremost interest to explore the putative role of this novel ghrelin gene 
variant in the pathophysiology of pituitary tumors. 
 
In1-ghrelin peptides induce intracellular signaling activation in pituitary 
adenoma cells: To test the capacity of In1-ghrelin peptides to induce functional 
responses in pituitary tumor cells, we measured the kinetics of free cytosolic calcium 
concentration ([Ca2+]i) in single cells derived from GH-omas, ACTH-omas, NFPAs and 
PRL-omas, as well as the levels of phosphorylation of two signaling pathways (MAPK and 
Akt; p-ERK1/2 or p-Akt, respectively) in GH-omas in response to treatment with 
acylated In1-ghrelin peptides as compared with that of AG. Calcium is a relevant second 
messenger well known for its involvement on pituitary cell physiology, where it triggers 
hormone secretion and has thus been widely used to evaluate pituitary cell function23. 
Therefore, two putative In1-ghrelin derived peptides (In1-19 and In1-40) were 
chemically synthesized and employed, in parallel with AG. AG induced [Ca2+]i changes in 
the majority of cells derived from all GH-omas and ACTH-omas tested (Table-2). 
Particularly, 74% of the cells from GH-omas and ACTH-omas responded to AG doubling 
the [Ca2+]i levels. Remarkably, both In1-ghrelin peptides induced similar responses in 
most GH-oma and ACTH-oma cells, with In1-19, in general terms, being more efficient 
than In1-40. In all cases, the increase in [Ca2+]i levels were slightly lower than those 
elicited by AG (Table-2). In NFPA, AG and In1-ghrelin peptides elicited [Ca2+]i responses 
in approximately 50% of the adenoma cultures, with lower proportion of responsive cells 
(29%, 18% and 10%, respectively) and lower maximal responses than those observed 
in GH- and ACTH-omas. Finally, PRL-oma cells showed a very modest response to 
ghrelin system peptides with less than 20% of cells increasing [Ca2+]i levels in response 
to AG and less that 10% of cells responding to In1-ghrelin peptides in only a subset of 
the PRL-omas. In1-ghrelin peptides exhibited a slightly lower potency than AG in all 
parameters tested in NFPAs and PRL-omas (Table-2). Altogether, these results 
demonstrate that AG and In1-ghrelin peptides impact Ca2+ signaling in pituitary 
adenoma cell cultures. To test the possibility that In1-ghrelin peptides could 
bind/activate GHSRs, CHO-K1 cells stably transfected with either GHSR1a or GHSR1b 
were employed to analyze [Ca2+]i levels in response to In1-ghrelin peptides. Both, In1-
19 and In1-40 induced [Ca2+]i changes in GHSR1a-transfected cells, with similar EC50 to 
that exhibited by ghrelin (Supplemental Table-3); while GHSR1b-transfected cells did not 
respond to any of the peptides tested (EC50>3000); therefore suggesting that In1-
ghrelin peptides can act, at least in part, through GHSR1a. Nevertheless, responses to 
AG18 and In1-ghrelin (data not shown) have been found in GHSR-lacking cells (e.g. 
prostate cell lines), suggesting the existence of additional receptors of the ghrelin 
system. Interestingly, treatment with both AG and acylated In1-19 induced a clear 
increase on p-ERK1/2 in somatotropinomas as compared to vehicle treated controls 
(Figure-2A), whereas only AG, but not In1-19, was able to increase p-Akt levels (Figure-
2B). 
 
In1-ghrelin peptides induce hormone secretion from pituitary adenoma 
cells: To confirm that the responsiveness of pituitary adenoma cells to In1-ghrelin 
peptides was translated into further functional outcomes, in vitro hormone secretion was 
assessed in a subset of tumors in response to In1-ghrelin peptides, and, when cells were 
available, also to AG. AG and In1-ghrelin peptides, similarly and significantly, increased 
GH secretion in GH-omas (4h and 24h treatments; Figure-3A). Likewise, AG and In1-
ghrelin peptides significantly increased ACTH secretion in ACTH-omas with similar 
efficacy, after 24h treatment (Figure-3B). In contrast, In1-19 was not able to alter PRL 
secretion in the samples tested (n=2) after 24h treatment (Figure-3C). Unfortunately, 
we could not investigate the effect of AG or In1-40 peptide in PRL-omas due to the 
limited source of preparations and of the number of cells obtained after dispersion. 
Finally, the results obtained in human ACTH-omas were further supported by the use of 
a widely accepted cellular model for ACTH-producing adenomas, the AtT-20 cell line. 
Specifically, AtT-20 cell line expressed higher levels of In2-ghrelin [the murine 
counterpart of In1-ghrelin12] compared with native ghrelin (Figure-4A), a situation 
similar to that found in human ACTH-omas where In1-ghrelin expression was higher 
than native ghrelin expression (p<0.01; data not shown). Treatment with AG did not 
significantly alter basal ACTH release in AtT-20 cell line (which might be explained by the 
lack of GHSR expression; Figure-4A and -4B), while treatment with In2-ghrelin peptide 
significantly increased basal ACTH release which further support the existence of 
additional receptors of the ghrelin system. 
 
In1-ghrelin enhances cell viability in pituitary adenoma cells: 
Administration of AG and In1-ghrelin peptides increased cell viability in vitro in all 
pituitary adenoma subtypes (Figure-5). In particular, cell viability was significantly 
increased in GH-oma cell cultures after 48 and 72h treatment in response to AG; after 
24, 48 and 72h treatment with In1-19 and after 72h treatment with In1-40, with In1-19 
apparently being more effective than AG and In1-40 at 72h (Figure-5A). In ACTH-omas, 
AG increased cell viability at 24h; while, In1-19 increased cell viability at 24, 48 and 72h, 
and In1-40 did not exert any effect (Figure-5B). Consistent with an effect of In1-ghrelin 
on ACTH-oma cell viability, In2-ghrelin peptide stimulated cell viability on AtT-20 cell line, 
while AG did not alter cell viability in these cells (Figure-4C). Furthermore, AG and In1-
ghrelin peptides exhibited modest but consistent increments in cell viability in NFPAs, 
reaching significant levels at 24h for AG and at 48h for In1-19 (treatment with In1-40 
did not alter cell viability in NFPA-cells) (Figure-5C). Finally, in PRL-oma cultures, AG and 
In1-40 but not In1-19 elicited significant increases on cell viability (Figure-5D). 
 
 In1-ghrelin decreases apoptotic rate in GH-omas cells: Administration of 
AG did not alter apoptotic rate as compared to vehicle treated controls in GH-oma cell 
cultures however; treatment with acylated In1-19 significantly reduced apoptosis in GH-
omas (n=3; Figure-5E) and in one ACTH-oma (n=1; Figure 5F). 
 
Effect of overexpression and silencing of In1-ghrelin on in vitro cell 
viability: In1-ghrelin but not native ghrelin overexpression increased cell viability in 
cultured GH-oma cells compared to controls (mock-transfected cells) (Figure-6A). 
Likewise, In1-ghrelin overexpression significantly increased cell viability in NFPA cell 
cultures (Figure-6B). A similar trend was observed in ACTH-oma cell cultures, where 
In1-ghrelin overexpression tended to increase cell viability (p=0.10) (Figure-6C). As 
mentioned above, analysis of additional treatments (i.e. native ghrelin overexpression) 
and time-points could not be performed due to limited cell preparations and/or number. 
Nevertheless, we implemented, as key proof of concept, the opposite approximation, 
namely In1-ghrelin silencing, in a subset of pituitary adenomas in which cultured cells 
were available. Validation of the siRNA and selection of the appropriate concentration 
were carried out using commercially-available cell lines that naturally express In1-
ghrelin, such as MDA-MB-231 (breast cancer cell line) and LnCAP (prostate cancer cell 
line) (data not shown). Specifically, In1-ghrelin expression silencing with a specific siRNA 
reduced cell viability in two independent GH-oma as well as in two NFPA cell cultures 
compared to control (scramble-transfected cells) (Figure-6D and -6E, respectively). 
 
Discussion 
Pituitary adenomas have been commonly considered a rare tumoral pathology 
due to an underestimated diagnosis and, consequently, low incidence worldwide. 
However, autopsy and imaging studies demonstrated that these tumors present an 
overall estimated prevalence of 16.7%31, thus representing the most common 
intracranial neoplasms, which are often accompanied by serious comorbidities through 
mass effects and inappropriate secretion of pituitary hormones. Unfortunately, 
establishment of effective and long-lasting therapeutic strategies has been hampered by 
the fact that pituitary adenomas comprise an extremely heterogeneous and complex 
subset of tumoral pathologies, wherein the finding of common and more global 
molecular and/or cellular targets for their diagnostic, prognostic and/or therapeutic 
treatment has been elusive.  
In this work, we hypothesized that the ghrelin system could play a role in the 
regulation of pituitary adenomas, based on previous reports indicating that this system 
exerts relevant actions in the control of pituitary secretions1,16,17, and that some 
components of this family are altered in certain pituitary adenomas subtypes1,13,21-23. 
Thus, it seemed reasonable to propose that identification of altered components of this 
ghrelin system might be useful in the exploration for new tools for the diagnostic, 
prognostic and/or therapeutic treatment of pituitary adenomas. To date, a 
comprehensive and systematic analysis of several of the components of the ghrelin 
system has not been implemented in parallel in an extensive collection of pituitary 
adenomas. Moreover, the presence and functional role of the novel ghrelin gene variants, 
as In1-ghrelin variant, has not been studied in pituitary adenomas. Thus, to better 
define the pattern of alteration of ghrelin system components in pituitary adenomas, we 
developed a parallel analysis of the expression pattern of native-ghrelin, In1-ghrelin 
variant, GHSR1a, GHSR1b and MBOAT4 in a battery of 169 human pituitary adenomas, 
including GH-, ACTH- and PRL-producing adenomas and NFPAs, compared with normal 
pituitaries. In line with previous reports, we found that these components were 
expressed in normal pituitaries6,13,19-21,32,33. Interestingly, the results generated in this 
study reveal that, compared to normal pituitaries, expression of the ghrelin system is 
dramatically altered in pituitary adenomas, which was dependent on tumor subtype and 
the specific component of the ghrelin system analyzed.  
Specifically, expression of GHRL-gene derived products (ghrelin and In1-ghrelin), 
GHSR1a and GHSR1b was markedly elevated in GH-omas, wherein MBOAT4 expression 
was also slightly albeit non-significantly increased, indicating an overall, profound 
upregulation of ghrelin system in GH-omas. This study reinforces previous data showing 
higher expression of ghrelin, GHSR1a and GHSR1b in GH-omas compared to normal 
pituitaries22, and extend this information by demonstrating, for the first time, the 
presence of appreciable levels of MBOAT4, a key element of this family that is required 
to activate ghrelin for its binding/action via GHSR1a, and would also presumably acylate 
the In1-ghrelin variant6,13,21, which, in addition, is heavily overexpressed in GH-omas. 
In the rest of tumoral types examined, the alteration of the ghrelin system, 
although apparent, was more complex. Specifically, in ACTH-omas, where ghrelin was 
previously shown to be downregulated13,22 and GHSR1a and GHSR1b upregulated21,22 
compared with normal pituitaries, we found similar tendencies, but with no significant 
reduction in ghrelin expression and elevation in GHSR1a expression, while GHSR1b 
expression was significantly elevated. Interestingly, we found a clear upregulation of 
In1-ghrelin and a reduction in MBOAT4 expression levels in ACTH-omas compared to 
normal pituitaries. In fact, comparison of the two ghrelin gene derived transcripts 
expression levels in ACTH-omas (and also in AtT-20 cell line) revealed that the 
expression of In1-variant was significantly higher than that of native ghrelin, which 
further supports a relevant role of this variant in ACTH-omas. Conversely, PRL-omas did 
not exhibit altered ghrelin expression levels, as previously reported21,22, and neither was 
GHSR1a and GHSR1b expression altered, which differs with the single report of 
upregulated ghrelin receptor in PRL-omas21. Remarkably, In1-ghrelin expression was 
also found to be upregulated in PRL-oma samples, while MBOAT4 expression was not 
altered compared to normal pituitaries. Finally, NFPA samples exhibited a high 
heterogeneity, probably related to their intrinsically diverse nature, showing a slight 
elevation in ghrelin expression, which is consistent with previous reports13,22, and a 
reduction in GHSR1a and GHSR1b expression levels. Notably, these receptors exhibited 
a remarkably elevated expression in some NFPA samples, which could be in agreement 
with previous reports showing an elevation in ghrelin receptor expression in NFPAs13,21,22. 
In addition, MBOAT4 expression levels were slightly downregulated in NFPAs and, similar 
to that found in all the pituitary adenomas included in this study, we found that In1-
ghrelin was significantly overexpressed in NFPAs. 
Taken together, our data confirm earlier studies supporting the existence of a 
profound alteration of some components of the ghrelin system in the most predominant 
pituitary adenoma subtypes13,21,22, and extend previous data by demonstrating the 
expression of In1-ghrelin and MBOAT4 in pituitary adenomas, which further supports the 
notion that an autocrine/paracrine functional loop involving the ghrelin system can be in 
place in the pituitary, and may contribute to the (patho)physiological control of the gland. 
Indeed, our study offers new clues in the understanding of the role of ghrelin 
system in the regulation of pituitary adenomas by demonstrating for the first time the 
significant overexpression of In1-ghrelin in all the pituitary adenoma subtypes analyzed 
compared to normal pituitaries. In fact, In1-ghrelin variant is the only component of the 
ghrelin system consistently overexpressed in pituitary adenomas, thus suggesting a 
putative utility of this variant for the development of new and more universal diagnostic, 
prognostic or therapeutic tools for the management of human pituitary adenomas. 
Indeed, In1-ghrelin is widely expressed in normal tissues but profoundly overexpressed 
in pathologic conditions such as breast cancer, wherein it can promote proliferation of 
breast cancer cell lines6. Here, we have demonstrated that the acylated In1-ghrelin could 
also play a relevant pathological role in pituitary adenomas. In particular, this study 
demonstrates that GH-oma cells respond to In1-ghrelin peptides by increasing [Ca2+]i, 
which was associated with augmented GH secretion in vitro34. Parallel administration of 
AG also increased [Ca2+]i and promoted GH secretion by GH-oma cells, which is 
consistent with previous reports showing similar effects using ghrelin-analogs35. In 
addition, we demonstrate, for the first time, that treatment with In1-19 increased p-
ERK1/2, but not p-Akt, levels in GH-omas. Interestingly, parallel administration with AG 
increased both, p-ERK1/2 as well as p-Akt, levels in GH-oma cells, which is also 
consistent with earlier findings in murine and human cell lines36-38 and, in primary 
pituitary cell cultures of a non-human primate model39. Although our results on 
intracellular signaling pathways ([Ca2+]i, as well as ERK and Akt activation) do not 
provide a definitive, complete elucidation of the intracellular signaling pathways involved 
in the response of In1-ghrelin peptide(s) and AG in GH-omas, we believe that the data 
presented provide novel evidence regarding how this novel ghrelin variant regulates 
some specific intracellular signaling pathways in GH-oma cells, and suggest the 
possibility that these pathways may be partially independent to those activated by AG in 
these cells. A working model summarizing the putative mechanisms and second 
messenger routes activated by ghrelin and In1-ghrelin in pituitary tumor cells is 
summarized in Figure 7. 
Remarkably, In1-ghrelin also influenced other key, clinically relevant process, 
such as cell viability, in these tumors, since the In1-19 peptide significantly increased 
cell viability. Of note, this effect is more effective than that elicited by In1-40 peptide 
(p=0.0079 at 72h) or by AG itself (p=0.0025 at 72h), which modestly increased GH-oma 
cell viability, consistent with a previous study in rat pituitary somatotrope cell lines 
indicating that AG can stimulate cell proliferation40. In accordance, we found that In1-
ghrelin overexpression also increased viability in GHoma cells, while In1-ghrelin silencing 
using a specific siRNA reduced cell viability, which, again, strongly suggests a relevant 
role of In1-ghrelin in GH-omas pathophysiology. Furthermore, we found that treatment 
with In1-19 also altered (decreased) apoptotic rate in GH-omas, whereas AG did not 
alter apoptotic rate as compared to vehicle-treated controls, which is in line with 
previous reports showing that AG treatment did not affect the apoptotic rate in other 
endocrine cell types (e.g. pancreatic cells)38. In fact, to the best of our knowledge, this is 
the first study examining the direct effect of AG or In1-ghrelin variant peptide on 
apoptotic rate on human GH-omas.  
Overall, these results observed in response to In1-ghrelin peptide(s) treatment 
(i.e. an increase in proliferation rate and a decrease apoptotic rate) suggest that In1-
ghrelin variant might represent a regulatory mechanism to control tumor growth in GH-
oma cells. In line with this, it should be mentioned that these effects might be directly 
associated to the activation of MAPK signaling (i.e. ERK1/2-phosphorylation) observed in 
response to treatment with In1-ghrelin peptide, since the activation of this signaling 
pathway has been commonly associated to the regulation of cell growth and 
proliferation41. 
In1-ghrelin peptides also increased [Ca2+]i and stimulated ACTH release from 
human ACTH-oma cells and from the mouse AtT-20corticotropinoma cell line. This was 
also observed with AG in human ACTH-omas, and is in line with previous data showing 
that AG is able to elicit an effect on ACTH release42, likely through an increase in 
[Ca2+]i
23. In addition, In1-ghrelin overexpression also stimulated ACTH-oma cell viability 
while treatment with In1-ghrelin peptide In1-19, but not In1-40, revealed similar effects, 
suggesting that In1-19 peptide rather than In1-40 peptide could be likely responsible for 
the observed effects of In1-ghrelin overexpression in ACTH-producing derived cells. In 
accordance, we also found that treatment with mouse In2-ghrelin peptide increased cell 
viability in AtT-20 cell line which further supports the influence of this novel variant of 
the GHRL in the control of clinically relevant endpoints (i.e. cell viability and hormonal 
release) in pituitary adenomas of different species. Moreover, it should be mentioned 
that we had the opportunity to observe that In1-19 treatment was able to exert a clear 
inhibition in the apoptotic rate in one ACTH-oma sample included in the study which, 
together with the previous results observed in GH-omas and ACTH-omas, further 
support the notion that treatment with the In1-ghrelin peptides influences multiple, 
clinically relevant parameters on human pituitary adenomas, and may thus offer the 
possibility of identifying new therapeutic tools to treat these adenomas. Obviously, 
future studies, using larger number of human culture samples and additional, different 
types of assays are warranted to unequivocally establish if the overexpresion of In1-
ghrelin variant observed in all the human pituitary adenomas analyzed herein is directly 
associated with an increase in proliferation and a decrease in apoptotic rate observed in 
these human pituitary pathologies. 
In NFPAs, no functional studies had been implemented to date and, therefore, the 
role of the ghrelin system in this pathology remained unknown1. Accordingly, our study 
is the first to demonstrate that a subset of NFPA cells is responsive to AG and In1-
ghrelin peptides in terms of [Ca2+]i kinetics. More importantly, both AG and In1-ghrelin 
peptides (mainly In1-19) increased NFPA cells viability, which was further confirmed by 
In1-ghrelin overexpression experiments. As proof of concept, silencing of In1-ghrelin 
expression significantly reduced NFPA cell viability, which is particularly relevant in this 
kind of pituitary adenomas since the main comorbidities are derived from tumor 
overgrowth and mass effects43. 
Results using [Ca2+]i kinetic assays suggested the existence of a reduced 
responsiveness of PRL-omas to AG, in that only a low proportion of these pituitary 
adenoma cells altered their [Ca2+]i in response to AG. Yet, this seems to be sufficient to 
elicit functional responses since AG treatment increases PRL secretion in this and in 
previous studies35. Conversely, In1-ghrelin peptides only elicited [Ca2+]i responses in a 
negligible percentage of PRL-oma cells, which is in accordance with the lack of effect of 
these peptides in the modulation of PRL release. However, In1-40 but not In1-19 peptide 
was found to be as potent as AG in stimulating PRL-oma cell viability, which is in striking 
contrast with that observed in other pituitary adenoma subtypes wherein In1-19 was 
found to be more effective than In1-40 in all endpoints analyzed.  
In sum, the data presented herein demonstrate, for the first time, a consistent 
upregulation of In1-ghrelin expression in the most predominant pituitary adenoma 
subtypes compared to normal pituitary. Moreover, the functional data collected strongly 
support the concept that In1-ghrelin substantially influences intracellular signaling, 
hormone secretion, and cell viability in pituitary adenoma cells. Hence, it seems 
reasonable to propose that the In1-ghrelin variant could play a relevant functional role in 
the regulation of pituitary adenoma pathology. As such, our results pave the way for 
using In1-ghrelin variant as a new tool to explore novel and more general diagnostic, 
prognostic and/or therapeutic targets in these human pathologies, where additional 
studies are warranted to determine the clinical implications of the alteration of specific 
components of the ghrelin family.  
Material and Methods 
 
 Patients and samples: Human pituitary specimens were obtained during 
transsphenoidal surgery from 169 patients [76 somatotropinomas, 57 non-functioning 
pituitary adenomas (NFPA), 29 corticotropinomas, and 7 prolactinomas]. In addition, 11 
normal pituitaries (normal pituitary) pieces were included in the study [10 obtained from 
autopsies and one from a commercial source (pool of multiple individuals); CLONTECH; 
Palo Alto, CA, USA]. The methods were carried out in accordance with the approved 
guidelines, including the ethical standards of the Helsinki Declaration of the World 
Medical Association, University of Córdoba/IMIBIC and University Hospital Ethics 
Committees; additionally informed consent from each patient or relative, in case of 
autopsy, was obtained. All experimental protocols were approved by University of 
Cordoba/IMIBIC licensing committee. The phenotype of the pituitary samples collected 
(normal pituitaries or adenoma subtypes) was confirmed by three separate methods: 
examination by an anatomopathologist, testing the hormonal phenotype using single-cell 
secretion23 (not possible in the case of normal pituitaries), and molecular screening by 
quantitative real-time PCR (qPCR)30. Available demographic and clinical data are 
summarized in Table 1.  
 
 Peptides: Human and rodent acylated ghrelin were commercially available 
(SC1357, and SC1356, respectively; PolyPeptide Laboratories, Limhamn, Sweden), while 
human, In1-ghrelin, and mouse, In2-ghrelin, acylated peptides were synthesized in 
collaboration with Ipsen Bioscience (Cambridge, MA, USA) and developed by CPC 
Scientific (Chinese Peptide Company, Hangzhou, China; see below). Although the mature 
endogenous In1/In2-ghrelin derived peptides have not yet been identified, pre-pro-In1-
ghrelin and pre-pro-In2-ghrelin precursors exhibit target sites for protein-convertases 
suggesting a further proteolytic processing. As previously reported6, In1-ghrelin 
precursor processing could generate 19-aa or 40-aa long peptides (named In1-19: 
GSSFLSPEHQRVQVRPPHK and In1-40: 
GSSFLSPEHQRVQVRPPHKAPHVVPALPLSNQLCDLEQQR), which share with native ghrelin 
the initial 13-aa, including the acylation site at Ser3. On the other hand, we have 
previously reported12 that In2-ghrelin precursor processing could generate a single32-aa 
long peptide (named In2-ghrelin: GSSFLSPEHQKAQVSQSVSLSPHIYPDLCVCV), and 
similarly share with native mouse ghrelin the initial 13-aa.  
 
 The acylated In1-19, In1-40 and In2-ghrelin peptides were synthesized using 
manual solid-phase peptide synthesis starting with Fmoc-Lys(Boc)-Wang resin on a 0.5 
mmol scale. The resins were treated with DCM/DMF (1:1) for 1 h, followed by standard 
Fmoc single coupling cycles with 1.5 mmol amino acid and coupling agent. All amino 
acids were Fmoc-protected except for Ser 3, which was unprotected. All amino acids 
were activated with HBTU or DICGly1 and HATU. Octanoic acid was coupled to Ser3 
using 2 x 5 mmol octanoic acid and HOBt, followed by 2 x 10 mmol octanoic acid and 
HOBt. The peptides were then treated with a cocktail of 
TFA/EDT/Thioanisole/Phenol/H2O (87.5:2.5:5:2.5) for 2.5 h to remove the peptides 
from the resins. The peptides were confirmed by ESI MS and analytical RP-HPLC. The 
peptides were eluted with a gradient of Buffer B (0.09% TFA in 80% CH3CN/H2O) in 
aqueous 0.1% TFA. The peptides solubility was determined to be 1 mg/mL in water. 
Finally, peptide content was determined by AAA. 
 
Overexpression vectors and specific siRNAs: To perform overexpression 
experiments, ghrelin sequence was purchased, cloned in pCMV-Sport6-vector (Harvard 
Cancer Center, Boston, MA, USA) and was subcloned into the expression vector 
pCDNA3.1+ (Life Technologies, Grand Island, NY, USA). In1-ghrelin sequence was PCR-
amplified (In1-Hind-Up: 5´-TCTCAAGCTTATGCCCTCCCCAGGGAC-3´ and In1-Bam-Low: 
5´-TGTGGGATCCCTAGAGCTCGGGGCTGCAG-3´) and cloned into pCDNA3.1+. Empty 
pCDNA3.1+ (mock) was used in all the experiments as negative control. For silencing 
experiments, a battery of custom-designed siRNAs specifically targeted against the 
unique In1-ghrelin mRNA sequence was chemically synthesized by Life Technologies and 
their efficiency, specificity and appropriate concentration tested in human cell lines 
expressing In1-ghrelin (MDA-MB-231 breast cancer cell line and LnCAP prostate cancer 
cell line) (data not shown). Among them, the herein named In1-ghrelin siRNA (5´-
GAGTCCTAAACAGACTGTT-3´) demonstrated a more robust silencing efficiency of In1-
ghrelin, but not native ghrelin, in all the models tested (data not shown). As a negative 
control, a commercial, validated negative control (scramble) was used in all the 
experiments, which according to the manufacturer’s instructions, has no significant 
sequence similarity to murine or human gene sequences (Silencer Select Negative 
Control No. 1 siRNA, Life Technologies, Green Island, NY, USA). 
For transfection assays (overexpression or silencing), 200,000-500,000 cells were 
seeded on 6-well plates in serum containing medium during 24-36h. Then, medium was 
replaced with antibiotic-antimycotic free medium. For overexpression experiments, 100 
ng/50,000 cell of ghrelin or In1-ghrelin plasmid was diluted in 50 µL of Opti-MEM and, 
0.5 µL of Lipofectamine 2000 (Life Technologies) were separately diluted in another 50 
µL of Opti-MEM. Both solutions were incubated for 5 minutes at room temperature and 
then, were mixed and incubated for 30 minutes at room temperature. After this 
incubation period, the solution (total of 100 µL) was added to the cells/per well. For 
silencing experiments, 7.5 µL of Lipofectamine RNAiMAX (Life Technologies) was diluted 
in 100 µL of Opti-MEM and, 100 nM of In1-ghrelin siRNA was separately diluted in 
another 100 µL of Opti-MEM. Both solutions were incubated for 5 minutes at room 
temperature and then, were mixed and incubated for 30 minat room temperature. After 
this incubation period, the solution (total of 200 µL)was added to the cells/ per well. In 
both cases (overexpression or silencing experiments), the solutions added to each well 
were incubated for 6-8 h at 37ºC and then, medium was replacedwith serum containing 
medium for 18h. Finally, cells were detached and seeded in 96-well plates for cell 
viability measurements and, some cells werecollected for validation of the transfection 
efficiency (measure by qPCR). 
 
 Cell lines and culturing: The mouse corticotroph pituitary derived cell line AtT-
20/D16v-F2 (ATCC® CRL-1795) was cultured and maintained in Dulbecco's Modified 
Eagle's Medium (DMEM) complemented with 10% FBS, 100 U/ml penicillin/streptomycin, 
0.024 M of 2-(4(2-hydroxyethyl)-1-piperazine)-ethane sulfonic acid (HEPES), and 
maintained at 37ºC and 5% CO2, under sterile conditions. CHO-K1 cell line(ATCC® CCL-
61) expressing recombinant human GHSR1a (GenBank accession number U60179) or 
GHSR1b (GenBank accession number U60181) were cultured and maintained in Ham’s 
F12 media (Corning #10-080-CV) supplemented with 10% FBS, 2 mM L-Glutamine and 
0.4 mg/mL Geneticin. 
 
 RNA isolation, reverse-transcription, qPCR of human transcripts from 
normal pituitaries and tumor samples: RNA extraction, quantification, reverse-
transcription as well as the development, validation and application of qPCR to measure 
the expression levels of different human transcripts have been previously reported 
elsewhere by our group23,44,45. Due to asynchronically collection of samples, total RNA 
was extracted from tumoral pieces with two commercial kits following the manufacturer’s 
protocol: Absolutely RNA RT-PCR Miniprep Kit (Agilent, La Jolla, CA, USA) with 
deoxyribonuclease treatment and AllPrep DNA/RNA/Protein Mini Kit followed by 
deoxyribonuclease treatment using RNase-Free DNase Set (Qiagen, Limburg, 
Netherlands). AtT-20 cell cultures were processed to isolate total RNA using TRIzol 
Reagent (Life Technologies, Barcelona, Spain) following the manufacturer’s protocol and 
subsequently treated with DNase (Promega, Barcelona, Spain). In all cases, total RNA 
concentration and purity was assessed using Nanodrop 2000 spectrophotometer 
(Thermo Scientific, Wilmington, NC, USA), and subsequently retro-transcribed using 
random hexamer primers and the cDNA First Strand Synthesis kit (MRI Fermentas, 
Hanover, MD, USA). cDNA derived from pituitary tissue and AtT-20 cell line were 
amplified by qPCR, where samples were run, in the same plate, against a standard curve 
to estimate mRNA copy number (1, 101, 102, 103, 104, 105, and 106 copies of synthetic 
cDNA template for each transcript) and a No-RT sample as a negative control. qPCR was 
performed using Brilliant II or III SYBR Green Master Mix in the Stratagene Mx3000p 
instrument (Agilent, La Jolla, CA, USA) as previously described23,44,45. Thermal profile 
consisted of a initial step at 95°C for 10 minutes, followed by 40 cycles of denaturation 
(95°C for 30 seconds), annealing (61°C for 1 minute), and extension (72°C for 30 
seconds); and finally, a dissociation cycle to verify that only one product was amplified. 
In human pituitary samples, expression levels of native ghrelin, In1-ghrelin variant, 
GHSR1a, GHSR1b, MBOAT4 and ACTB were determined, when possible, while in mouse 
AtT-20 cell line expression levels of native ghrelin, In2-ghrelin variant, Ghsr, Mboat4 and 
Actb, Ppia and Hprt were determined. Specific sets of primers used in this study are 
shown in Supplemental Table 1. To control for variations in the amount of RNA used and 
the efficiency of the reverse-transcription reaction and, the expression level (copy-
number) of each transcript was adjusted by ACTB expression in human samples, and by 
a normalization factor calculated with the expression levels of Actb, Ppia and Hprt using 
GeNorm 3.346 in mouse AtT-20 cell line. It should be noted that, as previously 
reported44,45 and based on the stringent criteria to maximize specificity and efficiency, 
the qPCR technique, as applied, can be used to accurately quantify copy numbers for all 
human transcripts included in this study. 
 
 Primary pituitary cell culture: Pituitary adenoma specimens were dispersed 
into single cells by enzymatic and mechanical disruption and cultured onto tissue culture 
plates in serum containing medium, as previously described23,30,47,48. Briefly, pituitary 
samples were resected by endoscopic transsphenoidal surgery and transferred to sterile 
cold (4ºC) culture medium (S-MEM, Gibco, Madrid, Spain) supplemented with 0.1% BSA, 
0.01% L-glutamine, 1% antibiotic-antimycotic solution, and 2.5% HEPES. Samples were 
minced under sterile conditions into 1-2mm3 pieces. Some pieces were stored at -80ºC 
for posterior RNA isolation and, when possible, the remaining tissue samples were 
washed and incubated in 30 mL S-MEM medium supplemented 0.3% trypsin (Beckson, 
Dickinson and Company, Sparks, MD, USA) in a spinner flask (Bellco Glass, Vineland, NJ, 
USA) for 2 h of gentle shaking at 37ºC and then, incubation was continued for another 5 
min in presence of 1 mg of DNAse I (Roche, Mannheim, Germany). Dispersed cells were 
decanted by centrifugation and then, by repeated aspiration into a smoothtipped glass 
Pasteur pipette. Cells suspensions were washed once in 4.5 g/L glucose containing 
DMEM medium (Gibco, Madrid, Spain) supplemented with 0.1% BSA, 0.01% L-glutamine, 
1% antibiotic-antimycotic solution, and 2.5% HEPES. Cell number and viability was 
estimated by the Trypan blue exclusion test in Neubauer chamber, where viability was 
always 90-100%. 
 
 Analysis of hormone secretion: To examine the effects of ghrelin system 
components (4- and/or 24h-incubation) on pituitary hormone release from primary 
pituitary adenoma and/or AtT-20 cell line, 100,000-200,000 cell/well were used. As 
previously reported15, hormone concentrations were measured in the culture media 
derived from human samples according to the pituitary adenoma type using commercial 
ELISAs [growth hormone, GH; adrenocorticotropin, ACTH; and prolactin, PRL (reference 
numbers: EIA-3552, EIA-3647 andEIA-1291, respectively; DRG, Mountainside, NJ, USA)] 
following the manufacturer’s instructions. All the information regarding specificity, 
detectability, and reproducibility for each of the assays can be accessed at the web site 
of the company. 
 
 Measurement of free cytosolic calcium mobilization ([Ca2+]i): As 
previously reported, changes in [Ca2+]i in single cells were measured using fura-2AM 
(50,000 cells/coverslip; Molecular Probes, Eugene, OR)23,30. Briefly, primary pituitary 
adenoma cells were grown onto glass cover slips for 36-48h (35-mm plates), and then 
incubated for 30 min at 37ºC with fura-2AM in phenol red-free DMEM containing 20mM 
NaHCO3 (pH 7.4). Coverslips were washed with phenol red-free DMEM and set on a 
Sykes-Moore chamber (Bellco Glass, Madrid, Spain) and placed on an inverted 
microscope Eclipse TE2000-E (Nikon, Tokyo, Japan) coupled to a digital camera ORCA II 
BT (Hamamatsu Photonics, Hamamatsu, Japan). Cells were examined for changes in 
[Ca2+]i after the appropriate treatment (native ghrelin, In1-19 or In1-40) using a 40x 
objective with Immersion Oil Type NF (Nikon, Tokyo, Japan) while exposed to alternating 
340-380 nm light beams, and the intensity of light emission at 505 nm was measured 
every 5 seconds using MetaFluor Software (Imaging Corp., West Chester, PA, USA). 
Phenol red-free DMEM and ionomycin (Sigma-Aldrich, Madrid, Spain) were used as 
negative and positive control, respectively. Changes in [Ca2+]i in CHO-K1 cell line 
expressing recombinant GHSR1a or GHSR1b receptor were measured using Calcium 4 
Explorer Kit (Molecular Devices, Sunnyvale, CA, USA). Briefly, cells were incubated at 
37°C, 5% CO2 overnight in growth media. After 24 hours, growth media was replaced 
with Calcium 4 indicating dye in HBSS buffer containing 20 mM HEPES and 0.1% BSA 
and incubated for 1 hour at 37°C. Fluorescent signals were then monitored using the 
FLIPR Tetra (Molecular Devices, Sunnyvale, CA, USA) during which cells were stimulated 
with compounds. Dose-response curves were analyzed using GraphPad Prism v5.04 (La 
Jolla, CA, USA). 
 
 Measurement of ERK1/2 and Akt signaling pathways by western blotting: 
500,000 cells were cultured in 6-well plates and incubated for 8 minutes with acylated 
ghrelin, acylated In-19 and vehicle-treated controls. Briefly, after the corresponding 
treatment, medium was removed and cells were washed twice using PBS, detached 
using a scrapper and immediately lysed in pre-warmed SDS-DTT sample buffer at 65ºC 
(62,5mM Tris-HCl, 2% SDS, 20% glycerol, 100mM DTT and 0,005% bromophenol blue) 
followed by sonication for 10 seconds and boiling for 5 minutes at 95º C as previously 
described49,50. Proteins were separated by SDS-PAGE and transferred to nitrocellulose 
membranes (Millipore, Darmstadt, Germany), and then membranes were blocked with 
5% non fat dry milk in Tris-buffered saline/0.05% Tween 20 and incubated with the 
primary antibodies for ERK1/2, p-ERK1/2, p-Akt, Akt and the appropriate secondary 
antibodies [primary total ERKs (Santa Cruz, CA, USA); primary p-ERK1/2, p-Akt, and Akt 
as well as, secondary anti-rabbit antibody from Cell Signaling (Danvers, MA, USA)]. 
Proteins were developed using an enhanced chemiluminescence detection system (GE 
Healthcare, UK) with dyed molecular weight markers. A densitometric analysis of the 
bands was carried out with ImageJ software51. Relative phosphorylation of ERK and Akt 
was obtained from normalization of p-ERK1/2 or p-Akt against the total ERK1/2 or β-Akt, 
respectively. 
 
Measurements of cell viability: As previously reported, cell viability was 
estimated using alamar-blue reagent (10,000 cells/well-plate; Biosource International, 
Camarillo, CA, USA)30,50,52. Briefly, cells were serum-starved for 12-16h before the 
measurements and treated with serum-free medium containing 10% alamar-blue for 3h. 
Reduction of alamar-blue reagent was quantified exciting at 560 nm and reading at 590 
nm using the FlexStation III system (Molecular Devices, Sunnyvale, CA, USA). 
Subsequently, media was replaced by serum-containing alamar-blue free medium and 
incubated for additional 24-72h, measuring the alamar-blue reduction every 24h. In 
experiments using the AtT-20 cell line, IGF1 and Paclitaxel (Sigma-Aldrich, Madrid, 
Spain) were used as positive and negative controls, respectively. 
 
Measurements of apoptosis: To evaluate the apoptotic rate in GH-oma and 
ACTH-oma cells, 150,000 cells/well were plated and cultured for 36-48h. Then, cell 
cultures were incubated for 12h with AG, acylated In1-19, hydrogen peroxide (used as 
positive control) and vehicle-treated controls. After the incubation period, culture cells 
were processed as follows: step-1) media were collected, centrifuged 5 min at 1,200 
rpm and, the supernatant was discarded and the pellet was maintained; step-2) cells 
were washed with PBS, detached using a cell scrapper and collected together with the 
previous pellet (step-1). Then, the mixture was centrifuged 5 min at 1,200 rpm and the 
supernatant was discarded while the pellet was processed following manufacturer’s 
instructions of Annexin-V-FITC/propidium iodide staining assay (Bender Medsystems, 
Barcelona, Spain) and measurement were carried out by flow cytometry (Beckman 
Coulter, Coulter Epics XL, Madrid, Spain). 
 
Statistical analysis: Data were evaluated for heterogeneity of variance using 
the Kolmogorov–Smirnov test. Statistical differences were assessed by Mann–Whitney U 
test or by one-way or two-way ANOVA followed by Fisher’s test. Correlations were 
studied using Spearman's correlation test. Data are expressed as median ± interquartile 
ranges or as mean ± S.E.M. p<0.05 was considered significant. All statistical analyses 
were performed using the GraphPad Prism5 (La Jolla, CA, USA) or the SPSS software 
(IBM, New York, NY, USA). 
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Figure legends 
 
Figure 1. Expression profile of ghrelin system components in normal and 
tumoral pituitaries. The expression of ghrelin system components (ghrelin, In1-ghrelin 
variant, MBOAT4, GHSR1a and GHSR1b) was determined by qPCR in a battery of 166 
pituitary adenomas (including 75 GH-omas, 28 ACTH-omas, 57 NFPAs and 7 PRL-omas) 
and compared to the expression levels found in 11 normal pituitaries (NPs). Data 
represent median ± interquartile range of absolute expression levels (copy number) of 
each transcript adjusted by the expression levels of a control gene (ACTB). Asterisks (*, 
p<0.05; **, p<0.01 and ***, p<0.001) indicate data that differ from normal pituitary 
expression by Mann-Whitney U test. 
 
Figure 2. Basal and SST-induced phosphorylation of ERK1/2 and Akt in 
somatotropinomas. Representative Western Blots and quantification of levels of p-
ERK1/2 / total ERK1/2 and p-Akt / total Akt in response to ghrelin and In1-19 (100nM) 
on GHomas (n=4). Data are expressed as percent of vehicle-treated controls (set at 
100%) within experiment. Values represent the mean ± S.E.M. Asterisks (* p<0.05, ** 
p<0.01) indicate significant differences between vehicle- and peptide-treatments. 
 
Figure 3. Hormone secretion in response to ghrelin and In1-ghrelin in tumoral 
pituitaries. Effect of 4- and/or 24-h treatment of ghrelin (100nM) and/or In1-ghrelin 
derived peptides (In1-19 and In1-40; 100nM) on GH, ACTH and PRL release from human 
GH-omas (A; n=3-7), ACTH-omas (B; n=3-9), and PRL-omas (C; n=2) primary cell 
cultures, respectively, determined by commercial ELISA kits. Data are expressed as 
percent of vehicle-treated controls (set at 100%) within experiment. Values represent 
the mean ± S.E.M. Asterisks (* p<0.05, ** p<0.01; *** p<0.001) indicate significant 
differences between vehicle- and peptide-treatments. 
 
Figure 4. Ghrelin and In2-ghrelin variant in AtT20 cell line. A) Expression profile 
of the ghrelin system (Ghrelin, In2-ghrelin variant, Mboat4 enzyme and Ghsr) in AtT-20 
cell line obtained by qPCR. Data represent absolute mRNA copy number adjusted by a 
normalization factor (NF) calculated from the expression levels of three control genes 
(Actb, Ppia and Hprt); B) ACTH secretion in response to 4h ghrelin and In2-ghrelin 
variant treatment; C)Cell viability in response to ghrelin and In2; IGF-1 and Paclitaxel 
were used as positive and negative controls, respectively. Values represent the mean ± 
S.E.M of 3-5 independent experiments. Asterisks (* p<0.05, *** p<0.001) indicate data 
that significantly differ from controls. 
 
Figure 5. Cell viability and apoptosis in response to In1-ghrelin and/or ghrelin 
in tumoral pituitaries. Effect of 24-, 48- and/or 72-h treatment of acylated ghrelin 
(100nM) and/or acylated In1-ghrelin derived peptides (In1-19 and In1-40; 100nM) on 
cell viability in human GH-omas (A; n=5-17), ACTH-omas (B; n=2-8), NFPAs (C; n=3-
15), and PRL-omas (D; n=2-3) primary cell cultures, determined by alamar-blue 
reduction. Effect of 12-14 h treatment with acylated ghrelin and In1-19 (100nM) on 
apoptotic rate in human GH-omas (E; n=3) and ACTH-oma (F; n=1), determined by 
Annexin V/Propidium Iodide staining. Data are expressed as percent of vehicle-treated 
controls (set at 100%) within experiment. Values represent the mean ± S.E.M. Asterisks 
(* p<0.05, ** p<0.01; *** p<0.001) indicate significant differences between vehicle- 
and peptide-treatments. 
 
Figure 6. Cell viability in response to In1-ghrelin overexpression and silencing 
in tumoral pituitaries. Effect of 24-, 48- and/or 72-h overexpression of ghrelin (Ghr) 
and/or In1-ghrelin (In1) on cell viability in human GH-omas (A; n=4-11), NFPAs (B; 
n=2-3) and ACTH-omas (C; n=3) primary cell cultures, determined by alamar-blue 
reduction. Overexpression was induced by transfection with specific expression vectors 
containing the appropriate CDS of each variant. Effect of 24- and 48-h silencing of In1-
ghrelin (In1) expression on cell viability of individual human GH-omas (D; n=2) and 
NFPAs (E; n=2) primary cultures, determined by alamar-blue reduction. In1-ghrelin 
silencing was induced by transfection with specific siRNAs. Representative validation by 
qPCR of In1-ghrelin (black bar) and ghrelin (grey bar) overexpression (F), and silencing 
(G) of In1-ghrelin, demonstrating a decrease of In1-ghrelin mRNA expression (black bar) 
but no significant decrease of ghrelin mRNA expression (grey bar). Data are expressed 
as percent of control vectors (A, B, C. Mock; set at 100%) and control random siRNA (D, 
E. Scr: Scramble; set at 100%) within experiment, respectively. Values represent the 
mean ± S.E.M. Asterisks (* p<0.05, ** p<0.01; *** p<0.001) indicate data that 
significantly differ from mock or scramble controls. 
 
Figure 7. Working model summarizing the putative mechanisms and second 
messenger routes activated by ghrelin and In1-ghrelin in pituitary tumor cells. 
The data presented here analyzing different intracellular signaling pathways indicate that 
ghrelin and In1-ghrelin triggers ERK1/2 and Ca2+ mobilization, whereas only ghrelin 
activates Akt phosphorylation. We propose that an additional receptor besides GHSR1a 
may exist that would bind In1-ghrelin (and possibly acylated ghrelin) to evoke functional 
endpoints such as hormone release or cell proliferation. It contrast neither ghrelin nor 
In1-ghrelin would be able to act through GHSR1b. MBOAT4 (GOAT) is responsible for 
ghrelin acylation in Ser3, and as In1-ghrelin share this Ser3, it seems plausible that In1-
ghrelin may be acylated as well.  
Table 1. Demographic and clinical parameters of patients included in this study 
 
 GH-omas ACTH-omas NFPAs PRL-omas 
Number of cases 75 28 57 7 
Mean age (years) 42.7 35.9 56.5 32.7 
Gender (% of women) 51% 75% 39.6 42.8 
Tumor size (% macroadenomas) 92% 36% 100% 100% 
Extrasellar growth 84% 60% 87% 50% 
 
 
Table 2. Results from free cytosolic calcium kinetics assays in tumoral pituitary cells in 
response to ghrelin gene derived peptides. 
 
GH-omas        
 # samples Cells analyzed % cell resp. % Max. Error T resp. Error 
AG 27/27 1500 74.0 199.4 9.7 18.9 2.2 
In1-19 13/15 983 60.4 179.3 12.6 15.9 1.4 
In1-40 9/13 520 49.2 142.7 6.4 17.6 3.1 
        
ACTH-omas        
 # samples Cells analyzed % cell resp. % Max. Error T resp. Error 
AG 9/9 742 74.1 217.6 19.0 14.3 6.6 
In1-19 3/5 230 43.9 187.5 35.2 20.0 8.9 
In1-40 3/4 143 37.8 161.1 8.0 25.0 1.3 
        
NFPA        
 # samples Cells analyzed % cell resp. % Max. Error T resp. Error 
AG 9/15 408 29.4 162.0 9.1 23.6 7.9 
In1-19 7/12 367 18.0 152.8 10.9 14.0 3.0 
In1-40 1/6 29 10.3 118.7 2.3 55.0 8.5 
        
PRL-omas        
 # samples Cells analyzed % cell resp. % Max. Error T resp. Error 
AG 2/6 217 19.8 178.5 1.4 35.1 7.9 
In1-19 1/5 160 4.4 155.3 7.5 18.6 5.0 
In1-40 1/3 88 8.0 147.5 8.8 29.3 4.8 
 
#samples: number of responsive samples of the total of samples analyzed 
Cells analyzed: total of individual cells analyzed 
% cell resp.: percentage of responsive cells in responsive samples 
%Max.: percentage of maximum response  
T resp.: time of maximum response 
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Supplemental Table 1. Primers used for quantification of human and mouse transcripts 
 
Transcript 
Accession 
number 
Sense Antisense 
Size 
bp 
Human 
Ghrelin NM_016362.3 CACCAGAGAGTCCAGCAGAGA CCGGACTTCCAGTTCATC 132 
In1-ghrelin GU942497.1 TCTGGGCTTCAGTCTTCTCC GTTCATCCTCTGCCCCTTCT 215 
MBOAT4 NM_001100916.1 TTGCTCTTTTTCCCTGCTCTC ACTGCCACGTTTAGGCATTCT 161 
GHSR1a NM_198407.2 TGAAAATGCTGGCTGTAGTGG AGGACAAAGGACACGAGGTTG 148 
GHSR1b NM_004122.2 GGACCAGAACCACAAGCAAA AGAGAGAAGGGAGAAGGCACA 107 
ACTB NM_001101.3 ACTCTTCCAGCCTTCCTTCCT CAGTGATCTCCTTCTGCATCCT 176 
Mouse 
Ghrelin NM_021488.4 TCCAAGAAGCCACCAGCTAA AACATCGAAGGGAGCATTGA 126 
In2-ghrelin DO_993169 GCTGTCTTCAGGCACCATCT GTGGCTTCTTGGATTCCTTTC 226 
Mboat4 NM_001126314.2 ATTTGTGAAGGGAAGGTGGAG CAGGAGAGCAGGGAAAAAGAG 120 
Ghsr NM_177330.3 TCAGGGACCAGAACCACAAA CCAGCAGAGGATGAAAGCAA 71 
Actb M12481 CTGGGACGACATGGAGAAGA ACCAGAGGCATACAGGGACA 205 
Ppia NM_008907 TGGTCTTTGGGAAGGTGAAAG TGTCCACAGTCGGAAATGGT 109 
Hprt NM_013556 CAGTCAACGGGGGACATAAA AGAGGTCCTTTTCACCAGCAA 183 
 
 
Supplemental Table 2. Significant correlations between expression levels of ghrelin system 
components in pituitary adenomas1 
 
 
 
Ghrelin In1-ghrelin MBOAT4 GHSR1a GHSR1b 
GH-omas 
Ghrelin   0.512 *** 0.493***     
In1-ghrelin 0.512 ***   0.322 * 
  MBOAT4 0.493*** 0.322 *   
  GHSR1a 
   
  0.849 *** 
GHSR1b       0.849 ***   
       
ACTH-omas 
Ghrelin           
In1-ghrelin 
 
  0.510 * 0.560 * 
 MBOAT4 
 
0.510 *   
  GHSR1a 
  
0.560 *   
 GHSR1b           
       
NFPAs 
Ghrelin   0.343* 0.564 *** 0.375 **   
In1-ghrelin 0.343*   0.452 ** 0.352 * 0.436 ** 
MBOAT4 0.564 *** 0.452 **   0.601 *** 0.522 *** 
GHSR1a 0.375 ** 0.352 * 0.601 ***    
GHSR1b   0.436 ** 0.522 ***     
 
1Only significant correlations are shown in the table 
 
Supplemental Table 3. Half-maximal Calcium signaling activation (EC50) in response to 
GHRL-gene derived peptides 
GHSR1a-transfected cells GHSR1b-transfected cells 
Acylated 
Ghrelin 1.5 ± 0.4 >3000 
In1-19 2.8 ± 1.5 >3000 
In1-40 17.2 ± 2.2 >3000 
 
 
Supplemental Figure 1. Expression profile of ghrelin system components in normal and tumoral
pituitaries. The expression of ghrelin system components (ghrelin, In1-ghrelin variant, MBOAT4,
GHSR1a and GHSR1b) was determined by qPCR in a battery of 169 pituitary adenomas (including 75
GHomas, 29 ACTHomas, 57 NFPAs and 7 PRLomas) and compared to the expression levels found in 11
normal pituitaries (NPs). Data represent median ± interquartile range of absolute expression levels
(copy number) of each transcript adjusted by the expression levels of a control gene (ACTB). Asterisks
(*, p<0.05; **, p<0.01 and ***, p<0.001) indicate data that differ from NP expression by Mann-Whitney
U test.
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Abstract 
Context: Somatostatin analogs (SSA) represent a primary medical treatment for pituitary 
adenomas to control hormone secretion and/or tumor growth. However, some patients are 
unresponsive, or escape from SSA-therapy. Novel SSAs (e.g. pasireotide) may help to 
overcome this problem, which may relate to somatostatin receptor (sst1-ssr5) 
presence/abundance, availability or signaling. Objective: To clarify this issue, and better 
define the cellular/molecular features associated to octreotide and pasireotide responsiveness, 
systematic, side-to-side comparisons of their in vitro effects on different types of pituitary 
tumors are required. Design: A methodology was devised to evaluate, in parallel, the in vitro 
response to octreotide and pasireotide using pituitary adenoma cell cultures, by evaluating 
sst1-5 expression, cell signaling (free cytosolic Ca2+ levels, [Ca2+]i), hormone secretion, and 
cell viability, in a series of 85 samples (32 somatotropinomas, 15 corticotropinomas, 28 non-
functioning pituitary adenomas (NFPAs), 4 prolactinomas, and 6 normal pituitaries). Results: 
Somatotropinomas showed sst5>>sst2 expression, yet octreotide appeared to reduce [Ca2+]i 
more efficiently than pasireotide, while both SSA similarly decreased GH release, GH mRNA 
levels and somatotrope cell viability. Corticotropinomas expressed high sst5 levels, but 
displayed a limited response to pasireotide, while octreotide moderately reduced [Ca2+]i 
levels, ACTH release and cell viability. NFPAs, which expressed high sst3 levels, were 
poorly responsive to SSA, yet appeared to be more sensitive to octreotide treatment in terms 
of [Ca2+]i kinetics. Surprisingly, both SSA, especially pasireotide, increased cell viability in a 
relevant proportion of NFPAs. Prolactinomas preferentially expressed sst1 and were mostly 
unresponsive to SSA both in [Ca2+]i kinetics and proliferation. Finally, octreotide and 
pasireotide reduced [Ca2+]i kinetics in a distinct proportion of normal pituitary cell samples. 
Conclusions: Our results indicate that both SSA act on the main types of pituitary adenomas 
by exerting both similar and distinct effects on [Ca2+]i kinetics, hormone release, gene 
expression, and cell viability. Since no evident correspondence was found between the 
observed effects and the specific sst1-sst5 profile of the target tumors, it is plausible that 
additional factors, besides the simple abundance of a given sst, such as receptor dynamics, 
interaction and signaling would substantially influence the response of pituitary tumor cells to 
SSA. 
 INTRODUCTION 
Pituitary tumors are generally benign adenomas arising in the anterior lobe from a 
mono/oligoclonal origin, which display heterogeneous clinical manifestations derived from 
over secretion of a single hormone and/or size effects due to excess growth (1). Surgery is 
commonly the first line of treatment for most pituitary tumors, except for prolactinomas, 
which often respond favorably to medical treatment with dopamine analogs (e.g. cabergoline). 
Synthetic somatostatin (SST) analogs (SSA) represent a valuable first-line medical treatment 
for various types of pituitary tumors, particularly somatotropinomas, but also thyrotropinomas 
and corticotropinomas, owing to the widespread distribution of the SST receptors (sst1-5). 
These receptors (except sst4) are commonly expressed, simultaneously, at different levels and 
proportions, in normal pituitary cells, where they convey SST actions to regulate hormone 
release (2). In pituitary tumors, previous studies (3-6) have reported different expression 
patterns of sst1-sst5 depending on the type of tumor: High expression of sst2 and sst5 is 
typical in most GH- and TSH-secreting adenomas; sst5 predominates in corticotropinomas; 
sst3 and sst2 in non-functioning pituitary adenomas (NFPAs); and high sst1 and sst5 levels 
are found in prolactinomas. The ability of these ssts to activate various, often overlapping and 
cross-talking signaling pathways provides the basis for the inhibitory actions of SSA on 
hormone secretion, and, in some cases, cell proliferation and tumor growth. Indeed, the 
original, widely used sst2-preferring SSA octreotide and lanreotide represent, in their various 
formulations, versatile therapeutic tools in acromegaly, and in thyrotropinomas (2). 
Unfortunately, a relevant proportion of patients with these tumors are (or become) partially or 
totally resistant to these drugs, while other types of pituitary tumors such as corticotropinomas 
or non-functioning pituitary adenomas (NFPAs) are largely unresponsive to treatment with 
these SSA (2, 7), a phenomenon that could be related to the specific presence, abundance, 
availability and/or signaling properties of sst1-sst5 in a particular tumor. In an attempt to 
circumvent this problem and expand the therapeutic potential of SSA, novel analogs with 
multi-receptor binding profiles have been developed over the last decade, such as pasireotide. 
This novel SSA binds with high affinity to sst5, but also to sst2 and sst3 (and less potently to 
sst1), is already being applied to treat pituitary tumors in clinical practice, as it successfully 
controls a relevant proportion of Cushing’s disease-causing corticotropinomas (8, 9), and is 
also being currently tested for other indications, like acromegaly (Phase III Clinical trial (10)).  
In spite of the recent advances achieved in the clinical development of SSA, there are 
still relevant aspects on the mechanisms mediating the effects of different SSA on pituitary 
tumors that remain incompletely understood. In particular, for instance, few studies have 
addressed what are the actual differences and similarities of the direct actions of sst2-
preferring (e.g. octreotide) and multi-sst (e.g. pasireotide) SSA on the different classes of 
pituitary tumors, which are not exclusively dependent on their distinct sst-binding profile. 
Indeed, there is ample evidence that a number of different factors, besides receptor affinity, 
substantially influence the functional capacities of a given analog, from dynamics of receptor 
internalization, recycling and degradation, to selectivity in signaling pathway activation, or 
receptor-receptor interaction, thereby defining precisely their actions, which would also 
depend on the target cell type (11). Accordingly, in the present study we have carried out a 
systematic analysis of the direct in vitro actions of octreotide and pasireotide in a 
representative series of pituitary tumors that includes the main classes of adenomas, as well as 
samples from normal, non-tumoral human pituitary. Unlike previous reports comparing the in 
vitro actions of these SSA, which mostly studied separately a single type of pituitary adenoma 
using one or few techniques (12-21), here we have established an integrative methodology to 
evaluate, in parallel, the in vitro response of human primary pituitary tumor cell cultures to 
both SSA by assessing several functional parameters, which include key aspects in pituitary 
tumor pathology. Thus, ssts expression analysis using quantitative real-time PCR was carried 
out on the tissue samples wherein we measured SSA-induced kinetics of free-cytosolic 
calcium concentration ([Ca2+]i), to evaluate receptor-activation-signaling, and also hormone 
release, and cell viability, as suitable markers for the secretory and growth response of the 
corresponding tumor. Our results unveil both similarities and differences between the actions 
of octreotide and pasireotide in the same tumors (thus bearing the same sst pattern) which 
could not be attributed exclusively to their divergent binding profile. These data would help to 
better understand the specific actions of these distinct SSA at the pituitary level, and may 
facilitate the future improvement of treatment selection and help in the development of more 
effective therapies.  
 
MATERIALS AND METHODS 
 
Reagents 
 Unless otherwise indicated, the reagents and products used in this study were 
purchased from Sigma-Aldrich (Madrid, Spain). Fetal bovine serum (FBS) was purchased 
from PAA (Pasching, Austria); plastic material for cell culture was purchased from TPP 
(Trasadingen, Switzerland). Octreotide was obtained from GP-Pharm (Barcelona, Spain) and 
pasireotide was generously provided by Novartis Pharma AG (Basel, Switzerland) and 
administered at 100nM as previously reported (22). 
 
Patients, tissue collection and pituitary cell culture 
 Pituitary specimens were obtained during transsphenoidal surgery resections from a 
total of 91 pituitary adenomas (36 somatotropinomas, 16 corticotropinomas, 34 NFPAs and 5 
prolactinomas), after informed consent was provided by each patient and with the approval of 
the University of Córdoba/IMIBIC and Hospital Ethics Committees. Additionally, 6 pieces 
corresponding to normal pituitaries were used in the study; these tissue pieces were resected 
during surgical removal of a pituitary adenoma. In all cases, tissue phenotype confirmation 
was supported by three separate methods as previously described: examination by an 
anatomopathologist, testing the hormonal phenotype using single-cell secretion, and 
molecular screening by quantitative real-time PCR (qPCR) (23); each pituitary piece was 
placed in sterile cold medium after surgery and transferred to our laboratory within 1-3 h on 
ice, where tissues were dispersed into single cells by enzymatic and mechanical disruption as 
previously reported (23). Available demographic and clinical data are in summarized in Table 
1. 
 
RNA isolation, reverse transcription, and analysis of gene expression by quantitative 
real-time PCR (qPCR) 
Total RNA extraction, quantification, reverse-transcription, qPCR procedure and 
primer sequences used to measure mRNA expression of the genes included in this study (sst1-
sst5, GH, PRL, POU1F1, ACTB) have been previously reported elsewhere by our group (3, 
4). As a control for variations in the amount of RNA used in the reverse-transcription reaction 
and its efficiency, the number of copies of each transcript was adjusted by beta-actin (ACTB) 
expression (23). 
 
Measurement of free cytosolic calcium concentration ([Ca2+]i) 
Changes in [Ca2+]i after treatment with octreotide and pasireotide were tracked using 
fura-2AM (Molecular Probes, Eugene, OR, USA) and the MetaFluor Software (Imaging 
Corp., West Chester, PA, USA) as previously described in detail (23, 24). 
 
Evaluation of pituitary hormone release 
Primary adenoma cell cultures were incubated with octreotide and pasireotide 
(somatotropinomas: 4- and 24-hour; corticotropinomas: 24-h incubation) in absence of serum. 
After treatment, media were collected and stored at -20ºC until hormone concentration was 
measured using commercial ELISAs [GH and ACTH (EIA-3552 and EIA-3647, respectively; 
DRG, Marburg, Germany). Whenever possible, in the case of somatotropinomas, cells were 
recovered for RNA analysis (see above). All the information regarding specificity, 
detectability, and reproducibility for each of the assays can be accessed at the web site of the 
company. 
 
Analysis of cell viability 
Cell viability was evaluated in cultured cells treated with octreotide and pasireotide 
using alamar-Blue reagent (Biosource International; Camarillo, CA, USA) and the 
FlexStation 3 system (Molecular Devices; Madrid, Spain) as previously described (23, 24).  
 
Statistical analysis 
Statistical analyses were performed by unpaired parametric t-test and nonparametric 
Mann-Whitney test according to normality, assessed by Kolmogorov-Smirnov test. We 
compared the effect of octreotide or pasireotide vs. vehicle-treated control (set at 100%). Data 
expressed as mean ± SEM. p<0.05 was considered significant. When p values ranged between 
<0.1 and >0.05, a trend for significance was indicated where appropriate. All statistical 
differences were assessed using GraphPad Prism 6 (GraphPad Software; La Jolla, CA, USA). 
 
 RESULTS 
The main aim of this study was to perform a systematic, comparative analysis of the 
effect of two SSA with distinct sst1-5 binding profile, octreotide and pasireotide, on basic 
functional parameters in the main types of pituitary adenomas. As a first step, mRNA 
expression levels of ssts were quantified in each tumor, to assess their informative potential as 
predictor of response. Then, effects of octreotide and pasireotide were evaluated, in parallel, 
on several key functional parameters: 1) Dynamics of the levels of [Ca2+]i, an essential second 
messenger required for hormone secretory vesicle release (25), whose microfluorimetric assay 
in single cells provide accurate information about several parameters, including, a) percentage 
of responsive cells (PRC), which indicates the percentage of cells that deploy a 
positive/negative response in [Ca2+]i kinetics in response to SSA; b) percentage of maximal 
response of the cells (PMR), which indicates the degree of the positive or negative change in 
[Ca2+]i reached; and c) time (T) to maximal response of cells responsive to SSA. 2) Hormone 
release was evaluated in GH- and ACTH-secreting adenomas, and mRNA expression in GH-
secreting adenomas. 3) Cell viability was assessed after 24-, 48- and 72-h incubation with 
SSA. 
1. Effects of octreotide and pasireotide on somatotropinomas 
In the present series of tumor samples, somatotropinomas (n=32) displayed on average 
high expression levels of sst5 and also sst2, followed by lower levels of sst3 and sst1 (Figure 
1A). This, in principle, would enable SSA, especially pasireotide, to act effectively on these 
tumors. Regarding their hormonal phenotype, the majority of these tumors expressed GH 
exclusively and not PRL (only present in a 20% of adenomas, with significant lower levels 
than GH; data not shown). Octreotide and pasireotide similarly decreased, on average, the 
levels of [Ca2+]i (23.5 vs. 24.8%; Figure-1B). However, adenomas appeared to be more 
responsive to octreotide than to pasireotide, both in terms of the overall proportion of tumors 
showing a [Ca2+]i response to each drug (15/21 vs. 11/21, respectively), and in the percentage 
of responsive cells within each tumor (PRC; 48.8% for octreotide vs. 32.3% for pasireotide ; 
Figure-1B). In line with this, octreotide and pasireotide decreased GH release in 2/2 cultures 
to a similar extent after 4h treatment (34.9 vs. 27.9%; Figure-1C, left panel) and in 7/7 and 
5/5 cell cultures, respectively, after 24h (24.8 vs. 27.9%; Figure-1C, right panel), as compared 
to vehicle treated cells. Likewise, both octreotide and pasireotide decreased mRNA levels of 
GH, but not of PRL, after 24h incubation (33.9 vs. 35.4%) without altering POU1F1 levels 
(Figure-1D, left-panel). In clear contrast, while pasireotide treatment drastically reduced sst2 
levels (44.7%) and induced an apparent, non-significant increase on sst5 levels (184.7%), 
octreotide did not significantly alter the expression levels of any ssts (Figure-1D, right-panel). 
In addition, the effect of SSA on cell viability was evaluated in 13 samples. Octreotide 
slightly, but significantly, decreased cell viability in 13/13 cell cultures after 24h (12.2%), in 
9/9 after 48h (16.4%) and 8/9 after 72h (15.1%), whereas pasireotide decreased cell viability 
in 13/13 after 24h (12.8%), in 9/9 after 48h (14.3%) and 8/9 after 72h (16.1%) (Figure-1E). 
2. Effects of octreotide and pasireotide on corticotropinomas 
Corticotropinomas (n=15) expressed, on average, high levels of sst5, followed by sst2, 
which would enable a positive response to SSA, especially pasireotide (Figure-2A). In terms 
of hormone expression, these samples almost exclusively displayed high mRNA levels of 
POMC, whereas only a moderate expression of PRL was found in some tumors (data not 
shown). Both octreotide and pasireotide were able to decrease [Ca2+]i kinetics in vitro in 
roughly half of the corticotropinomas studied (4/10 and 5/9, respectively); yet, unexpectedly, 
octreotide appeared to be more efficient than pasireotide, as it exerted a greater degree of 
inhibition (31.3 vs. 17.5%) in a higher percentage of cells (56.1% vs. 12.9%; Figure-2B) and, 
in a shorter period of time (31s vs. 46s). In line with these results, 24h incubation with 
octreotide inhibited ACTH release in 2 of the three tumors studied [43.2% and 29.9% 
inhibition], while pasireotide only induced a non-significant reduction trend (∼20%) in 2 of 
the 4 tumors assayed (Figure-2C). Similarly, octreotide induced a moderate, albeit significant 
reduction in cell viability in 2 of the three tumors studied (15.3% at 24h, p<0.05), whereas, in 
contrast, pasireotide did not evoke any comparable, significant reduction in cell viability in 
the 2 tumors studied (Figure-2D).  
3. Effects of octreotide and pasireotide on non-functioning pituitary adenomas (NFPAs) 
 The NFPAs analyzed in the present study were characterized by high sst3 expression, 
followed by lower levels of sst2 and the rest of ssts (n=28; Figure-3A); suggesting the 
possibility that pasireotide actions on NFPAs, given its a higher affinity to sst3, might be 
more effective than those of octreotide. As expected, CGA (α subunit), FSHB, and LHB were 
highly expressed in this type of tumors (data not shown) . By and large, cultured cells derived 
from NFPAs were rarely —and poorly— responsive to the two compounds tested. Octreotide 
appeared more effective than pasireotide (7/18 vs. 3/18), although it only evoked a moderate 
inhibition in [Ca2+]i kinetics (79.8 vs. 87.5%), in a reduced subset of cells (38.9 vs. 16.7%; 
Figure-3B). We could not corroborate whether NFPAs also have a differential response to 
these compounds in terms of hormone release as these tumors respond poorly to inhibiting (or 
releasing) factors in altering their secretory activity. In contrast, both compounds were able to 
exert clear (and divergent) responses in terms of cell viability in NFPAs, which were 
consequently classified in two different groups: “inhibitory responders” or “stimulatory 
responders”. Specifically, octreotide tended to moderately (non-significantly) decrease cell 
viability in 5/16 cell cultures after 24h (16.5%), in 2/8 after 48h (12.5%), and in 2/7 after 72h 
(8.5%); while pasireotide only appeared to exert comparable, also non-significant action on 
cell viability in 4/15 cell cultures after 24h (18.7%), in 1/7 after 48h (9.6%), and in 1/4 after 
72h (6%)  (Figure-3C). On the other hand, octreotide consistently induced moderate, albeit 
significant increases in cell viability as compared to vehicle-treated cells in 11/16 cell cultures 
after 24h (23.5%), in 5/8 after 48h (8.9%), and in 2/6 after 72h (7.7%). Likewise, pasireotide 
modestly, but significantly augmented cell viability in 11/15 NFPA cell cultures after 24h 
(35.3%), in 6/7 after 48h (14.7%), and in 3/4 after 72h (33.5%) (Figure-3D). 
4. Effects of octreotide and pasireotide on prolactinomas 
Prolactinomas in this series were characterized by high sst1 expression, with lower 
levels of the other ssts (n=4; Figure-4A). Regarding hormone expression, PRL was 
exclusively and very highly expressed in these prolactinomas (data not shown), which were 
resistant to treatment with cabergoline. In fact, cells derived from these tumors also displayed 
poor responses to SSA. Specifically, octreotide decreased [Ca2+]i (45.6%) in 2/4 cell cultures, 
but only in a very low percentage of the tumor cells (7.0%), whereas it moderately increased 
[Ca2+]i (26.9%) in 1/4 cell cultures, and also in a low percentage of the cells (5.9%) (Figure-
4B). In contrast, pasireotide did not evoke any appreciable [Ca2+]i response (Figure-4B). In 
terms of cell viability, both octreotide and pasireotide were able to decrease cell viability after 
48-72h in 1 out of 3 tumors examined (Figure-4C). 
5. Effects of octreotide and pasireotide on normal pituitary 
The set of normal pituitary samples analyzed were characterized by high sst5 
expression levels, with lower levels of sst2 and very low of sst3 and sst1 (Figure 5A). In 
terms of hormonal phenotype, as expected, GH and PRL were highly expressed, followed by 
POMC, CGA, and LHB/FSHB, while TSHB was faintly expressed (data not shown). 
Octreotide appeared less effective than pasireotide in decreasing [Ca2+]i (2/5 vs. 4/5 cell 
cultures). However, in responsive cultures, octreotide affected more cells (51.9 vs. 23.7%) 
and caused reductions of comparable amplitude to pasireotide (24.0 vs. 24.9%; Figure-5B). 
We were able to test SSA effects on cell viability in cells derived from one normal pituitary, 
where pasireotide, but not octreotide, significantly decreased cell viability after 24- (11.2%), 
48- (18.4%) and 72-hour (16.7%) of incubation (Figure 5C).  
DISCUSSION 
The assessment of the sst1-sst5 expression profiles in the present tumor series revealed 
that they compare well, by and large, with those described in previous studies for each of the 
tumor types examined (3-5), thereby supporting the contention that the samples investigated 
provide a representative picture of the tumors under study. On the other hand, it is important 
to note that the actual, precise sst1-sst5 profile in each tumor examined did not always match, 
necessarily, that observed, on average, for its corresponding tumor type. It is widely —and 
reasonably— assumed that the actions of a specific SSA in a given pituitary tumor would 
result from the functional correspondence between the sst1-sst5 binding profile of that SSA 
and the pattern of sst1-sst5 expression in the tumor. Accordingly, it has been suggested by 
different authors that, in the future, recommendations to select a specific SSA could be done 
on the basis of sst expression pattern, e.g. octreotide would be recommendable when sst2 is 
highly and predominantly expressed, whereas high expression of sst5, and sst2, sst3, or sst1 in 
pituitary adenomas would predict pasireotide responsiveness (6). However, this logical 
contention, which likely applies in general terms, when large numbers of tumors or patients 
are considered on average, might not be similarly evident on an individual tumor basis, and, 
anyhow, such a theoretical assumption has not been unequivocally demonstrated through 
experimental testing so far. In fact, previous studies have indicated that sst2 presence in 
somatotropinomas positively correlated with in vivo SSA response (26, 27), and a recent 
study revealed that octreotide-responsive patients were characterized by high sst2 and low 
sst5 presence, while octreotide-resistant patients show high sst5 expression (28). However, in 
the present study, although somatotropinomas were characterized by sst5>>sst2 expression, as 
previously described (4, 5, 26), we observed that octreotide and pasireotide induced in vitro 
comparable levels of inhibition of both, GH release after 4- or 24-h treatment, and of cell 
viability at 24, 48, and 72h. Moreover, it was noteworthy that pasireotide evoked less 
responses from tumor cells than octreotide in terms of [Ca2+]i kinetics, which would argue 
against the theoretical superiority of pasireotide predicted by the higher sst5 levels observed 
in these GH tumors. The reason for these latter differences is still unknown, but, as pointed 
earlier, could be related to the existence of distinct, tumor-specific sst1-sst5 distribution 
patterns, receptor-agonist and receptor-receptor interaction and dynamics, resulting in 
activation of different signaling pathways, etc. In any case, our data suggest that the mere 
abundance or paucity of a given, single sst would not provide sufficient support to explain the 
level of response of a somatotropinoma to a SSA with strong affinity for that specific 
receptor, and, thus, that additional mechanisms should be required to explain the precise 
actions of each SSA in a tumor target cell. 
On the other hand, our in vitro results are in line with recent comparative in vivo 
analysis of octreotide and pasireotide treatment (29), where both compounds suppressed 
similarly GH levels, being pasireotide more efficient than octreotide, since more patients were 
biochemically controlled after 12 month-treatment, although concerns have been raised about 
pasireotide doses being higher than those of octreotide, and, on different grounds, regarding 
adverse events related to hyperglycemia, more frequent in pasireotide-treated patients. 
Interestingly, in our study, differences between the actions of both SSA were found in the 
control of gene expression, since both analogs similarly decreased GH mRNA, but, while 
octreotide did not appear to alter sst expression, pasireotide decreased sst2 levels and 
moderately augmented sst5 expression, a receptor-specific positive feedback effect that could 
potentially contribute to enhance in vivo responsiveness to this SSA (29). Thus, on the whole, 
our results illustrate a substantial similitude between the actions of octreotide and pasireotide 
on GH secretion and cell survival in somatotropinomas in vitro, with some differences in 
regulation of Ca2+ signaling and sst expression. This would suggest that both analogs may 
exert comparable, albeit not identical effects at the pituitary level in acromegalic patients, thus 
raising the possibility that some of the differences observed in their in vivo actions may relate 
to extra-pituitary effects, which could help to explain, for example, the differential in vivo 
response in terms of IGF1 decrease (29), and may also be responsible for hyperglycemia 
events (29, 30). 
Analysis of corticotropinomas showed the typical sst5 predominant profile, yet, our 
results on [Ca2+]i kinetics, ACTH release and cell survival demonstrated that these tumors are 
significantly responsive, in vitro, to octreotide treatment, similar to that previously reported 
on primary cultures (16, 31) and in the mouse corticotropinoma AtT-20 cell line (16, 17, 31). 
Our data is also in keeping with (and extends) the accepted view that octreotide may exert 
strikingly divergent actions in vivo and in vitro on corticotropinomas. Indeed, it is well known 
that glucocorticoids downregulate sst2, affecting octreotide response in corticotropinomas 
(17, 21), which suggests that octreotide therapy in untreated Cushing’s disease patients 
presenting high levels of cortisol would be ineffective in vivo as previously reported in small 
series of Cushing’s disease untreated patients (12, 32-34). Additionally, a recent study, using 
primary corticotropinoma cell cultures demonstrated that in cortisol-normalized patients, sst2 
expression is increased at the mRNA but not at the protein levels (21), which led the authors 
to suggest that a pharmacological treatment to decrease cortisol levels, such as ketoconazole, 
followed by octreotide therapy may be an effective option. The reason for the clear responses 
observed in this study to octreotide may relate to a recovery of sst2-related responsiveness, 
but the role of other ssts, particularly sst5, should not be discarded. In marked contrast, and to 
our initial surprise, pasireotide did not induce any significant response in terms of ACTH 
release or cell viability in the corticotropinomas studied, where only a faint effect was 
observed on [Ca2+]i kinetics. These negative results are not in line with previous in vitro 
studies (16, 17, 21, 31, 35), wherein pasireotide markedly reduced ACTH release. However, 
when viewed from a broader perspective, our present data may not be so unexpected, since in 
in vivo studies, pasireotide has been shown to normalize urinary free cortisol only in 17-29% 
of the patients (8, 9, 36), thus raising the possibility that the limited number of cases 
examined in our study only included unresponsive tumors. However, the lack of effect of 
pasireotide on these corticotropinomas despite their high expression levels of sst5 and also 
sst2, and their clear response to octreotide, strongly suggest that additional, still unknown 
mechanisms, distinct from the mere presence of a given receptor target, are required for a 
drug such as pasireotide to achieve its desired functional inhibitory effect o ACTH-producing 
tumors. 
The sst expression profile observed in NFPAs (sst3>>sst2>sst5) is similar to that 
reported previously (4), and suggested a possible responsiveness to pasireotide. However, our 
data demonstrate that only a small proportion of NFPA are responsive, in vitro, to both SSA, 
at least in the parameters evaluated. Moreover, some of the effects observed could be 
considered as paradoxical and, from a clinical perspective, undesirable. Indeed, cell viability 
assay demonstrated that both SSA, and particularly pasireotide, might increase cell viability 
compared to vehicle-treated cells in the majority of responsive tumors. Similar stimulatory 
actions of pasireotide (19) and of a sst5 specific agonist (15) have been described previously 
in NFPAs, but the precise underlying mechanisms and the specific sst involved remain 
unclear. A reduction in cell viability can result from decreased cell growth and/or activation 
of apoptosis; whereas, an increase of viability compared to control cell cultures indicates that 
these compounds may protect primary cells from natural cell death or may activate survival or 
proliferative mechanisms in these cells. In the tumors examined here, there were no statistical 
differences in the sst expression profile between inhibitory responders and stimulatory-
responder populations. However, the fact that sst3 is uniquely expressed at high levels in 
NFPAs and that pasireotide seems more effective in stimulating cell viability in these tumors 
invites speculation that this receptor may be involved in such responses. Nevertheless, further 
studies should be required to elucidate the precise role of this and the rest of ssts in this 
unique response of NFPAs, which, as such, already adds potentially useful information for the 
current understanding of SSA effects on these tumors. Actually, despite promising in vivo 
experiences with octreotide treatment in patients that refuse surgical treatment (37) and 
patients not cured after surgery (38), which showed stabilized tumor size in most cases (but 
not tumor volume reduction), the poor in vitro response and the paradoxical increases in cell 
viability reported in response to both SSA, discourages the use of SSA as first-line treatment 
in NFPAs. 
Prolactinomas are often responsive to dopamine agonists. However, 10% of patients 
fail to normalize PRL levels and tumor growth (20). SSA therapy has been proposed as an 
alternative, since prolactinomas express ssts and several works demonstrated that SSA are 
able to inhibit PRL release in prolactinoma primary cell cultures (14, 39) and germane cell 
lines (40). Our results showed that octreotide decreased cell viability in one prolactinoma 
after 48-72h treatment and only inhibited [Ca2+]i in a very low proportion of cells, pasireotide 
being even less effective despite the high levels of sst1 expression in these tumors. These 
results are in keeping with in vivo studies, which did not find consistent inhibitory effects (41-
43). It has been proposed that combining SSA with dopamine agonists could enhance the 
response to treat resistant prolactinomas (44).  
Finally, we were also able to evaluate the effect of octreotide and pasireotide on a 
limited set of normal pituitary cell cultures. This revealed that, similarly to in vivo analyses on 
healthy volunteers with octreotide (45, 46), and pasireotide (47-49), where both SSA were 
able to act on normal pituitary by decreasing hormone levels, particularly GH, in our studies 
both SSA directly acted on pituitary cells to evoke decreases in [Ca2+]i kinetics, and 
pasireotide, but not octreotide, also reduced cell viability after 24, 48 and 72h treatment in cell 
cultures derived from a normal pituitary. 
In summary, our results indicate that both SSA act on the main types of pituitary 
adenomas by exerting both similar and distinct effects on [Ca2+]i kinetics, hormone release, 
gene expression and cell viability. However, we did not observe any evident correspondence 
between the effects observed and the specific sst1-sst5 profile of the target tumors. Hence, the 
picture that emerges is that there might not be a simple predictive correspondence between the 
presence of a sole receptor and the response to a given SSA with high affinity for this 
receptor, but that other factors may substantially influence the response of pituitary tumor 
cells, such as the proportion of other receptors for which the SSA may not have high affinity, 
the signaling status of the target cell, etc. Therefore, further studies are warranted to better 
understand the functional actions of the two SSA investigated here as well as novel SSA that 
are in the pipeline, wherein the relevant endpoints and underlying mechanisms should be 
tested preferentially in the same ultimate targets for these drugs, i.e. the primary pituitary 
tumor cells, as they may provide a more precise and realistic portrait of the actual response 
that can be expected and, hopefully, predicted, for a given type of tumor.
FIGURE LEGEND 
 
Figure 1: GH-secreting adenomas. (A) sst mRNA expression profile adjusted by beta-actin 
(ACTB) (n=29); (B) Summarized table of free cytosolic calcium kinetics assay: n stands for 
“responsive samples/total samples” analyzed; proportion of responsive cells (PRC) showing 
changes in [Ca2+]i levels in response to SSA ; percentage of maximum response (PMR) and 
time of response to SSA administration are also indicated; data are indicated as mean ± SEM; 
(C) Effect of SSA on GH release after 4- (octreotide and pasireotide: n=2) and 24-h 
(octreotide: n=7; pasireotide: n=5) incubation. Values are expressed as percent of vehicle-
treated controls, set at 100% within experiment; (D) GH, PRL, POU1F1, sst2 and sst5 mRNA 
expression profile in response to SSA (octreotide and pasireotide: n=3); (E) Cell viability (24-
72h treatment) in response to octreotide (n=13/9/8 at 24/48/72h, respectively) and pasireotide 
(n=13/9/8 at 24/48/72h, respectively). Values are expressed as percent of vehicle-treated 
controls, set at 100% within experiment. Asterisks show significant differences between SSA 
treated and vehicle-treated controls (* p<0.05, *** p<0.001). 
 
Figure 2: ACTH-secreting adenomas. (A) sst mRNA expression profile adjusted by beta-
actin (ACTB) (n=12); (B) Summarized table of free cytosolic calcium kinetics assay: n stands 
for “responsive samples/total samples” analyzed; proportion of responsive cells (PRC) 
showing changes in [Ca2+]i levels in response to SSA ; percentage of maximum response 
(PMR) and time of response to SSA administration are also indicated; data are indicated as 
mean ± S.E.M.; (C) Effect of SSA on ACTH release after 24-h incubation (octreotide: n=4; 
pasireotide: n=5). Values are expressed as percent of vehicle-treated controls, set at 100% 
within experiment; (E) Cell viability (24-72h treatment) in response to octreotide (n=4/2/1 at 
24/48/72h, respectively) and pasireotide (n=4/3/2 at 24/48/72h, respectively). Values are 
expressed as percent of vehicle-treated controls, set at 100% within experiment. 
 
Figure 3: Non-functioning pituitary adenomas. (A) sst mRNA expression profile adjusted 
by beta-actin (ACTB) (n=28); (B) Summarized table of free cytosolic calcium kinetics assay: 
n stands for “responsive samples/total samples” analyzed; proportion of responsive cells 
(PRC) showing changes in [Ca2+]i levels in response to SSA ; percentage of maximum 
response (PMR) and time of response to SSA administration are also indicated; data are 
indicated as mean ± S.E.M.; (C) Inhibitory response in cell viability assay (24-72h treatment) 
in response to octreotide (n=5/2/2 at 24/48/72h, respectively) and pasireotide (n=4/1/1 at 
24/48/72h, respectively). (D) Stimulatory response in cell viability assay (24-72h treatment) 
in response to octreotide (n=11/5/3 at 24/48/72h, respectively) and pasireotide (n=11/5/3 at 
24/48/72h, respectively). Values in C and D are expressed as percent of vehicle-treated 
controls, set at 100% within experiment. Asterisks show significant differences between SSA 
treated and vehicle-treated controls (* p<0.05, *** p<0.001). 
 
Figure 4: PRL-secreting adenomas. (A) sst mRNA expression profile adjusted by beta-actin 
(ACTB) (n=4); (B) Summarized table of free cytosolic calcium kinetics assay: n stands for 
“responsive samples/total samples” analyzed; proportion of responsive cells (PRC) showing 
changes in [Ca2+]i levels in response to SSA ; percentage of maximum response (PMR) and 
time of response to SSA administration are also indicated; data are indicated as mean ± 
S.E.M.; (C) Cell viability (24-72h treatment) in response to octreotide (n=3/3/3 at 24/48/72h, 
respectively) and pasireotide (n=3/3/3 at 24/48/72h, respectively). Values are expressed as 
percent of vehicle-treated controls, set at 100% within experiment. Asterisks show significant 
differences between SSA treated and vehicle-treated controls (*** p<0.001). 
 Figure 5: Normal pituitary. (A) sst mRNA expression profile adjusted by beta-actin 
(ACTB) (n=6); (B) Summarized table of free cytosolic calcium kinetics assay: n stands for 
“responsive samples/total samples” analyzed; proportion of responsive cells (PRC) showing 
changes in [Ca2+]i levels in response to SSA ; percentage of maximum response (PMR) and 
time of response to SSA administration are also indicated; data are indicated as mean ± 
S.E.M.; (C) Cell viability (24-72h treatment) in response to octreotide (n=2/1/1 at 24/48/72h, 
respectively) and pasireotide (n=2/1/1 at 24/48/72h, respectively). Values are expressed as 
percent of vehicle-treated controls, set at 100% within experiment. Asterisks show significant 
differences between SSA treated and vehicle-treated controls (* p<0.05).
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Table 1: Demographic and clinical data of patients included in the study 
Variable GH-omas ACTH-
omas 
NFPAs PRL-
omas 
Normal 
pituitary 
n 32 15 28 4 6 
Sex/Age  
(min-max) 
Male n=15 44(12-75) 
n=2 
33(23-43) 
n=14 
57(22-74) 
n=3 
35(18-47) n=0 
Female n=16 41 (12-62) 
n=13 
41(25-68) 
n=14 
51(27-75) 
n=1 
21 
n=6 
43(21-69) 
Missing data - - - -  
Pretreatment 
Untreated 6 1 20 - - 
SSA 20 - - - - 
SSA/DA 5 1 - - - 
DA - - 1 4 - 
Ketoconazole - 12 - - - 
Missing data 1 1 7 - - 
Size 
Macroadenoma 28 5 21 4 - 
Microadenoma 2 9 - - - 
Missing data 2 1 - - - 
Cure after 
surgery 
Cured 3 7 7 - - 
Biochemically 
controlled 3 - - - - 
Cured after 
radiotherapy 3 - - - - 
Cured after 
adrenalectomy - 1 - - - 
Active disease 14 2 11 3 - 
Missing data 9 5 10 1 - 
 
 
[Ca2+]i n PRC (%) PMR (%) Time (s)
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control octreotide pasireotide
4h 24h 24h 48h 72h
[Ca2+]i n PRC (%) PMR (%) Time (s)
Octreotide 4/10 56.1 68.7 ± 6.4 30.9 ± 10.7
Pasireotide 5/9 12.9 82.5 ± 1.6 46.1 ± 6.0
B
control octreotide pasireotide
A C D
24h 24h 48h 72h
[Ca2+]i n PRC (%) PMR (%) Time (s)
Octreotide 7/18 22.2 79.8 ± 2.2 56.1 ± 10.2
Pasireotide 3/18 17.2 87.5 ± 4.1 53.3 ± 15.7
B
control octreotide pasireotide
A C D
24h 48h 72h 24h 48h 72h
[Ca2+]i n PRC (%) PMR (%) Time (s)
Octreotide
2/4 7.0 54.4 ± 7.4 67.5 ± 2.5
1/4 5.9 126.9 ± 10.3 26.3 ± 2.1
Pasireotide 0/4 - - -
B
control octreotide pasireotide
A C
24h 48h 72h
[Ca2+]i n PRC (%) PMR (%) Time (s)
Octreotide 2/5 51.9 76.0 ± 2.9 58.5 ± 13.1
Pasireotide 4/5 23.7 75.1 ± 2.6 16.9 ± 16.9
B
control octreotide pasireotide
A C
24h 48h 72h
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Abstract 
 
Background: Pituitary adenomas are common neoplasms presenting notable morbidities due to 
excessive hormonal secretion or compression of intracranial structures, such as growth abnormalities, 
sexual-related dysfunctions, and cognitive and emotional disturbances. Somatostatin analogs and 
dopamine agonists have been largely used for the pharmacological treatment of pituitary adenomas; 
but surgical resection of the tumor is required in most cases. Hence, pharmacological companies are 
designing novel compounds to improve medical treatment. Chimeric somatostatin/dopamine 
compounds, such as BIM-23A760, an agonist for somatostatin receptors-2 and -5 and for dopamine 
receptor-2, have emerged as promising new approaches to treat pituitary adenomas. However, 
information on direct in vitro effects of BIM-23A760 in normal and tumoral pituitary is still limited 
and remains incomplete.  
 
Methods: Analysis of key functional parameters (free cytosolic Ca2+ kinetics, hormonal expression and 
secretion, cell viability and apoptosis) was carried out, in response to BIM-23A760 in the main types 
of human pituitary adenomas (n=74; including GH and ACTH-producing adenomas causing 
acromegaly and Cushing’s disease, respectively) as well as in normal pituitaries from humans (n=5) 
and from a non-human primate model (olive baboon; n=3). 
 
Results: BIM-23A760 decreased GH and PRL expression/release in human and baboon normal 
pituitaries, and inhibited ACTH and LH release in baboon normal pituitaries. BIM-23A760 
differentially impacted Ca2+ signaling, hormone/receptor expression, hormone secretion, and other 
clinically relevant parameters, like cell viability and apoptosis in human pituitary adenomas. 
Interestingly, certain pituitary adenomas displayed distinct, even opposite responses to BIM-23A760 
(i.e. appropriate/inhibitory vs. inappropriate/stimulatory), which were associated with the relative 
somatostatin and dopamine receptor subtypes
 
expression levels. Specifically, we found that expression 
levels of somatostatin receptor 5 (sst5) and, particularly its truncated variant (sst5TMD4), might 
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represent potential molecular signatures contributing to the differential, inhibitory/stimulatory 
response of pituitary adenomas to BIM-23A760.  
 
Conclusions: Therefore, chimeric compounds for the somatostatin/dopamine receptor system such as 
BIM-23A760 affect multiple, clinically relevant parameters on pituitary adenomas and may represent 
new therapeutic tools to treat these adenomas. The relative somatostatin/dopamine receptor expression 
profile, particularly the levels of sst5 and/or its truncated variant sst5TMD4 in GH-producing and 
ACTH-producing adenomas might represent useful molecular markers to predict the ultimate response 
of these pituitary adenoma types to BIM-23A760. 
 
Keywords: BIM-23A760, pituitary adenoma, primate, acromegaly, Cushing’s disease  
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1. Introduction 
 Pituitary adenomas represent the most common intracranial neoplasms and are often 
accompanied by serious comorbidities, due to excessive hormonal secretion and/or compression of 
intracranial structures, such as amenorrhea, galactorrhea, growth abnormalities, hypopituitarism, 
sexual-related dysfunctions (Asa and Ezzat, 2002), and particularly, cognitive and emotional 
disturbances in acromegalic patients, that present an excess of GH and IGF1 release (Leon-Carrion et 
al., 2010; Martin-Rodriguez et al., 2013) and, in patients with Cushing’s disease, characterized by 
ACTH and cortisol hypersecretion (Forget et al., 2002; Valassi et al., 2012). 
 Somatostatin (SST) and dopamine (DA) are two well-known factors that regulate numerous 
(patho) physiological, and often overlapping functions in humans and other species (Brazeau et al., 
1973; Missale et al., 1998; Theodoropoulou and Stalla, 2013). Both, SST and DA bind to its own 
family of receptors, encoded by 5 separate genes, which are highly conserved across species and 
exhibit a wide expression pattern in normal and tumoral tissues, including pituitary adenomas (Gahete 
et al., 2010; Missale et al., 1998). Activation of SST- and DA-receptors (sst1-5 and D1-5, respectively) 
by their ligands results in multiple, mostly inhibitory actions on endocrine and/or exocrine hormonal 
secretions and cellular proliferation (Missale et al., 1998; Theodoropoulou and Stalla, 2013). 
Accordingly, these receptors serve as valuable targets for the pharmacological management of 
pituitary adenomas and other tumoral pathologies. Interestingly, pituitary adenomas often express, 
simultaneously, high levels of various ssts and Ds, showing expression profiles substantially altered 
compared with those of normal pituitaries or those of the cell types from which a given pituitary 
adenoma is originated (Neto et al., 2009; Taboada et al., 2007). Based on this and additional 
evidences, pharmaceutical companies have developed functional compounds selective for one or 
multiple sst-subtypes, with those selective for sst2 and sst5 being particularly useful (e.g., lanreotide, 
octreotide), as these are the most abundant receptors in the majority of pituitary adenomas 
(Theodoropoulou and Stalla, 2013). Similarly, DA agonists selective for D2 (e.g., cabergoline), the 
most abundant receptor in pituitary adenomas, have been generated which are also efficiently used to 
treat some pituitary adenomas types, especially prolactin-secreting adenomas (Colao and Savastano, 
2011). 
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 Although ssts and Ds are highly present in pituitary adenomas, and the efficiency of the 
individual selective sst2/5 or D2 compounds have been proven in the treatment of pituitary adenomas, 
an appreciable subset of patients are poorly responsive or totally resistant to conventional therapy with 
SST- or DA-analogs (Colao and Savastano, 2011; Feelders et al., 2010; Theodoropoulou and Stalla, 
2013). For that reason, new approaches are already being tested or are currently under clinical 
investigation to treat patients with pituitary adenomas, as is the case of the use of combined drug 
therapies (SST- plus DA-analogs), which have been shown to be more effective than treatment with 
the individual compounds (Theodoropoulou and Stalla, 2013). 
 In this same context, and based on the well-known developing central interaction between the 
somatostatinergic- and dopaminergic-systems (Rocheville et al., 2000), and on the evidence on the 
ability of sst2 and sst5 to establish physical and functional interactions with D2 resulting in altered 
pharmacological or/and signaling properties (Baragli et al., 2007; Rocheville et al., 2000), an 
interesting new approach that is currently under basic and clinical investigation is the development and 
application of chimeric SST/DA compounds. As previously shown (Jaquet et al., 2005b), these drugs 
can retain the ability to interact with ssts and D2, and can display greater effects in reducing pituitary 
secretions than individual compounds. One of these promising chimeric SST/DA compounds is BIM-
23A760, an agonist for sst2/sst5/ D2 receptors, which has been used in clinical trials (Culler, 2011; 
Froehlich et al., 2009; Lesage et al., 2009). Specifically, the effect of BIM-23A760 has been tested in 
pituitary cell lines (Gruszka et al., 2007) and in limited series of primary pituitary adenoma cell 
cultures (Cuny et al., 2012; Florio et al., 2008; Fusco et al., 2008; Gatto et al., 2012; Gruszka et al., 
2012; Jaquet et al., 2005b; Peverelli et al., 2010); however, to the best of our knowledge, the data 
collected to date on the direct in vitro effect of BIM-23A760 in pituitary adenomas is still incomplete, 
with some apparently contradictory results, which renders the available evidence somewhat 
inconclusive. Moreover, the studies reported so far have not been focused to specifically analyze and 
compare the distinct effects of this compound on several functional parameters (i.e. contribution of 
signaling pathways, hormonal expression/secretion, cell viability and apoptosis) in parallel in the same 
samples and/or in a wide range of cell types from pituitary adenomas, nor the responses of these 
pituitary adenoma-cells have been compared with those observed in normal pituitary cells in vitro. 
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Therefore, the aim of this study was to analyze, for the first time, a set of key functional parameters 
(signaling pathways, hormonal expression and secretion, cell viability and apoptosis), in response to 
BIM-23A760 in the main types of human pituitary adenomas and, in human/primate normal pituitaries 
cells. It should be mentioned that, although BIM-23A760 has been withdrawn from clinical 
development after discovering a dopaminergic metabolite that accumulates and interferes with the 
activity of the parent compound in vivo (Culler, 2011; Lesage and IPSEN, 2011), BIM-23A760 is still 
considered a good prototype molecule for this class of compounds and therefore, the results generated 
in this study using primary pituitary cell cultures from pituitary adenomas and normal pituitaries may 
be really useful in predicting the response to members of this class of compounds (i.e. new generation 
of chimeric agonist for sst2/sst5/D2 receptors) that may be used for clinical purposes in the future. 
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2. Materials and Methods 
 
2.1. Reagents.  
All reagents used in this study were purchased from Sigma-Aldrich (St. Louis, MO, USA) 
unless otherwise specified. α-Minimum essential media, HEPES, horse serum, and penicillin-
streptomycin were obtained from Invitrogen (Grand Island, NY, USA). BIM-23A760 was kindly 
provided by IPSEN Bioscience (Cambridge, MA, USA) and prepared as previously described 
(Gruszka et al., 2012). 
 
2.2. Patients, animals, tissue collection and pituitary cell culture.  
Human pituitary specimens were obtained during transsphenoidal surgery (from 2008 to 2014) 
from a total of 74 patients [22 somatotropinomas (GHomas), 5 mixed GH/PRL-omas, 26 
nonfunctioning pituitary adenoma (NFPAs), 6 PRL secreting adenomas (PRLomas), 11 
corticotropinomas (ACTHomas), 1 FSH secreting gonadotropinoma (FSHoma) and 3 
thyrotropinomas]. Moreover, 5 samples corresponding to normal pituitary tissue were used, which 
were obtained from patients who underwent surgical removal of a pituitary adenoma, and the tissue 
piece obtained by our laboratory was confirmed as normal pituitary tissue. Specifically, both human 
normal and tumoral pituitary  tissue pieces were confirmed by 3 separate methods: examination by an 
expert anatomopathologist, molecular screening by quantitative real time PCR of the main pituitary 
hormonal products and membrane receptors, and analysis of the hormonal phenotype using single-cell 
secretion by a cell-blotting assay, as previously described (Luque et al., 2013). Before surgery, all 
patients with a GHoma or a PRLoma were treated with somatostatin and dopamine analogs, 
respectively. All the pieces (normal and tumoral pituitaries) were immediately collected after surgery, 
placed in sterile cold media and rapidly moved to our laboratory on ice within 1-3 hours, where they 
were dispersed into single cells for culture by enzymatic and mechanical disruption following the 
methods and reagents previously reported (Luque et al., 2013). Available patients’ demographic data 
are summarized in Table-1. Due to the extensive time-range required for collection of samples, 
histological and genetic information of the patients and samples obtained were limited, and therefore 
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additional information about immunohistochemistry, granulation pattern of the tumors, presence of 
AIP or GNAS mutations, or other novel factors that have been demonstrated to affect the response to 
pharmacological treatment could not be provided (Theodoropoulou and Stalla, 2013). Informed 
consent from each patient and approval of the University of Córdoba/IMIBIC and Hospital Ethics 
Committees were obtained. 
Primate (Olive Baboon, Papio anubis; a species that more closely models human physiology; n=3, 
9-10 yr of age) pituitaries were obtained from randomly cyclic control females within 15 min after 
sodium pentobarbital overdose as previously reported (Luque et al., 2014). It should be mentioned that 
the baboons used represent control animals from a breeding colony, all under Institutional Animal 
Care and Use Committee approved studies conducted by other University of Illinois at Chicago 
investigators. Anterior pituitaries were cut into small pieces, and one-two fragments was rapidly 
frozen in liquid nitrogen and stored at -80ºC until extraction for total RNA, while the remaining pieces 
were placed in sterile cold media and dispersed into single cells for culture following the 
methods/reagents previously reported (Luque et al., 2014). 
To avoid fibroblast contamination, suspensions of dispersed human and baboon pituitary cells 
were filtered through a nylon gauze of 130µM-mesh, and D-Valine-modified Dulbecco’s minimum 
essential medium (DMEM) and minimum essential medium (MEM) respectively, both replaced for L-
valine were used to selectively inhibit fibroblast proliferation/overgrowth as previously reported 
(Córdoba-Chacón et al., 2012a). In addition, visual inspection of primary cell cultures at the time of 
experimental assays showed no sign of cells displaying the typical fibroblast-like morphology. All the 
individual pituitary cultures showed cell viability higher than 95%, as determined by the trypan blue 
dye exclusion method (American Type Culture Collection, Manassas, VA). 
 
2.3. Measure of pituitary hormones.  
Pituitary cell cultures (100,000 – 200,000 cell/well, n=3-4 wells/treatment) were incubated 
with media alone (controls) or media containing BIM-23A760 (100nM) for 4h (primate normal 
pituitary cells) or 24h (human normal pituitary and pituitary adenoma cells). At the end of the 
incubation with the corresponding treatment, media were recovered for hormone analysis and, 
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whenever possible, cells were recovered for RNA analysis (see below). As previously reported 
elsewhere (Luque et al., 2014), hormone concentrations were measured in the culture media derived 
from human samples according to the pituitary adenoma type and, when possible, all pituitary 
hormones concentrations were measured in the human and baboon normal pituitary samples using 
human/primate commercial ELISA kits [GH, LH, FSH, PRL, ACTH and TSH (reference numbers: 
EIA-1787/EIA-3552, EIA-1289, EIA-1288, EIA-1291, EIA-3647 and EIA-1790, respectively; DRG, 
Mountainside, NJ, USA)] following the manufacturer’s instructions. All the information regarding 
specificity, detectability, and reproducibility for each of the assays can be accessed at the website of 
the company. 
 
2.4. RNA isolation, reverse transcription, and analysis of gene expression by quantitative real-
time PCR (qPCR).  
Details of RNA extraction, quantification, reverse-transcription (RT), application of qPCR and 
primer sequences used to measure the expression levels of human and baboon transcripts included in 
this study (pituitary hormones, sst2, sst5 and D2 [long (D2L) and total (D2T) isoforms] and POU1F1) 
have been previously reported elsewhere by our group (Córdoba-Chacón et al., 2012b; Neto et al., 
2009; Taboada et al., 2007). Briefly, tissues and, when possible, pituitary cell cultures were processed 
for recovery of total RNA and RNA amount was quantified using the Ribogreen RNA Quantification 
Kit (Molecular Probes, Eugene, OR). Total RNA (1µg for whole human and baboon tissues; ∼0.15µg 
for pituitary cell cultures treated with vehicle or BIM-23A760) was reversed transcribed and the 
cDNAs were amplified by qPCR using a Stratagene Mx3000p real-time PCR machine and the brilliant 
SYBR Green QPCR Master Mix (Stratagene, La Jolla, CA, USA). Samples were run against synthetic 
standards for each transcript of interest to estimate mRNA copy number. Since it is not possible to 
design a specific set of primers for qPCR that only amplified the short isoform of D2 (Neto et al., 
2009), a set of primers that amplify both, the long and short, isoforms (D2T) and a set of primers that 
only amplify the long isoform (D2L) were used in this study. As previously reported, to control for 
variations in the amount of RNA used in the RT reaction and the efficiency of the RT reaction, the 
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expression level (copy-number) of each transcript was adjusted by ACTB [human samples (Luque et 
al., 2013)] or by PPIA [baboon samples (Luque et al., 2014)] expression (used as control genes). 
 
2.5. Measurements of free cytosolic calcium concentration ([Ca2+]i).  
As we have previously described in detail elsewhere (Duran-Prado et al., 2009; Luque et al., 
2013), changes in [Ca2+]i in response to treatment with BIM-23A760 were measured in cultured human 
pituitary cells (50,000 cell/well) by using fura-2AM probe (Molecular Probes, Eugene, OR, USA) and 
MetaFluor Software (Imaging Corp, West Chester, PA, USA). 
 
2.6. Measurements of cell viability and apoptotic rate.  
Cell viability was evaluated in primary cell cultures (10,000 cell/well; n=4-5 well/treatment) 
treated with BIM-23A760 as compared with vehicle-treated controls using the alamar-Blue reagent 
(Biosource International; Camarillo, CA, USA) and the FlexStation 3 system (Molecular Devices; 
Madrid, Spain) following the manufacturer’s instructions, as previously reported (Duran-Prado et al., 
2009; Luque et al., 2013). In addition we were able to measure the apoptotic rate in GHomas treated 
with BIM-23A760 as compared with vehicle-treated controls by flow cytometry (Beckman Coulter, 
Coulter Epics XL, Madrid, Spain) using Annexin-V-FITC/propidium iodide staining (Bender 
Medsystems, Barcelona, Spain). 
 
2.7. Statistical analysis and Receiver Operating Characteristic (ROC) analysis.  
Statistical differences were assessed by Student’s t-tests to compare the effect of BIM-23A760 
vs. vehicle-treated control in vitro. As previously reported (Luque et al., 2014; Luque et al., 2013) to 
normalize values within each treatment and minimize intragroup variations in the different 
experiments (i.e. different age of the tissue donor, different stage of the estrus cycle or metabolic 
environment), the values obtained were compared with vehicle-treated controls (set at 100%). 
Specifically, to generate these values, individual values (adjusted by the corresponding level of control 
gene in the case of qPCR), within each individual experiment were divided by the mean value of the 
control group and multiplied times 100, and the means of these adjusted values are presented with 
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their associated standard error. It should be emphasize that this style of data presentation does not alter 
the relative differences between BIM-23A760-treated and vehicle-treated groups. Raw data were 
evaluated for heterogeneity of variance and, where found, values were log transformed. All data are 
expressed as mean ± S.E.M. p<0.05 was considered significant. When p-values ranged between <0.1 
and >0.05, a trend for significance was indicated where appropriate. All statistical analyses were 
performed using GraphPad Prism 6 (GraphPad Software; La Jolla, CA, USA). As previously reported 
(Puig-Domingo et al., 2014), ROC analyses were performed for evaluation of diagnostic test 
sensitivity and specificity. Specifically, in this study ROC analyses was used as a tool to measure how 
well the expression of sst2, sst5 and D2 could distinguish between the two groups of patients with the 
same pituitary adenoma type where we found a differential, even opposite response to BIM-23A760. 
Statistical analysis of ROC analyses were performed by calculating the area under the curve (AUC) of 
each receptor and comparing them with the AUC of the reference line using Student’s t-test. 
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3. Results and Discussion 
  
3.1. Expression profile of sst2, sst5 and D2 in human and baboon normal pituitaries and direct 
effects of BIM-23A760 on humans and baboons primary normal pituitaries cell cultures.  
As previously reported (Córdoba-Chacón et al., 2012b; Neto et al., 2009), normal pituitaries 
from baboons (n=3) and humans (n=5) expressed high levels of sst5, sst2 and D2, with relative order 
of D2T> D2L>sst5>sst2 (Figure-1A). Notably, the expression profile of sst2/sst5/D2, the target 
receptors for BIM-23A760, was virtually identical in both species. These results, coupled to the data 
showing that baboon pituitary cultures maintain the same expression profile after dispersion and 
culture as whole-pituitaries (Supplemental Table-1), strongly suggest that baboon normal pituitaries 
might represent an appropriate model to study how BIM-23A760, or other pharmaceutical compounds, 
modulate human pituitary cell function. 
 Incubation of cultured baboon pituitary cells with BIM-23A760 revealed clear inhibitory 
effects on GH and PRL expression/release (Figure-1B, left-panels). BIM-23A760 administration also 
decreased LH release, but not its expression, and also tended to inhibit ACTH secretion. Conversely, 
expression and/or release of proopiomelanocortin (POMC, the ACTH-precursor), FSH or TSH was 
not significantly altered in response to BIM-23A760 (Figure-1B, left-panels). Because of the limited 
available amount of human normal pituitary samples, we could not study in depth the effects of BIM-
23A760 on human normal pituitaries; however we obtained a limited number of cells derived from a 
dispersed human normal pituitary preparation to study the effect of BIM-23A760 on the secretion of 
some, selected, hormones. Of note, as observed in baboons, we found that BIM-23A760 treatment 
significantly inhibited GH/PRL, but not ACTH release in cultured human normal pituitary cells 
(Figure-1B, right-panel). To the best of our knowledge, this is the first report showing, the direct, 
effect of in vitro BIM-23A760 on the expression and/or secretion of all major pituitary hormones in 
nonhuman primates and/or humans normal pituitaries. As such, our results extend and reinforce 
previous preliminary data, which indicated that s.c. administration of BIM-23A760 suppressed 
circulating PRL secretion in human healthy male volunteers (Froehlich et al., 2009) and, GH, IGFI 
and PRL secretion in normal cynomolgus monkeys in vivo (Culler et al., 2006). 
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 Furthermore, the present study is the first report demonstrating that BIM-23A760 effects on 
normal pituitary cells are not just confined to regulate the release or expression of pituitary hormones, 
but also include an up-regulation of sst2, sst5, D2T and D2L expression (Figure-1C). These findings 
suggest that, even though qPCR of receptor mRNA may not always necessarily reflect the precise, 
final protein levels of functional receptors available at the cell membrane (a technically challenging 
assay that we could not perform given the limited tissue availability), the changes observed herein 
likely represent a relevant up-regulation in the expression of these receptors, which would reflect an 
additional regulatory mechanism, an extra level of control that is typically observed in GPCRs (i.e. 
somatostatin/GHRH/ghrelin receptors) (Kineman and Luque, 2007), on cells of the 
somatotrope/lactotrope lineage (Mangalam et al., 1989), and enables to finely tune the response of 
pituitary cells to their ligands. Moreover, our data indicate the effects of BIM-23A760 on 
somatotropes/lactotropes might be mediated by the inhibition of POU1F1 mRNA production (Figure-
1C). Altogether, these novel results support the notion that the use of chimeric molecules as BIM-
23A760 could provide a new, valuable therapeutic tool for medical treatment of different pituitary 
adenoma types, and thereby invite further exploration of the underlying molecular mechanisms of its 
effects. 
 
3.2. Direct effects of BIM-23A760 on [Ca2+]i levels, pituitary hormone expression and release, 
cell viability, and apoptosis in human pituitary adenomas and normal pituitaries.  
An additional aim of this study was to systematically analyze the effect of BIM-23A760 on 
key functional parameters in all major human pituitary adenoma cell types. Because of the limited 
amount of pituitary adenoma cells available for culture after surgical resection and cell dispersion, we 
decided to firstly test the effect of BIM-23A760 on [Ca2+]i kinetics, a second messenger well-known 
for being directly involved and required in hormone secretory vesicle release (Stojilkovic et al., 1988). 
[Ca2+]i measurement is a sensitive assay, routinely used in our laboratory, that only requires a small 
number of cells compared to other assays (i.e. hormonal secretion). In addition, this assay provides 
useful information about several parameters including:1) the percentage of maximum response (PMR), 
which indicates the maximal response (positive or negative) achieved in [Ca2+]i in response to a 
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specific treatment; 2) the proportion of responsive cells (PRC), which indicates the percentage of cells 
that elicit a positive or negative response in terms of [Ca2+]i levels in response to an specific treatment; 
and3) the time to maximal response of sensitive cells to the specific compound, which indicates the 
time when the maximal response (positive or negative) is achieved in terms of [Ca2+]i levels in 
response to the specific treatment (Duran-Prado et al., 2009; Luque et al., 2013). When remaining cells 
were available from pituitary adenoma cultures, we additionally measured hormonal secretion and/or 
expression, cell viability and apoptosis in response to BIM-23A760. Normal pituitary cell cultures 
were also tested when cells were available. 
 
3.3. [Ca2+]i Kinetics.  
BIM-23A760 inhibited [Ca2+]i levels (Table-2) in cell cultures of all normal pituitaries tested 
(n=4; PMR: 77%, PRC: 42%), in 65% of GHomas (n=13/20; PMR: 72%, PRC: 64%), in 80% of 
mixed GH/PRLomas (n=4/5; PMR: 79%, PRC: 42%), in 67% of PRLomas (n=4/6; PMR: 69%, PRC: 
30%), in 30% of ACTHomas (n=3/10; PMR: 73%, PRC: 24%), in 25% of NFPA (n=4/16; PMR: 81%, 
PRC: 44%), in the available FSHoma (PMR: 65%, PRC: 66%) and, in one of the two TSHomas 
included in the study (PMR: 53%, PRC: 65%). BIM-23A760 did not alter [Ca2+]i levels in 5%, 20%, 
33%, 40%, 63% and 50% of the GHomas, mixed GH/PRLomas, PRLomas, ACTHomas, NFPAs and 
TSHomas analyzed, respectively (Table-2). Interestingly, we also found that BIM-23A760 increased 
[Ca2+]i levels in 30% of GHomas and ACTHomas(PMR: 212 and 223%; PRC: 69 and 35%, 
respectively),and in 13% of the NFPAs analyzed (PMR: 170%, PRC: 19%). Representative profiles 
depicting changes in [Ca2+]i levels in normal and tumoral pituitary cell cultures in response to BIM-
23A760 are presented in Supplemental Figure1. Therefore, our data indicate that BIM-23A760 is also 
able to directly acts on human pituitary adenoma and normal pituitary cells by increasing [Ca2+]i. In 
this regard, the only previous study exploring activation of signaling pathways in response to BIM-
23A760 indicated that the antiproliferative effect of BIM-23A760 involved phosphorylation of 
ERK1/2 and p38 MAPK pathways in NFPAs (Peverelli et al., 2010). However, to the best of our 
knowledge, our study is the first to characterize, in a wide range of pituitary adenomas and in normal 
pituitaries, a key element of the signaling pathway activated by BIM-23A760 directly linked to 
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hormone release, i.e. [Ca2+]i (Stojilkovic et al., 1988). Unfortunately, the limited amount of cells 
available precluded the desired in-depth study on the possible mechanisms associated to these changes 
in [Ca2+]i on human pituitary adenoma and normal pituitary cells in response to BIM-23A760. 
Nevertheless, the question still arises, why some GHomas, ACTHomas and NFPAs exhibit such a 
differential, even opposite (apparently stimulatory) response to BIM-23A760? As will be discussed 
further below, a different receptor expression profile, and the possible interactions between receptors 
(homo- and/ hetero-dimerization) in the various pituitary adenoma types, might provide at least a 
partial explanation for the effects of BIM-23A760. 
 
3.4. Hormonal expression/release.  
Incubation with BIM-23A760 (24h) inhibited: GH release (Figure-2A) and tended to inhibit 
GH expression (p=0.06; Figure-2B) in GHomas; both PRL expression/release in PRLomas (Figure-2C 
and 2D); ACTH release (Figure-2E) but not POMC expression (Figure-2F), in ACTHomas; and, CGA 
expression in NFPAs (Figure-2G). These results and those previously shown in Table-2 are in line 
with previous reports showing that BIM-23A760 potently decreased hormone release in cultures from 
GHomas and the GH3 cell line (Gruszka et al., 2012; Gruszka et al., 2007; Jaquet et al., 2005a; Jaquet 
et al., 2005b), PRLomas and the MMQ cell line (Fusco et al., 2008; Gruszka et al., 2007), mixed 
GH/PRLomas (Gruszka et al., 2012; Jaquet et al., 2005b), ACTHomas (Hofland et al., 2010) and 
TSHomas (Gatto et al., 2012), and it also agrees with the results of a Phase-II clinical study in 
acromegalic patients showing that BIM-23A760 inhibits basal circulating GH levels (Culler, 2011; 
Lesage et al., 2009).Accordingly, these results provide evidence to support the potential use of 
chimeric SST/DA compounds as a pharmacological treatment to reduce hormonal expression/secretion 
from various pituitary adenoma types. In favor of this idea is the elegant report of Saveanu and 
coauthors demonstrating that the potency of a chimeric SST/DA compound (BIM-23A387) in 
suppressing GH secretion was 100-times higher than individual sst2 or D2 analogs (Saveanu et al., 
2002). However, it should be noted that, in line with both the stimulatory and inhibitory effects of 
BIM-23A760 observed on [Ca2+]i levels, we also observed that BIM-23A760 increased GH and ACTH 
release in a subpopulation of GHomas and ACTHomas. Specifically, BIM-23A760 administration 
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elicited the typically inhibitory effect in some GHomas and ACTHomas (Figure-2A and -2E, 
respectively), whereas in another population, BIM-23A760 increased hormonal levels in GHomas and 
ACTHomas (Figure-2H). We could not corroborate whether NFPAs also have a differential response 
to BIM-23A760 in terms of hormone release as these tumors respond poorly to stimulatory (or 
inhibitory) factors in altering their secretory activity.  
 Hence, and despite exercising due caution, our results reinforce the notion that at least two 
populations may exist in pituitary adenomas (within GHomas and ACTHomas) that respond 
differentially, even oppositely, to BIM-23A760 (hence forth referred to as “inhibited pituitary 
adenoma” and “stimulated pituitary adenoma”). At this point, it should be noted that the stimulatory 
effect of BIM-23A760 should not necessarily be surprising, based on previous studies which have 
revealed that SST, DA and/or their analogs can directly stimulate pituitary hormone secretion in 
primates and other species (Córdoba-Chacón et al., 2012b; Luque et al., 2006; Murray et al., 2004), 
and in a select population of human pituitary adenomas (Florio et al., 2003; Murray et al., 2004; Spada 
et al., 1982). Furthermore, it is well-known that different SST-agonists can elicit different effects in 
the same pituitary adenoma cell-type, known as “biased agonism” (Schonbrunn, 2008), which might 
be directly depending on the agonist-receptor and receptor-receptor interactions, on the active 
receptor-conformations, etc. Therefore, comparison of the receptor expression profiles between the 
pituitary adenoma inhibitory-population and stimulatory-population in response to BIM-23A760 
might be important for determining the molecular mechanism involved in the opposite responses to 
this and other compounds (see below). 
 
3.5. Cell viability and apoptotic rate.  
Direct effects of BIM-23A760 on cell viability and apoptotic rate were also tested in some 
human normal pituitaries and pituitary adenomas cultures. BIM-23A760 moderately, but significantly, 
inhibited cell viability at different incubation-times in all normal pituitaries (95.1%, 86.1% and 86.1% 
at 24, 48 and 72h respectively; Figure-3A), GHomas (88.6%, 85.3% and 87.0% at 24, 48 and 72h 
respectively; Figure-3B), mixed GH-/PRL-omas (90.3%, 75.2% and 70.6% at 24, 48 and 72h 
respectively; Figure-3C) and NFPAs (93.2%, 93.8% and 91.1% at 24, 48 and 72h respectively; Figure-
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3E) analyzed. Additionally, BIM-23A760 tended to down-regulate cell viability in PRLomas at 72h 
(95.1%, 92.3% and 88.5% at 24, 48 and 72h respectively; Figure-3D; p=0.07), but had no effect in 
TSHomas (95.6% at 24h; Figure-3F). To the best of our knowledge, this is the first report 
documenting that BIM-23A760 stimulates apoptosis in GHomas (Figure-3G). These results are, in 
part, consistent with data showing that BIM-23A760 decreased cell viability/proliferation in NFPAs 
(Florio et al., 2008; Gruszka et al., 2006; Peverelli et al., 2010) and TSHomas (Gatto et al., 2012), and 
with previous observations indicating that BIM-23A760 could increase apoptosis in NFPAs (Gruszka 
et al., 2006). Although further studies, with larger number of cell cultures and including all pituitary 
adenoma types, will be necessary to unequivocally establish the effects of BIM-23A760 on apoptosis 
in pituitary adenomas, these and previous results suggest that, in addition to suppressing [Ca2+]i levels 
and hormonal hypersecretion, BIM-23A760 may be able to decrease cell viability in the majority of 
the pituitary adenoma-types analyzed and, to increase apoptotic rate in GHomas. Taken together, our 
results provide relevant information from both a mechanistic/therapeutic perspective, since 
demonstrate that BIM-23A760 can alter (decrease) key cellular parameters and also influences 
clinically relevant endpoints in a significant subset of pituitary adenomas, of different types. Once 
again, these findings invite further exploration of the potential value of SST-DA chimeric compounds 
as therapeutic approaches for patients with pituitary adenomas. 
 
3.6. Molecular mechanisms underlying the differential, inhibitory/stimulatory, response to BIM-
23A760 in human GHomas and ACTHomas.  
 In order to identify molecular determinants that could explain the differential, 
inhibitory/stimulatory, responses to BIM-23A760, expression levels of sst2/sst5/D2 were measured in 
GHomas and ACTHomas and the results were compared between inhibited pituitary adenomas and 
stimulated pituitary adenomas, based on the data of [Ca2+]i-kinetics (Table-2). In GHomas, D2 and sst5 
expression levels were significantly higher than sst2 in inhibited pituitary adenomas (Figure-4A); 
whereas, sst5 levels were lower than those of D2 in stimulated pituitary adenomas. When comparing 
the expression levels across GHomas, the only difference found was a significantly lower sst5 
expression in stimulated GHomas vs. inhibited GHomas (Figure-4A). 
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In ACTHomas, there were no differences between the average expression levels of sst2, sst5 
and D2 in inhibited pituitary adenomas (Figure-4B). In contrast, D2 expression levels were 
significantly higher than those of sst2 and sst5 in stimulated pituitary adenomas. Interestingly, when 
expression levels were compared across ACTHomas, we found a similar situation to that previously 
observed in GHomas, in that sst5 levels were lower in stimulated pituitary adenomas vs. inhibited 
pituitary adenomas (Figure-4B). Interestingly, when results from both GHomas and ACTHomas are 
viewed together, we observed that both pituitary adenoma types present two common, distinctive 
molecular signatures, namely, a lower sst5expression in stimulated pituitary adenomas vs. inhibited 
pituitary adenomas, and a higher D2 expression level as compared with sst5 expression in stimulated 
pituitary adenomas. Therefore, these findings suggest that the relative sst5expression levels (i.e. lower 
sst5 levels in stimulated pituitary adenomas vs. inhibited pituitary adenomas as well as, lower sst5 as 
compared with D2 levels in the stimulated pituitary adenomas) might represent a potential molecular 
signature contributing to the differential, inhibitory/stimulatory response of pituitary adenomas to 
BIM-23A760. In support of this idea, the ROC analysis carried out for all receptors individually 
demonstrated that only expression of sst5 discriminates between the two populations (inhibited 
pituitary adenomas vs. stimulated pituitary adenomas) in both GHomas and ACTHomas (Figure-4C; 
the closer the ROC curve is to the upper left corner of the graphic, i.e., higher sensitivity and 
specificity, the higher the overall accuracy of the marker used). Thus, whereas expression of sst2 and 
D2 had a poor ability to distinguish between the two pituitary adenomas populations (ROC analyses 
similar to the reference line; data not shown), the ROC analysis of sst5 expression levels was 
significantly different from the reference line in GHomas and ACTHomas, [AUC of 0.872 and 1.0 (p= 
0.02 and 0.04) respectively; Figure-4C]. 
These results, coupled to our previous demonstration that a human truncated sst5 variant, 
sst5TMD4, is overexpressed in pituitary adenomas and plays a relevant pathophysiological role in 
GHomas (Duran-Prado et al., 2009; Duran-Prado et al., 2010) and other endocrine-related tumors 
(Duran-Prado et al., 2012; Puig-Domingo et al., 2014), prompted us to analyze the expression levels of 
sst5TMD4 in the two pituitary adenoma populations. Notably, while sst5TMD4 expression levels did 
not change between both GHomas populations (mean of 187 copies/0.05µg of total RNA), the 
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stimulated population of ACTHomas expressed appreciable levels of sst5TMD4 (mean of 96 
copies/0.05µg of total RNA), which were not detectable in the inhibited population of ACTHomas (0 
copies/0.05µg of total RNA; Figure-4D). Although we noticed that full length sst5mRNA is the 
dominant sst5 gene transcript in the stimulated population of ACTHomas, with absolute levels much 
greater than those of sst5TMD4 (27-fold), our results unveil the fact that sst5TMD4 variant is 
selectively expressed only in the stimulated population of ACTHomas, thus suggesting a potential 
involvement of sst5TMD4 in the unique stimulatory response of some ACTHomas to BIM-23A760, 
which invite to develop further, more detailed studies on the potential physiological role of sst5TMD4 
in corticotropinoma patients. 
Another possible mechanism involved in the stimulatory effects exerted by BIM-23A760 in 
certain pituitary adenomas might be related to the use of one, relatively high concentration of BIM-
23A760 (likely higher than the concentrations expected in circulation in clinical settings). There are 
many examples in the literature off the “hook effect” with SST-based analogue, including BIM-
23A760 (Jaquet et al., 2005b). Differences in sensitivity of the individual adenomas could shift the 
response curve so that 100nM in some cells might be within the suppressive range, while in others it 
might be past the maximal point of suppression, and be probably in the stimulatory portion of the 
curve. Differences in sensitivity that would shift the response curve could also be due to difference in 
receptor expression and interactions as discussed below. Thus, future studies should be necessary to 
fully understand the present findings, involving full-range dose- and time-response assays, which are 
far beyond our capabilities at this time given the limited availability of human pituitary adenoma 
samples and cell cultures obtained after the cellular dispersion. 
Nevertheless, when viewed together, our results strongly suggest that sst5 expression in 
GHomas and ACTHomas, and sst5TMD4 expression in ACTHomas might represent useful molecular 
markers to predict the ultimate response of these pituitary adenoma types to BIM-23A760.This idea is 
supported by: 1) the ROC analyses indicating the high sensitivity and specificity of both sst5 variants 
in GHomas and/or ACTHomas; 2) previous data indicating that sst5 is the receptor involved in the 
stimulatory actions of SST or its synthetic analogs on GH release in non-human primates and other 
species (Córdoba-Chacón et al., 2012b; Luque et al., 2006);and3) a study showing that presence of 
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sst5TMD4 is linked to a reduced in vivo hormonal response to SST-analogue treatment in acromegalic 
patients (Duran-Prado et al., 2010).Further support that the low sst5 expression level in the stimulated-
population of GHomas and ACTHomas may serve as a potential signature to distinguish between the 
differential response of pituitary adenomas is provided by a previous study in patients with TSHomas, 
which showed that tumors displaying a stimulatory response to octreotide expressed relatively low 
levels of sst5 in comparison with sst2, while tumors with higher sst2 than sst5 expression obtained a 
beneficial response to octreotide (Gatto et al., 2012). Nevertheless, it should not be discounted that 
other factors could also contribute to the differential, inhibitory/stimulatory response of GHomas and 
ACTHomas to BIM-23A760. One of these factors could be the precise number of receptors and/or 
their specific proportion available on the tumor cells, i.e. the receptor expression profile available in 
the pituitary adenomas. In this scenario, it seems conceivable that a specific expression profile [i.e. 
high D2 vs. sst5 expression levels in stimulated-pituitary adenomas compared to similar D2/sst5 
expression levels in inhibited-pituitary adenomas (Figure-4A/B)] could be a key molecular 
determinant for the response to BIM-23A760, as it could dictate the possible interactions between 
receptor-subtypes (homo and/or heterodimerization). Obviously, further, specifically directed, studies 
will be required to formally prove this notion with regard to the effect of BIM-23A760 in pituitary 
adenoma cells. However, this concept is supported by several studies demonstrating that the 
therapeutic response of pituitary adenomas to different drugs is directly dependent on the relative 
expression pattern of both SST and DA receptor subtypes (Colao et al., 2011; Taboada et al., 2007). 
The existence of heterodimers between SST/DA receptors (e.g. sst5 and D2) that result in changes in 
the functional, pharmacological and signaling properties of the receptors is well established 
(Rocheville et al., 2000). In particular, this concept is supported by results from a recent report 
demonstrating that only the amount of dimers between sst5 and D2, and not between sst2 with D2, 
were directly and positively correlated with an enhanced antiproliferative effect of BIM-23A760 in 
prostate and lung cancer cell lines (Arvigo et al., 2010), thereby reinforcing the main idea derived 
from our results, i.e. that chimeric compounds for the sst2/sst5/D2 system might represent valuable 
tools for the design and development of new therapeutic drugs for the management of certain pituitary 
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adenomas and its associates comorbidities (e.g. cognitive and emotional disturbances) in the near 
future.  
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Figure legends 
 
Figure 1: Expression profile and hormone release in the presence or absence of BIM-23A760 
in normal pituitaries from baboons and humans. (A) Expression profile of sst2, sst5, D2 (Total and 
Long) receptors in whole pituitary of female baboons (n=3) and human pituitary (n=5). (B) Effect of 
BIM-23A760 (100 nM) after 4-h treatment on the secretion and mRNA expression of all pituitary 
hormones in baboon primary pituitary cell cultures (n=3; top and bottom panel on the left, 
respectively) and, 24-h treatment on GH, PRL and ACTH release in human primary pituitary cell 
cultures (n=1; right-panel). (C) Effect of BIM-23A760 on POU1F1, sst2, sst5, D2 (Total and Long) 
after 4-h treatment in baboon primary pituitary cell cultures (n=3). Values in figure B/C are expressed 
as percent of vehicle-treated controls, set at 100% within experiment. Hormonal release was 
determined by commercial ELISA kits. mRNA expression levels were measured by qPCR, and 
mRNA copy numbers were normalized with Cyclophilin A (PPIA) and beta-actin (ACTB) mRNA 
copy number expression in baboons and humans, respectively. Values represent the mean ± S.E.M (3-
4 wells/treatment/experiment). Asterisks show significant differences between BIM-23A760 and 
vehicle-treated controls in figure B and C (* p<0.05, ** p<0.01; *** p<0.001). 
 
Figure 2: Effect of BIM-23A760 (100 nM; 24h) on pituitary hormone release and/or 
expression in primary human pituitary cell cultures from GHomas (A and B; n=3-4), PRLomas (C and 
D; n=1-2), ACTHomas (E and F; n=1) and NFPAs (G; alpha-subunit (CGA); n=1). (H) Stimulatory 
effect of BIM-23A760 on GH and ACTH release in GHomas and ACTHomas (n=1). Values are 
expressed as percent of vehicle-treated controls, set at 100% within experiment. Hormonal release was 
determined by commercial ELISA kits and, mRNA expression levels were measured by qPCR. 
mRNA copy numbers were normalized with beta-actin mRNA copy number. Values represent the 
mean ± S.E.M. Asterisks show significant differences between BIM-23A760 and vehicle-treated 
controls (* p<0.05, ** p<0.01). 
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Figure 3: (A) Effect of BIM-23A760 (100nM) on cell viability (24-72-h treatment) in human 
normal pituitaries (NP; n=1), GHomas (n=11), mixed GH/PRLomas (n=1), PRLomas (n=2), NFPAs 
(n=18) and TSHomas (n=1). Effect of BIM-23A760 on apoptosis in GHomas (n=3). Values represent 
the mean ± S.E.M. Asterisks show significant differences between BIM-23A760 and vehicle-treated 
controls (* p<0.05, *** p<0.001). 
 
Figure 4: Differential expression profile of sst2, sst5 and D2 Total according to the inhibitory 
and stimulatory responses observed in terms of [Ca2+]i kinetics (Table-2) in GHomas (A; n=12, and 
n=6, inhibitory and stimulatory populations, respectively) and ACTHomas (B; n=3 and n=3, inhibitory 
and stimulatory populations, respectively). (C) Receiver operating characteristics (ROC) analysis to 
determine the accuracy of sst5 receptor as diagnostic test to discriminate between inhibitory and 
stimulatory populations of GHomas (black dots) and ACTHomas (white dots). (D) Expression profile 
of sst5TMD4 in the inhibitory population (n=3) and stimulatory population (n=3) of ACTHomas. 
Values represent the mean ± S.E.M. Asterisks show significant differences between the same receptor-
subtype in the inhibitory and stimulatory populations of GHomas and ACTHomas (* p<0.05,). “a” 
indicates a statistical difference in the expression levels of sst5 or D2 as compared with sst2 expression 
in the inhibitory population. “b” indicates a statistical difference in the expression levels between sst5 
and D2 in the stimulatory population. 
Table 1. Demographic data of all the patients included in this study. 
 
n 
Age, years 
(min-max) 
Gender,  
male/female 
Normal pituitary 5 43 (21-69) 0/5 
Somatotropinoma 22 43 (13-64) 8/14 
Mixed GH-PRL adenomas 5 39 (32-60) 2/3 
Prolactinoma 6 32 (18-47) 3/3 
Corticotropinoma 11 38 (23-68) 1/10 
Non functioning pituitary adenoma 26 58 (22-74) 14/12 
Gonadotropinoma 1 35 0/1 
Thyrotropinoma 3 58 (47-71) 1/2 
 
Table 2. Effect of BIM-23A760 on free cytosolic calcium kinetics. Proportion of 
responsive cells (PRC) showing changes in [Ca2+]i levels in response to BIM-23A760 
is indicated for all the pituitary cell culture preparations. Percentage of maximum 
response (PMR) and time of response to BIM-23A760 administration are also 
indicated. Pituitary adenomas in which an stimulatory response to BIM-23A760 was 
observed are indicated by an asterisk (*) while adenomas that did not respond to 
BIM-23A760 are indicated by a cross (†). 
 
 
PRC 
(%) 
PMR (%) ± 
SEM 
Time ± SEM 
Normal pituitary-1 60.0 71.2 ± 2.4 109.4 ± 0.5 
Normal pituitary-2 52.0 79.1 ± 2.2 74.2 ± 0.7 
Normal pituitary-3 16.3 76.0 ± 3.0 59.1 ± 3.4 
Normal pituitary-4 37.5 83.2 ± 1.1 69.7 ± 0.3 
GHoma-1 52.5 65.0 ± 2.2 38.3 ± 2.4 
GHoma-2 83.5 71.9 ± 6.0 42.11 ± 7.2 
GHoma-3 97.5 81.3 ± 1.05 30.13 ± 0.97 
GHoma-4 90.0 74.2 ± 2.8 30.0 ± 0.6 
GHoma-5 80.0 68.8 ± 2.0 42.0 ± 1.7 
GHoma-6 76.6 68.3 ± 8.7 47.8 ± 2.4 
GHoma-7 77.3 72.5 ± 2.3 25.6 ± 2.0 
GHoma-8 87.5 61.1 ± 2.2 54.3 ± 2.0 
GHoma-9 65.0 74.8 ± 0.8 104.8 ± 0.2 
GHoma-10 58.2 80.6 ± 3.2 38.6 ± 0.3 
GHoma-11 20.0 64.8 ± 3.2 36 ± 3.5 
GHoma-12 12.5 72.6 ± 4.3 61.0 ± 5.7 
GHoma-13 27.5 77.4 ± 1.3 71.4 ± 4.5 
GHoma-14 * 90.0 243.8 ± 9.1 27.8 ± 1.6 
GHoma-15 * 89.5 228.4 ± 3.3 18.0 ± 7.1 
GHoma-16 * 86.3 254.7 ± 15.2 37.0 ± 4.4 
GHoma-17 * 11.3 123.3 ± 6.7 31.5 ± 3.5 
GHoma-18 * 97.5 199.5 ± 6.8 26.2 ± 0.7 
GHoma-19 * 37.5 222.7 ± 13.6 56.3 ± 3.7 
GHoma-20 † 0.0   
Mixed GH/PRLoma-1 30.0 76.9 ± 2.0 43.8 ± 2.0 
Mixed GH/PRLoma-2 63.9 63.1 ± 2.4 53.0 ± 2.0 
Mixed GH/PRLoma-3 32.5 77.0 ± 1.7 77.7 ± 4.5 
Mixed GH/PRLoma-4 41.2 81.5 ± 2.4 26.0 ± 3.0 
Mixed GH/PRLoma-5 † 0.0   
PRLoma-1 41.0 63.0 ± 3.0 49.0 ± 2.4 
PRLoma-2 25.0 59.9 ± 2.8 92.0 ± 4.5 
PRLoma-3 42.9 63.0 ± 5.5 48.3 ± 4.9 
PRLoma-4 9.5 88.0 ± 1.3 35 ± 0 
PRLoma-5 † 0.0   
PRLoma-6 † 0.0   
ACTHoma-1 100.0 58.5 ± 3.8 82.5 ± 8.8 
ACTHoma-2 32.5 58.5 ± 4.3 53.1 ± 3.2 
ACTHoma-3 15.0 86.5 ± 3.7 48.3 ± 4.9 
ACTHoma-4 * 2.5 232.7 ± 0.0 20.0 ± 0.0 
ACTHoma-5 * 15.0 172.0 ± 17.0 28.0 ± 4.5 
ACTHoma-6 * 55.0 247.7 ± 13.0 67.5 ± 2.4 
ACTHoma-7 † 0.0   
ACTHoma-8 † 0.0   
ACTHoma-9 † 0.0   
ACTHoma-10 † 0.0   
NFPA-1 70.7 82.4 ± 0.3 52.9 ± 24.6 
NFPA-2 20.5 78.1 ± 2.3 58.4 ± 4.6 
NFPA-3 42.5 81.3 ± 8.8 47.8 ± 4.8 
NFPA-4 43.5 83.3 ± 0.6 65.0 ± 2.0 
NFPA-5 * 17.6 163.0 ± 17.0 51.0 ± 2.7 
NFPA-6 * 20.0 177.1 ± 18.8 30.0 ± 5.0 
NFPA-7 † 0.0   
NFPA-8 † 0.0   
NFPA-9 † 0.0   
NFPA-10 † 0.0   
NFPA-11 † 0.0   
NFPA-12 † 0.0   
NFPA-13 † 0.0   
NFPA-14 † 0.0   
NFPA-15 † 0.0   
NFPA-16 † 0.0   
FSHoma-1 66.2 64.5 ± 0.6 52.9 ± 5.7 
TSHoma-1 64.7 52.9 ± 3.0 14.0 ± 0.8 
TSHoma-2 † 0.0   
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Supplemental table-1. Absolute cDNA copy number/50ng total RNA of gene transcripts in the 
whole pituitary versus primary pituitary cell cultures (control groups) of female baboons, as 
determined by quantitative real-time PCR. Values represent means ± SEM (from 3 separate 
whole pituitary extracts and primary pituitary cell cultures of the same baboons).  
Gene Whole pituitary Primary pituitary cell cultures 
sst2 2,182 ± 229 2,018 ± 309 
sst5 4,465 ± 357 3,809 ± 479 
D2T 28,269 ± 4,239 20,347 ± 2,785 
D2L 16,116 ± 3,077 11,420 ± 1,620 
Cyclophilin A 79,469 ± 5,578 88,280 ± 1,626 
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Supplemental Figure 1. Representative profiles of changes in [Ca2+]i in primary cell
culture from normal pituitaries (NPs, n=4) as well as from GHomas (n=20), mixed
GH/PRLomas (n=5), PRLomas (n=6), ACTHomas (n=10), NFPAs (n=16), FSHomas (n=1)
and TSHomas (n=2) in response to BIM-23A760 administration (100 nM; arrow).
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Highlights 
• Presence of sst5TMD4 increases aggressive features in acromegaly 
• Lower sst2/sst5TMD4 ratio is associated with poorer GH/IGF response to SSA 
• sst5TMD4 provides a plausible predictive marker for tumor invasiveness in 
acromegaly 
• In vitro overexpression of sst5TMD4 enhanced cell viability in somatotropinomas 
• sst5TMD4 expression may provide an attractive target for therapeutic research 
 
ABSTRACT 
 
The GH/IGF1 response of somatotropinomas to somatostatin analogues (SSA) is 
associated to their pattern of somatostatin receptor (sst1-sst5) expression. Recently, we 
demonstrated that expression of a truncated sst5-variant (sst5TMD4) can influence the 
secretory response of somatotropinomas to SSA-therapy; however, its potential relationship 
with aggressive features (e.g. invasion/proliferation) is still unknown. Here, we show that 
sst5TMD4 is present in 50% of non-functioning pituitary-adenomas (NFPA) (n=30) and 89% 
of somatotropinomas (n= 36), its expression levels being highest in 
somatotropinomas>>NFPAs>>>normal pituitaries (negligible expression; n=8). In 
somatotropinomas, sst5TMD4 mRNA and protein levels correlated positively, and its 
expression was directly associated with tumor invasiveness (cavernous/sphenoid sinus), and 
inversely correlated with age and GH/IGF1 reduction after 3-6 month with octreotide-LAR 
therapy. GNAS+ somatotropinomas expressed lower sst5TMD4 levels. ROC analysis revealed 
sst5TMD4 expression as the only marker, within all sst-subtypes, capable to predict tumor 
invasiveness in somatotropinomas. sst5TMD4 overexpression increased cell viability in 
cultured somatotropinoma (n=5). Hence, presence of sst5TMD4 associates with increased 
aggressive features and worse prognosis in somatotropinomas, thereby providing a potentially 
useful tool to refine somatotropinoma diagnosis, predict outcome of clinical response to SSA-
therapy and develop new therapeutic targets. 
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Keywords: sst5TMD4, acromegaly, invasion, proliferation. 
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1. Introduction 
Acromegaly results from increased release of GH and IGF1 caused by a GH-producing 
adenoma (somatotropinomas). Consequently, the main therapeutic goal in this disease is 
reduction of circulating GH and IGF1 levels and of tumor size, particularly in patients 
presenting macroadenomas (around 65% of the cases), wherein invasiveness becomes a 
crucial problem [1]. Somatostatin and its receptors (sst), especially sst2 (and to a lesser extent 
sst5), comprise the critical regulatory system for the negative control of hormonal secretion 
and tumor size in pituitary somatotropinomas [2]. Accordingly, medical treatment with 
synthetic somatostatin analogs (SSA [2]; synthetic versions of somatostatin presenting longer 
half-life and more stability) have been successfully used to treat GH secreting adenomas (i.e. 
to obtain biochemical control of the patients and/or achieve tumor shrinkage); however, a 
significant percentage of patients are biochemically resistant to SSA therapy and tumor 
shrinkage is also unsuccessful [3-6]. 
Lack of ssts expression in tumor cells has been postulated as a logical key molecular 
determinant underlying SSA resistance. In line with this, we previously demonstrated that sst2 
expression directly correlates with percent decrease of GH and IGF1 levels and tumor volume 
reduction in response to octreotide-LAR in a population of Brazilian acromegalic patients [7, 
8]. Yet, we also found, unexpectedly, a negative correlation between sst5 expression and 
percent decrease of GH and IGF1 after octreotide-LAR treatment [7, 8]. Soon thereafter, our 
studies on independent populations of Spanish [9] and French [10] acromegalic patients, 
revealed the existence of novel truncated variants of the sst5 receptor, which could be 
clinically relevant. Specifically, the truncated receptors, termed sst5TMD5 and sst5TMD4 
based on the number of transmembrane domains (TMDs) [9], are extremely infrequent in 
normal tissues but sst5TMD5 is present in a subset of pituitary adenomas while sst5TMD4 is 
frequently present in pituitary tumors [9], where they seem to exhibit a subcellular 
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localization. More interestingly, and in line with that mentioned above, the expression of 
sst5TMD4 was negatively linked to poorer clinical response in a series of patients with partial 
resistance to SSA-therapy [10]. On a different scenario, we have demonstrated that sst5TMD4 
presence is associated with poor prognosis in breast cancer, and its expression in a germane 
cell model (MCF-7 cell line) increases malignancy features (proliferation, invasiveness and 
migration) [11]. Similarly, sst5TMD4 presence is associated with poor prognosis in thyroid 
cancer [12]. 
However, the possible influence of sst5TMD4 on aggressiveness features in 
somatotropinomas, beyond reduced SSA-response (i.e. invasion/proliferation abilities) has not 
been reported hitherto. In addition, the putative association between the levels of truncated 
sst5 variants, especially sst5TMD4, and the response to octreotide-LAR therapy was not 
originally explored in the well-characterized, and previously reported, population of Brazilian 
acromegalic patients [7, 8, 13], as the truncated receptors were not yet discovered at that time. 
Accordingly, this study has three main goals: 1) To evaluate and compare truncated sst5 
variants levels in somatotropinomas, normal pituitaries and non-functioning pituitary 
adenomas (NFPA); 2) To assess potential correlations between truncated sst5 variants 
expression levels in somatotropinomas and response to SSA-therapy and/or presence of 
GNAS mutation (indicative of good response to SSA-therapy) [14]; and, 3) To investigate the 
potential role of the truncated sst5 variants in conferring aggressiveness features to GH 
secreting adenomas(i.e. invasion/proliferation abilities) in vivo and in vitro. 
 
2. Patients and methods 
 
2.1. Patients and samples 
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 For in vivo studies, we used a set of 74 pituitary samples (66 pituitary adenomas and 8 
normal pituitaries; Tables 1-3), in which demographic/clinical data of patients, profile of sst1-
5 and, presence of GNAS oncogene in somatotropinomas were previously characterized [13, 
15]. Briefly, somatotropinoma (n=36; median age: 38 year old; Table-1) and NFPA (n=30; 
median age: 51 year old; Table-2) samples were obtained during transsphenoidal surgery of 
pituitary adenoma (PA) tumors. None of the patients belongs to pituitary adenoma kindred. In 
acromegalic patients, only 3 patients were treated with octreotide-LAR before surgery and, 
prevalence of GNAS oncogene was 10% [15]. In line with this last point, we have previously 
reviewed [16] that the prevalence of the GNAS oncogene in somatotropinomas is 
approximately 40% however; it has been shown that this prevalence dramatically vary 
between studies (ranging from 4.4 to 55%) considering previous series from several countries. 
The reason for this low prevalence is not known, but is most likely the result from 
randomness, since the recruitment of patients was not based in any pre-defined criteria that 
could bias the selection of non GNAS-mutated patients.  
 As previously reported, normal pituitaries (n=8; median age 40 year old; Table-3) 
were obtained during autopsy, after accidental death [13, 15]. Tumors were classified as 
invasive or noninvasive according to radiological criteria as previously reported [17]. As 
previously published [8], patients with acromegaly were classified as pharmacologically 
controlled when achieving the criteria of normal IGF1 levels for age as well as, GH<2.5 µg/L 
(indeed, all patients also achieved the more stringent criteria of 1 µg/L). As previously 
published [8], basal GH and IGF levels and tumor volume data of the acromegalic patients are 
indicated in Table-1 in order to improve global insight of the data. 
 For in vitro studies, somatotropinoma specimens were obtained during transsphenoidal 
surgery (n=7), placed in sterile cold media and dispersed into single cells for culture by 
enzymatic and mechanical disruption following the methods previously reported [18]. 
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 This study was in accordance with the ethical standards of the Helsinki Declaration of 
the World Medical Association, and it was approved by the Ethic Committees of the Hospital 
Universitário Clementino Fraga Filho (Brazil) and of the University of Cordoba (Spain). 
Informed consent was obtained from each patient or relative, in case of autopsy, before study 
entry. 
 
2.2. RNA isolation, reverse transcription, and analysis of truncated sst5 variants gene 
expression by quantitative real-time PCR (qPCR) 
Details of RNA extraction, quantification, reverse-transcription (RT), application of 
qPCR and primer sequences used to measure the expression levels of human transcripts 
included in this study have been previously reported elsewhere by our group [9, 19]. Briefly, 
samples were processed for recovery of total RNA, its concentration quantified and, 1µg was 
reversed transcribed. cDNAs were amplified by qPCR and run against synthetic standards for 
each transcript of interest to estimate mRNA copy number. As previously described, to 
control for variations in the amount of RNA used in the RT reaction and the efficiency of the 
RT reaction, the expression level (copy-number) of the transcripts of interest were adjusted by 
the normalization factor (NF) within sample calculated from the expression levels of three 
control genes [glyceraldehyde-3-phosphate dehydrogenase (GAPDH), beta-actin (ACTB) and 
hypoxanthine ribosyltransferase (HPRT1)] using the GeNorm3.3 application [20]. 
 
2.3. Immunohistochemical analysis (IHC) of sst5TMD4 in somatotropinomas 
IHC was performed using the Ultra-Sensitive ABC Peroxidase Staining Kits and the 
Metal Enhanced DAB Substrate Kit (Thermo Scientific, Rockford, IL, USA) as previously 
described but with some modifications [9]. Specifically, the sections were deparaffinized and 
boiled for 20min in 10mM citric acid (pH 6.0) to unmask the epitopes and were treated with 
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3% hydrogen peroxide for 10min to inhibit the endogenous peroxidase activity. Then, 
sections were treated with blocking solution (PBS+ 1%BSA+ 0.1%Triton-X) for 30min and 
the specific sst5TMD4 primary rabbit antibody [9] was subsequently added (it should be 
mentioned that an specific antibody for sst5TMD5 is not available and that is the reason why 
IHC was not performed for sst5TMD5). After an overnight incubation with the primary 
antibody at 4
o
C, the sections were washed and incubated with an anti-rabbit horseradish 
peroxidase-conjugated antibody (Cell Signaling, Danvers, MA, USA) for 60min, the ABC 
complex for 30min and 3,3’-diaminobenzidine tetrahydrochloride for 10min. The sections 
were counterstained with hematoxylin. Negative controls were obtained by omitting the 
primary antibodies or preadsorbing the sst5TMD4-specific antibody with molar excess of the 
immunizing peptide. Cell number counting and signal intensity estimation was performed 
independently by 3 different researchers in a blinded manner and a minimum of 1000 cells 
were analyzed. 
 
2.4. Pituitary adenoma cell culture, cloning of truncated sst5 receptors (sst5TMD4 and 
sst5TMD5) into pCDNA3.1+ expression vector, transfection of cultured 
somatotropinoma cells and measurement of in vitro cell viability 
To explore the functional consequences of the presence of truncated sst5 variants on 
cell viability, we overexpressed sst5TMD4 and sst5TMD5 in human primary 
somatotropinoma cell cultures. Details of the cloning of truncated sst5 variants (sst5TMD4 
and sst5TMD5) and transfection methods into cultured cells have been previously reported 
elsewhere by our group [9, 19]. Briefly, 7 human somatotropinoma obtained after 
transsphenoidal surgery were dispersed into single cells by enzymatic and mechanical 
disruption and cultured onto tissue culture plates in serum containing medium, as previously 
indicated [18]. Then, dispersed GH secreting adenoma cells were plated in 6-well plate using 
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DMEM supplemented with 10% fetal bovine serum and 1% antibiotic-antimycotic, and 
transfected with 1µg of sst5TMD4 (n=5) or sst5TMD5 (n=3) plasmid using Lipofectamine 
2000 (Life Technologies, Barcelona, Spain). Somatotropinoma cells transiently transfected 
with empty pCDNA3.1+ (mock transfected) were used as negative control. Efficacy of the 
transfection was assessed by qPCR. After 24h, transfected cells were detached and plated 
(10,000 cells/well) in 96-well plate, and cell viability rate was assessed using the alamar-Blue 
reagent (Biosource International; Camarillo, CA) in the FlexStation-3 system (Molecular 
Devices; Madrid, Spain), as previously reported [18]. Unfortunately, commonly used models 
of tumor pituitary cell lines (i.e. GH3, GH4 or GC cells) could not be employed in these 
assays, as they derive from rodent pituitary tumor cells that endogenously express truncated 
sst5 variant orthologues [21], which would confound and preclude an adequate analysis of the 
functional consequences of the presence of human sst5 variants in these cell lines. 
 
2.5. Statistical analysis and Receiver Operating Characteristic (ROC) curve of 
sst5TMD4, sst2 and sst5 
All statistical analyses were performed by SPSS 19.0 (Chicago, IL) and GraphPad 
Prism 6.0 (La Jolla, CA). sst5TMD4 expression among normal pituitaries, somatotropinomas 
and NFPA samples, was analyzed using Kruskal-Wallis’ test (p<0.001) followed by a manual 
analysis with Mann-Whitney for each pair of samples using Bonferroni’s correction (p was 
considered statistically significant if <0.017). Correlations between variables were assessed 
using the Spearman’s correlation test. As previously reported [18] to normalize values within 
each different in vitro experiments, the values obtained in the in vitro cell viability 
experiments were compared with mock-transfected controls (set at 100%). p<0.05 was 
considered significant. When p-values ranged between <0.1 and >0.05, a trend for 
significance was indicated where appropriate.  
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 As previously reported [12], ROC was performed for evaluation of diagnostic test 
sensibility and specificity. Specifically, in this study ROC was used as a tool to measure how 
well the expression of sst5TMD4, sst2 and sst5 could distinguish between the diagnostic 
groups [patients presenting extension into sinus (total invasion and invasion into cavernous or 
sphenoid sinus)]. Statistical analysis of ROC curves was performed by calculating the Area 
Under the Curve (AUC) of each receptor and comparing them with the AUC of the reference 
line using Student’s t-test. 
 
3. Results 
 
3.1. Expression of truncated somatostatin receptor 5 variants (sst5TMD4 and 
sst5TMD5) in somatotropinomas, NFPA and normal pituitary 
Our results indicate that truncated sst5 variants are differentially expressed in human 
pituitary adenomas and that they are not relevantly expressed in normal pituitaries. 
Specifically, sst5TMD4 variant is expressed in a high proportion of somatotropinomas (89%; 
32/36; median: 208 mRNA copies; Table 1), in 50% of the NFPA (15/30; median: 9 mRNA 
copies; Table 2) and in 2 of the 8 normal pituitaries analyzed (median: 1 mRNA copy; Table 
3). Interestingly, we also found that the sst5TMD4 expression levels were significantly higher 
in somatotropinomas than in NFPA (Figure 1A; somatotropinomas>>> NFPA >>> normal 
pituitaries). However, the sst5TMD5 variant was only detected in a small subset of the 
samples analyzed [11% of somatotropinomas (n=4/36), 7% of NFPAs (n=2/30) and, 0% of 
normal pituitaries; Tables 1-3], and sst5TMD5 expression levels were significantly lower as 
compared with truncated sst5TMD4 in somatotropinomas (comparing the 4 samples 
coexpressing sst5TMD4/sst5TMD5; Table 1). For this reason (i.e. only 4 samples available 
expressing sst5TMD5), we could not performed correlations between its expression and the 
clinical data available.  
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IHC of sst5TMD4 in 22 paraffin-embedded somatotropinomas available samples 
(Table 1 and Figure 1B) revealed a positive correlation between mRNA levels and IHC data 
(both with signal intensity and percent of stained cells; Figure 1C). Unfortunately, formalin 
fixed paraffin-embedded samples from NFPA patients were not available, and therefore, we 
could not perform IHC analysis of sst5TMD4 in these samples. 
 
3.2. Association between sst5TMD4 expression and age of acromegalic patients, the in 
vivo response of acromegalic patients to octreotide-LAR and GNAS mutation status 
We found that sst5TMD4 expression levels showed a clear inverse correlation with 
age of patients with somatotropinomas (Figure 1D). It should be noted that this correlation 
with age was exclusive of sst5TMD4 and, it was not previously observed with other receptors 
(sst1-sst5) in this population of patients subtypes [7, 8, 13]. Interestingly, no correlations were 
found between the pharmacological response to octreotide-LAR therapy and individual 
sst5TMD4 expression levels however, we found a marked inverse correlation between 
sst2/sst5TMD4 ratio and percent decrease of GH and IGF1 levels after 3 and 6 months 
postsurgical octreotide-LAR treatment [Figure 2A; no significant correlations for 
sst5/sst5TMD4 ratio (data not-shown)]. Additionally, a higher sst2/sst5TMD4 ratio was 
observed among patients achieving hormonal control (GH and IGF1 levels after octreotide-
LAR therapy) compared with uncontrolled patients (Figure 2B; p= 0.06). Furthermore, our 
data indicate that sst5TMD4 expression was significantly lower in patients positive for GNAS 
mutation than in patients with no mutation, while a higher sst2/sst5TMD4 ratio was observed 
in patients with GNAS positive tumors (Figure 2C).  
 
3.3. Association between sst5TMD4 expression and invasion of intracranial structures 
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We found that expression levels ofsst5TMD4, but not sst2 or sst5, were significantly 
higher in somatotropinomas presenting extension into sinus [total (cavernous + sphenoid) and 
individual sinus extension; Figure 3, top-panels and Supplemental Figure 1A and 1B). In fact, 
ROC analysis of sst2, sst5 and sst5TMD4 showed that only expression of sst5TMD4 
discriminates between the two diagnostic groups of invasiveness [patients presenting total and 
individual (cavernous or sphenoid sinus)extension into sinus; Figure 3, bottom-panels; closer 
the ROC curve is to the upper left corner of the graphic (i.e., higher sensitivity and 
specificity), the higher the overall accuracy of the marker used]; conversely, sst2 and sst5 
expression showed a poor ability to distinguish between the two somatotropinoma-
populations (ROC curves similar to the reference line; Supplemental Figure 1A and 1B). It 
should be mentioned that similar clinical data from NFPA patients (invasiveness) were not 
available and therefore, we could not determine the potential association between sst5TMD4 
expression and increased aggressive features in these patients. 
 
3.4. Overexpression of truncated somatostatin receptor 5 variants increase cell viability 
abilities of somatotropinomas 
We found that overexpression of truncated sst5 variants was directly associated with 
increased cell viability in cultured somatotropinoma cells compared to controls (mock-
transfected somatotropinoma cells). Specifically, somatotropinoma cells transfected with 
sst5TMD4 significantly increased cell viability 24, 48 and 72h after transfection (Figure 4A), 
whereas cell viability was only significantly increased in sst5TMD5-transfected cells after 
48h after transfection (Figure 4B). Validation of transfection was performed using qPCR as 
shown in Figure 4C and 4D which showed that only sst5TMD4 or sst5TMD5, but not sst5, 
were overexpressed in these experiments. 
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4. Discussion 
 Departing from a clinically and molecularly well characterized series of pituitary 
adenomas (for demographic/clinical data and sst1-5 expression profile in these samples see 
ref. [13]), in this report we demonstrate that truncated sst5 variants are expressed 
differentially in pituitary adenomas [e.g. sst5TMD4 in 89% of somatotropinomas vs. 50% of 
NFPAs (median: 208 vs. 9 mRNA copies)], and that they are not relevantly expressed in 
normal pituitaries [irrelevant median expression (1 copy) based on method detection limit for 
ssts] [7, 9], which is consistent with our previous reports using smaller cohorts of samples 
(n=6, 22 and 1, respectively) [9]. Altogether, these data indicate that truncated sst5 variants, 
especially sst5TMD4 (which is expressed in a high proportion of pituitary adenomas), could 
play a relevant pathophysiological role in pituitary adenomas, particularly in GH secreting 
adenomas, where its expression levels are notably higher than sst5TMD5 (comparing the 4 
samples coexpressing sst5TMD4/sst5TMD5; Table 1), and also higher than in NFPAs (Figure 
1A). Additionally, we have found a positive correlation between sst5TMD4 mRNA and 
protein (IHC data) expression levels in somatotropinomas, suggesting that this mRNA is 
appropriately translated to build sst5TMD4 protein, and that sst5TMD4 expression levels may 
serve as a reliable indicator to perform further analyses. 
 Interestingly, sst5TMD4 expression showed a clear inverse correlation with age of 
patients with GHomas, which was not observed previously with other sst-subtypes [7, 8, 13]. 
Since previous results indicate age of acromegalic patients as a good clinical predictor of 
biochemical activity and aggressive features in acromegaly [3, 22], our finding showing an 
inverse correlation between sst5TMD4 expression and age suggest that expression of 
sst5TMD4 could be associated, perhaps causally, with these clinical parameters in 
somatotropinomas. In fact, in line with this, we previously reported that sst5TMD4 expression 
is associated with poorer secretory response in a population of French acromegalic patients 
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partially resistant to SSA therapy [10]. However, no studies have analyzed hitherto the 
relationship between sst5TMD4 expression, aggressive features and pharmacological 
response to octreotide-therapy in acromegaly. Hence, we subsequently studied whether 
sst5TMD4 expression associates with aggressiveness in GH secreting adenomas in vivo (i.e., 
reduced pharmacological response to octreotide-LAR and invasive features, in the Brazilian 
acromegalic population) and in vitro (i.e., proliferative capacities in cultured 
somatotropinoma cells expressing high sst5TMD4 levels). 
 No correlations were found between the pharmacological response to octreotide-LAR 
therapy and individual sst5TMD4 expression levels. This observation was not surprising 
despite its apparent discrepancy with our previous report where sst5TMD4 expression was 
related to lower GH levels in a subset of acromegalic patients [10], as our present study was 
performed in an larger, unselected cohort of patients, whereas the former set of patients was 
specifically analyzed because they had been previously found to be partially resistant to SSA 
therapy in vivo and/or in vitro [10]. Moreover, it is worth noting that, as our group and others 
have previously demonstrated, pharmacological SSA-therapy response in acromegaly might 
be more dependent on the relative expression levels between the critical sst-subtypes involved 
in negative control of hormonal secretion (i.e. low sst2/sst5 ratio is present in resistant 
somatotropinomas to SSA-therapy) than on individual expression levels of a single sst-
subtype [7, 23]. Accordingly, we next sought to determine the potential associations between 
sst2/sst5TMD4 or sst5/sst5TMD4 ratios and pharmacological response to octreotide-LAR. 
Interestingly, we found a marked inverse correlation between sst2/sst5TMD4 ratio and 
percent decrease of GH and IGF-I levels after 3 and 6 months postsurgical octreotide-LAR 
treatment suggesting that patients with high sst2 levels and low sst5TMD4 levels respond 
better to octreotide-LAR. In keeping with this notion is the higher sst2/sst5TMD4 ratio 
observed among patients achieving hormonal control (GH and IFG-I levels after octreotide-
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LAR therapy) compared with uncontrolled patients. Furthermore, when results from previous 
reports suggesting that presence of the GNAS mutation can be considered as a clinical 
indicator of a good response to SSA-therapy in acromegalic patients [14, 22], and our 
previous data showing that patients with GNAS positive tumors expressed high levels of sst2 
[15], are viewed in light of our present results showing that sst5TMD4 expression is 
significantly lower in patients positive for the GNAS mutation than in patients with no 
mutation (and additionally, a higher sst2/sst5TMD4 ratio is observed in patients with GNAS 
positive tumors), it is reasonable to suggest the existence of an overall negative association 
between sst5TMD4 presence and pharmacological response to SSA-therapy in acromegaly. 
 Results of this study, especially the connection betweensst2/sst5TMD4 with clinical 
response in acromegalic patients, might be patho-physiologically relevant because: 1) in this 
and previous studies [9, 10, 24], sst5TMD4 and sst2 are often coexpressed in pituitary 
adenomas; 2) sst-subtypes are known to form homo/heterodimers, which modify functional, 
pharmacological, and signaling properties of individual sst in response to their natural and 
synthetic ligands [25]; 3)a similar association and functional connection also occurs between 
sst2 and truncated sst5 variants [11]; and, 4) in coexpression experiments, using FRET 
technology, we observed that sst2 preferentially localizes at the plasma membrane in the 
absence of truncated sst5TMD4 but when sst5TMD4 colocalize with sst2 in the same cells, 
they interact and sst2 is partly retained in intracellular compartments, thus reducing/disrupting 
the normal inhibitory functioning of sst2, as sst5TMD4 would act as a dominant-negative 
modulator for sst2-mediating signaling [11]. 
 Most importantly, we found that expression levels of sst5TMD4 were significantly 
higher in somatotropinomas presenting extension into sinus (total and individual sinus 
extension). Of note, these differences in expression levels between patients with and without 
invasion were specific for sst5TMD4, at least in this patient population, and was not found for 
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sst2 or sst5, suggesting that the relative sst5TMD4 expression levels might represent a 
potential unique molecular signature contributing to invasion abilities of somatotropinomas. 
In support of this, the ROC analysis ofsst2, sst5 and sst5TMD4 demonstrated that only 
expression of sst5TMD4 discriminates between the two diagnostic groups of invasiveness 
[patients presenting extension into sinus (total invasion and invasion into cavernous or 
sphenoid sinus)].Importantly, in support of the invasion/proliferation abilities of truncated 
sst5 variants in somatotropinomas, our in vitro results revealed, for the first time, that 
overexpression of sst5TMD4 (and also of truncated sst5TMD5) enhanced cell viability of 
cultured somatotropinoma in a modest but consistent and significant manner in comparison 
with mock-transfected somatotropinoma cells. 
 In conclusion, our data demonstrates that presence of truncated sst5 variants, 
especially sst5TMD4, is associated with increased aggressiveness in GH secreting adenomas, 
thereby suggesting that sst5TMD4 could contribute to worsen somatotropinoma prognosis 
and may provide an attractive target for therapeutic research. Accordingly, it seems plausible 
that analysis of sst5TMD4 expression, particularly in relation to sst2, could represent in the 
future a genuine, valuable diagnostic and/or prognostic tool to help in predicting aggressive 
properties of somatotropinomas (proliferative and invasive capacities), and outcome of 
clinical response to SSA-therapy in these patients.  
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Figure legends 
 
Figure 1: (A) Median sst5TMD4 mRNA levels in normal pituitaries (NP; n=8), 
somatotropinomas (GHomas; n=36) and non-functioning pituitary adenomas (NFPA; n=30). 
(B) Representative IHC images of sst5TMD4 in somatotropinomas. (C) Positive correlation 
between IHC intensity and percentage of positive cells with sst5TMD4 mRNA levels. D) 
Negative correlation between the age of acromegalic patients at diagnosis and sst5TMD4 
levels. (A, B, C, D) mRNA copy number corrected by a normalization factor (NF) derived 
from the expression of three control genes (HPRT1, ACTB, and GAPDH).  
 
Figure 2: (A) Negative correlations between sst2/sst5TMD4 ratio and GH and IGF1 levels 
after 3 and 6 months postsurgical treatment with octreotide-LAR in acromegalic patients. (B) 
sst2/sst5TMD4 ratio in pharmacologically controlled and uncontrolled patients with GH 
secreting adenomas (GHomas). (C) sst5TMD4 expression and sst2/sst5TMD4 ratio in patients 
with GNAS negative and positive tumors.  
 
Figure 3: sst5TMD4 expression levels in invasive somatotropinomas [total (cavernous + 
sphenoid) sinus extension; left, top-panel], as well as in tumors with cavernous (middle, top-
panel) or sphenoid (right, top-panel) sinus extension; Receiver operating characteristics 
(ROC) curve to determine the accuracy of sst5TMD4 receptor as diagnostic test to 
discriminate between invasive and non-invasive somatotropinomas (bottom-panels).  
 
Figure 4: Cell viability (24-, 48- and/or 72-h) in primary culture of somatotropinoma 
transfected with sst5TMD4 (A, n=5; black columns) and sst5TMD5 (B, n=3; grey-columns) 
as compared with mock-transfected control cells (white-columns). Representative validation 
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by qPCR sst5TMD4 (C, black bar) and sst5TMD5 (D, light grey bar) demonstrating an 
increase in sst5TMD4, but not in sst5 (C and D, dark grey bar), mRNA levels. Data are 
expressed as percent of mock, set at 100%. 
Table 1. Demographic, laboratory, qPCR data (sst5TMD5 and sst5TMD4 mRNA copy number levels) 
and immunohistochemistry analysis (IHC) of sst5TMD4 in individual somatotropinomas. mRNA copy 
number have been corrected by a normalization factor (NF) derived from the expression of three 
control genes (glyceraldehyde-3-phosphate dehydrogenase; GAPDH, hypoxanthine ribosyltransferase; 
HPRT1, and beta-actin; ACTB). 
No. S A 
Basal GH 
(μg/L) 
Basal IGF1 
(%ULRV) 
Tumor 
volume 
(cm
3
) 
mRNA copy number/NF sst5TMD4 IHC 
sst5TMD5 sst5TMD4 Intensity % cells 
1 F 24 139.0 151.4 4.0 30 262 ++ 37.5 
2 F 26 5.7 110.6 NA 18 347 ++ 25.0 
3 F 31 3.2 103.0 NA 0 715 + 3.0 
4† F 36 133 181 4.7 0 71 - 0.0 
5 F 40 6.8 221.9 0.2 0 86 NA NA 
6 F 41 33.6 239 15.5 12 136 + 8.1 
7† F 42 10.3 171.2 10.9 0 103 NA NA 
8 F 45 4.2 144.8 0.1 0 1413 NA NA 
9 F 48 2.3 197.3 NA 0 0 NA NA 
10 F 51 2.5 276.3 NA 0 93 ++ 49.0 
11 F 31 NA NA NA 0 773 + 3.1 
12 F 32 NA NA NA 0 103 - 0 
13 F 32 NA NA NA NA NA NA NA 
14 F 37 NA NA NA NA NA NA NA 
15 F 39 NA NA NA 0 214 ++ 61.9 
16 F 40 2.1 616.0 NA 0 312 NA NA 
17 F 41 NA NA NA 0 392 +++ 89.3 
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18 F 42 NA NA NA 0 0 - 0.0 
19 F 46 NA NA NA 0 36 NA NA 
20 F 52 3.71 NA NA 0 241 - 0.0 
21 F 59 0.5 148.0 NA 0 261 - 0.0 
22 M 28 5.7 190.9 NA 0 242 ++ 25.0 
23 M 31 197 238 NA 0 147 NA NA 
24 M 31 46 177 11.6 0 497 - 0.0 
25^ M 33 17 377 24.5 0 1167 NA NA 
26 M 34 21.3 209.5 2.1 10 312 ++ 54.0 
27^ M 38 112.0 137.0 3.3 0 494 + 5.0 
28† M 50 7.3 277.5 NA 0 0 NA NA 
29 M 58 2.8 193.0 NA 0 89 NA NA 
30 M 62 36.0 300.4 5.2 0 182 - 0.0 
31 M 18 NA NA NA 0 201 + 68.7 
32 M 26 NA NA NA 0 84 - 0.0 
33† M 28 NA NA NA 0 81 - 0.0 
34 M 30 1.5 207.9 NA 0 632 +++ 90.0 
35 M 33 NA NA NA 0 347 NA NA 
36 M 38 NA NA NA NA NA NA NA 
37 M 45 NA NA NA 3 500 NA NA 
38^ M 63 NA NA NA 0 0 NA NA 
39# M 46 32.7 479 NA 0 101 NA NA 
Median - 38 7.1 197.3 4.7 0 208 - - 
 
NA: not available sample; 0: zero copies. In IHC analysis: -, +, ++, +++ stands for not expressed and 
low, medium, and high intensity of the signal expression; % cell: Percentage of positive cells. S: Sex; 
A: Age at diagnosis; #: Microadenoma; ^: Patients that used octreotide-LAR before surgery; †: 
Patients presenting GNAS mutation; GH levels in μg/L; IGF1 levels: ULRV, upper limit of the 
reference values; Tumor volume in cm
3.
 It should be noted that expression levels of ssts system in 
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samples no. 13, 14 and 36 were not included in this and the previous study [13] due to the limited 
available amount of cDNA however, samples are arranged similarly to the previous study in order to 
keep the order of the samples in both reports. Basal GH and IGF1 levels and tumor volume data were 
previously reported [8]. 
 
Table 2: Demographic and qPCR data somatostatin receptor subtype sst5TMD5 and 
sst5TMD4 mRNA levels in individual non-functioning pituitary adenomas estimated mRNA 
copy number corrected by a normalization factor (NF) derived from the expression of three 
control genes (GAPDH, HPRT1 and ACTB). 
 
 
No. S A sst5TMD5/NF sst5TMD4/NF 
1 F 18 0 5 
2 F 25 0 0 
3 F 43 0 27 
4 F 47 0 111 
5 F 49 0 0 
6 F 50 0 0 
7 F 52 0 6 
8 F 57 0 0 
9 F 61 0 0 
10 F 68 0 0 
11 F 72 0 11 
12 F 74 0 61 
13 F 80 0 100 
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14 F 81 138 0 
15 F 84 0 73 
16 M 31 0 28 
17 M 32 0 20 
18 M 32 0 25 
20 M 39 0 13 
21 M 40 0 69 
22 M 44 0 0 
23 M 46 0 20 
24 M 48 0 0 
25 M 48 38 216 
26 M 51 0 0 
27 M 53 0 0 
28 M 53 0 37 
29 M 56 0 72 
30 M 60 0 0 
Median 51 0 9 
 
 
Table 3: Demographic and qPCR data: somatostatin receptor subtype sst5TMD5 and 
sst5TMD4 mRNA levels in individual normal pituitaries estimated mRNA copy number 
corrected by a normalization factor (NF) derived from the expression of three control genes 
(GAPDH, HPRT1 and ACTB). 
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No. S A sst5TMD5/NF sst5TMD4/NF 
1 F 30 2 2 
2 F 40 0 34 
3 F 40 0 1 
4 M 34 0 12 
5 M 40 3 0 
6 M 40 6 1 
7 M 42 0 1 
8 M 50 0 1 
Median 40 0 1 
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A Cellular and Molecular Basis for the Selective
Desmopressin-Induced ACTH Release in Cushing
Disease Patients: Key Role of AVPR1b Receptor and
Potential Therapeutic Implications
R. M. Luque,* A. Ibáñez-Costa,* L. M. López-Sánchez, L. Jiménez-Reina,
E. Venegas-Moreno, M. A. Gálvez, A. Villa-Osaba, A. M. Madrazo-Atutxa,
M. A. Japón, A. de la Riva, D. A. Cano, P. Benito-López, A. Soto-Moreno,
M. D. Gahete, A. Leal-Cerro,† and J. P. Castaño†
Context: Desmopressin is a synthetic agonist of vasopressin receptors (AVPRs). The desmopressin
stimulation test is used in the diagnosis and postsurgery prognosis of Cushing disease (CD). How-
ever, the cellular andmolecular mechanisms underlying the desmopressin-induced ACTH increase
in patients with CD are poorly understood.
Objective: The objectives of this studywere to determine, for the first time,whether desmopressin
acts directly and exclusively on pituitary corticotropinoma cells to stimulate ACTH expression/
release and to elucidate the cellular andmolecular mechanisms involved in desmopressin-induced
ACTH increase in CD.
Design: A total of 8 normal pituitaries (NPs), 23 corticotropinomas, 14 nonfunctioning pituitary
adenomas, 17 somatotropinomas, and 3 prolactinomas were analyzed for AVPR expression by
quantitative real-time RT-PCR. Primary cultures derived from corticotropinomas, nonfunctioning
pituitary adenomas, somatotropinomas, prolactinomas, and NPswere treatedwith desmopressin,
andACTHsecretion/expression, [Ca2]i kinetics, andAVPRexpressionand/orproliferative response
were evaluated. The relationship between AVPR expression and plasma adrenocorticotropin/cor-
tisol levels obtained from desmopressin tests was assessed.
Results:Desmopressinaffects all functionalparametersevaluated in corticotropinomacellsbutnot
in NPs or other pituitary adenomas cells. These effects might be due to the dramatic elevation of
AVPR1bexpression levels found in corticotropinomas. In linewith thisnotion, theuseofanAVPR1b
antagonist completely blocked desmopressin stimulatory effects. Remarkably, only AVPR1b ex-
pression was positively correlated with elevated plasma adrenocorticotropin levels in
corticotropinomas.
Conclusions:Thepresent results providea cellular andmolecularbasis to support thedesmopressin
stimulation test as a reliable, specific test for the diagnosis and postsurgery prognosis of CD.
Furthermore, our data indicate that AVPR1b is responsible for the direct/exclusive desmopressin
stimulatory pituitary effects observed in CD, thus opening the possibility of exploring AVPR1b
antagonists as potential therapeutic tools for CD treatment. (J Clin Endocrinol Metab 98:
4160–4169, 2013)
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Cushing syndrome is caused by prolonged exposure toexcessive cortisol levels, which may lead to severe
health problems and even death (1). The first crucial step
in the management of Cushing syndrome is to diagnose it
correctly and to establish its particular features by means
of obtaining conclusive clinical and biochemical data. The
second step is the differential diagnosis to determine
whether the syndrome is caused by an ACTH-releasing
pituitary tumor, known as Cushing disease (CD), by an
ACTH-releasing ectopic tumor, or by an adrenal tumor
overproducing cortisol (1). To date, the tests used for the
diagnosis of CD (eg, CRH stimulation and dexameth-
asone suppression) are often not sufficiently conclusive,
and this is also the case when the efficacy of the surgery
is determined. Consequently, it is frequently necessary
to perform various tests to obtain a reliable diagnosis
and differential diagnosis of CD, which is not always
definitive (2).
Desmopressin is a synthetic analog of the endogenous
neuropeptide arginine-vasopressin (AVP), which binds
with high affinity to the different AVP receptors (named
AVPR1a [or V1R], AVPR1b [or V3R], and AVPR2 [or
V2R]) and stimulates ACTH secretion and cortisol levels
inpatientswithCD(3,4). Basedon these andother results,
the desmopressin test, either as an iv injection to evaluate
ACTH and cortisol levels or by bilateral inferior petrosal
sinus sampling, has been proposed as a reliable test for the
differential diagnosis and postsurgery prognosis of CD (3,
5–11). However, some studies have questioned the use of
the desmopressin test based, in part, on the limited and
often conflicting information available regarding the cel-
lular and molecular mechanisms underlying the response
of ACTH-producing tumoral cells to desmopressin (12).
Therefore, in light of this controversy, the aim of the pres-
ent work was to elucidate whether desmopressin directly
stimulates ACTH release and/or influences other func-
tional parameters (eg, gene expression and the prolifera-
tive response) in human pituitary corticotropinomas,
what types of receptor(s) and mechanisms (eg, [Ca2]i)
would mediate such actions, and whether these effects are
exerted selectively on these tumor cells derived from pa-
tients with CD or are also found in normal pituitary (NP)
cells or cells derived from other types of pituitary
adenomas.
Materials and Methods
Patients and samples
The study was approved by ethics committees of the 3 insti-
tutions participating in this research: University of Córdoba
(Córdoba, Spain), Reina Sofía University Hospital (Cordoba,
Spain), andVirgendelRocíoUniversityHospital (Seville, Spain).
Written informed consent was obtained from each patient. A set
of 69 human pituitary samples resected using transsphenoidal
surgery was included in this work. Specifically, 23 corticotropi-
nomas, 17 somatotropinomas, 14 nonfunctioning pituitary ad-
enomas (NFPAs), 3 prolactinomas, 2 mixed prolactin/growth
hormone–secreting adenomas, and 1 thyrotropinoma were an-
alyzed. In addition, 9 tissue pieces corresponding to NP glands
were included in the study. Two of these were obtained from a
commercial source (pool of multiple individuals; Clontech),
whereas the other 7were obtained frompatientswhounderwent
surgical removal of a pituitary tumor, but the tissue piece ob-
tained by our laboratorywasNP tissue, confirmed, as in the case
of pituitary tumors, by 3 separate methods: examination by an
anatomopathologist, testing of the hormonal phenotype using
single-cell secretion studiesbyacell-blottingassayon Immobilon
membranes, as reported previously (see Supplemental Figure 1
published on The Endocrine Society’s Journals Online web site
at http://jcem.endojournals.org.) (13), and molecular screening
by quantitative real-time RT-PCR (qrtRT-PCR) of the main pi-
tuitary hormonal products andmembrane receptors (see below).
Available demographic (sex and age) and laboratory/biochem-
ical data (type of tumor [macroadenoma vs microadenoma] by
magnetic resonance imaging or computed tomography and
plasma ACTH, serum cortisol and urinary free cortisol per 24
hours) of patients with CD are summarized in Table 1. ACTH
and cortisol levels were determined by specific assays (see Sup-
plemental Materials and Methods for details). NPs from male/
female C57BL/6 wild-type mice (10- to 12-weeks-old) were also
used to determine the effect of desmopressin onACTH release in
mouse corticotrope cells.
RNA isolation, reverse transcription, and qrtRT-PCR
of human transcripts from normal pituitaries and
tumor samples
Expression levels of proopiomelanocortin (POMC) (ACTH
precursor), AVPR subtypes (AVPR1a, AVPR1b, and AVPR2)
and -actin (used as a housekeeping gene) were determined,
when possible, in the samples included in this study by qrtRT-
PCR, as described previously (14–16); for details, see Supple-
mental Materials and Methods. Specific sets of primers used in
this study are shown in Supplemental Table 1. Correlations be-
tween qrtRT-PCRdata and demographic and laboratory data of
CD patients included in Table 1 were examined.
Primary pituitary cell culture and analysis of ACTH
concentrations and gene expression modulation in
response to desmopressin
To examine the direct effects of desmopressin (100 nM, dose
selected according to previous studies [12]; 4- or 24-h incuba-
Department of Cell Biology, Physiology and Immunology (R.M.L., A.I.-C., L.M.L.-S., A.V.-O., M.D.G., J.P.C.), University of Córdoba, Reina Sofía University Hospital, Instituto Maimónides
de Investigación Biomédica de Córdoba, CIBER Fisiopatología de la Obesidad y Nutrición, E-14014 Córdoba, Spain; Department ofMorphological Sciences (L.J.-R.), University of Córdoba,
E-14014 Córdoba, Spain; Instituto de Biomedicina de Sevilla (E.V.-M., A.M.M.-A., D.A.C., A.S.-M., A.L.-C.), University Hospital Virgen del Rocío/Consejo Superior de Investigaciones
Científicas/University of Seville and Endocrinology, Metabolism and Nutrition Unit, Virgen del Rocío University Hospital, 41013 Seville, Spain; Service of Endocrinology and Nutrition
(M.A.G., P.B.-L.), Reina Sofía University Hospital, InstitutoMaimónides de Investigación Biomédica deCórdoba, 14004Córdoba, Spain; Department of Pathology (M.A.J.), Virgen del Rocio
University Hospital, 41013 Seville, Spain; and Service of Neurosurgery (A.d.l.R.), Reina Sofía University Hospital, 14004 Córdoba, Spain
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tion; Ferring SAU)onACTHexpressionand release andonother
functional parameters (see below), human and mouse pituitary
samples were dispersed into single cells by enzymatic and me-
chanical disruption and cultured onto tissue culture plates in
serum-containing medium, as described previously (17, 18); for
details see Supplemental Material and Methods.
In vivo desmopressin test and correlation with
AVPR subtype expression
PlasmaACTHand cortisol levels in response to desmopressin
were available froma set of patients (n8). In these patients, the
desmopressin stimulation test had been performed for CD diag-
nostic purposesbefore surgery (VirgendelRocíoUniversityHos-
pital). Specifically, after overnight fasting, ACTH/cortisol levels
were measured before an iv injection of desmopressin (10 g;
time 0) and 15, 30, 60, 90, and 120minutes after the iv injection.
An ACTH increment of50% and cortisol20% above base-
line levels was considered positive. Correlations between basal
plasma levels of ACTH and cortisol and AVPR subtype mRNA
levels in the corticotropinomas of those patients were examined.
Measurements of free cytosolic calcium
concentration ([Ca2]i) and cell proliferation in
response to desmopressin and statistical analysis
See Supplemental Materials and Methods (13–19).
Results and Discussion
To the best of our knowledge, to date this is the first study
to perform a complete cellular and molecular character-
ization of the effect of desmopressin on a series of corti-
cotropinomas causingCDcomparedwith that onNPsand
other types of pituitary tumors and to evaluate the corre-
lation of absolute mRNA copy numbers of AVPR sub-
types obtained by qrtRT-PCR in corticotropinomas with
the in vivo clinical data of patients with CD and with the
response to the desmopressin test (ACTH and cortisol
plasma levels) performed right before surgical removal of
the pituitary adenoma in patients with CD. Our findings
are the following.
1. Patients with CD or other pituitary tumors exhibit
differential expression profiles of AVPR. The demo-
graphic and/or laboratory data and the in vivo POMC/
AVPR subtype expression profile of the 23 patients with
corticotropinomas and 9 NP samples included in this
study are shown in Tables 1 and 2, respectively.
Use of qrtRT-PCR revealed that corticotropinomas ex-
pressed POMCat high levels comparedwith those forNPs
(P .0034) (Figure 1A and Tables 1 and 2). This finding
serves as a positive control, indicating that accurate quan-
titative PCRmeasures reflect physiologically relevant dif-
ferences in gene expression. Corticotropinomas expressed
all AVPR subtypes; however, the relative expression levels
variedmarkedly between AVPR subtypes, AVPR1b being
the predominant subtype followed by AVPR2AVPR1a
Table 1. Demographic and Laboratory Data and Copy Numbers of POMC and Vasopressin Receptor Subtype
(AVPR1a, AVPR1b, and AVPR2) mRNA Content Corrected by -Actin in Corticotropinomas
CD S A
Absolute mRNA Copy Number/50 ng of Total RNA
mRNA Copy Number/-Actin
mRNA Copy Number
Tumor
Typea
BMI,
kg/m2
ACTH,
pg/mL
Urine
Cortisol
24 h,
nmol/L
Postsurgical
Cortisol,
nmol/L
Ki-67,
%BACT POMC AVPR1a AVPR1b AVPR2 POMC AVPR1a AVPR1b AVPR2
1 F 50 216 580 106 924 1109 40 972 1300 0.494 0.00512 0.189 0.006 Micro ND 33.0 2374 33.1 ND
2b F 30 11 000 295 358 000 467 910 364 2611 0.033 0.00004 0.083 0.000 Micro ND 31.7 5481.0 15.4 ND
3b,c F 34 5 031 000 1 754 213 809 1 206 467 5685 0.349 0.00016 0.240 0.001 Micro 30.8 49.9 2877.0 44.6 4.5
4b,c F 33 3 546 000 15 084 824 1426 303 339 8952 4.254 0.00040 0.086 0.003 Micro 27.8 33.9 1131.0 483.2 4
5b,c F 25 65 314 1 237 944 48 5 958 565 4099 18.954 0.00074 91.229 0.063 Micro 29.4 12.5 1408.0 108.6 4
6b,c F 23 1404 143 732 8 54 841 0 102.409 0.00568 39.074 0 Macro 35.0 47.4 3823.0 246.4 5
7c,d M 25 153 514 573 494 27990 70 651 749 67 666 3.736 0.18233 460.230 0.441 Macro 42.0 ND ND 264.0 1
8 F 20 72 774 785 372 42 238 882 ND 10.792 0.00058 3.283 Micro 33.7 ND ND ND 3–4
9 F 39 6 111 416 13 433 393 784 1 925 000 10 674 2.198 0.00013 0.315 0.002 Micro 38.0 73.2 35769.6 179.4 ND
10 M 65 5959 164 375 1942 260 496 12 474 27.586 0.32594 43.717 2.093 Micro 30.5 203.9 12751.2 ND ND
11 F 40 489 299 24 925 009 61 1 510 000 8670 50.940 0.00012 3.086 0.018 Micro 29.3 105.2 15856.2 33.1 ND
12 F 32 346 900 11 198 535 455 604 200 3944 32.282 0.00131 1.742 0.011 Micro 22.8 87.1 38722.8 30.4 ND
13 F 20 1 191 338 22 361 146 3995 1 117 172 26 985 18.770 0.00335 0.938 0.023 Micro 20.1 30.2 4802.4 463.7 ND
14c F 67 876 459 1 354 707 10 247 768 49 858 1.546 0.00001 0.283 0.057 Macro 29.3 196.0 698.3 314.6 ND
15c F 58 81 221 10 537 175 26 146 002 97 790 129.735 0.00032 1.798 1.204 Macro 51.0 ND 5409.6 ND ND
16 F 45 132 582 201 689 1150 144 972 13 451 1.521 0.00868 1.093 0.101 Micro 26.9 17.0 33120.0 44.2 ND
17c M 56 556 826 1 944 934 290 2 788 689 2228 3.493 0.00052 5.008 0.004 Macro 30 ND ND ND 1
18 ND ND ND ND 283 2 025 000 3336 ND ND ND ND ND ND
19b M 39 1 327 591 41 112 220 ND 3 700 000 ND 30.968 2.787 Micro 29.0 42.0 705.0 405.1 1
20b M 41 729 843 9 952 707 0 2 500 161 0 13.637 0 3.426 0 Micro 28.0 138.0 210.0 177.0 1
21c,d M 27 296 996 2 015 731 48 950 252 1151 6.787 0.00016 3.200 0.004 Macro 54.0 97.8 394.0 1141.0 1
22b,c F 45 193 048 2 459 344 426 1 133 580 2861 12.740 0.00221 5.872 0.015 Micro 30.4 47.0 8225.0 712.6 ND
23 M 25 209 474 146 602 3316 128 189 909 0.700 0.01583 0.612 0.004 Macro 23 ND 191.0 251.6 1.5
M 38 6 520 336 2031 4 284 637 15 459 21.542 0.026 30.377 0.202
Abbreviations: A, age; BACT, -actin; BMI, body mass index; CD, Cushing disease sample; F, female; M, male; ND, not determined; S, sex.
a Tumor type: macroadenoma (Macro) or microadenoma (Micro).
b Patients in which an in vivo desmopressin test was carried out (patients 2–6).
c Patients in which tumoral pieces were available for cell culturing experiments.
d Tumoral samples CD7 and CD21 were obtained from the same patient who was operated on 22 months after the first operation (sample CD7)
because of tumor recurrence (sample CD22); “zero” indicates no expression (0 copies in the qrtRT-PCR analysis).
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(Table 1). In NPs, AVPR1b was also predominant, fol-
lowed by AVPR2AVPR1a (Table 2). In other adenoma
subtypes (NFPAs, somatotropinomas, and prolactino-
mas), AVPR1b was also the most expressed receptor sub-
type, whereas mRNA levels of AVPR1a and AVPR2were
similarly lower (Supplemental Figure 2A). When expres-
sion levels of AVPRs were compared across sample sub-
types, AVPR1b was significantly more expressed in cor-
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Figure 1. Expression profile and hormone release in the presence or absence of desmopressin in NPs and corticotropinomas. A and B, Expression
profiles of POMC (A) and AVPRs (B) in NP (n 8) and corticotropinoma (CD; n 22). C, Basal ACTH release in NP (n 3) vs CD (n 5) cell cultures.
Values are expressed as a percentage of NPs (set at 100%; basal NP values of 85.0 17.2 vs CD values of 38,483.7 3500.5 pg/mL). D, ACTH secretory
rate, determined by a cell-blotting assay, of individual corticotrope cells derived from NPs (n 2) and CDs (n 3). Integrated optic density (IOD) in
arbitrary units (a.u.) of the halo (left panel) or inside the cells (right panel) multiplied by the number of cells in nitrocellulose membranes immunostained
for ACTH. E, Effect of a 4- and/or 24-hour treatment with desmopressin (Dm; 100 nM) on ACTH release in human CDs (4 hours, n 3 [250%, 490%,
and 170% significant increase with respect to control, set at 100%, in CD3, CD4 and CD5 samples of Table 1, respectively]; 24 hours, n 5 [200%,
120%, 210%, 120%, and 140% significant increase with respect to control, set at 100%, in CD4, CD6, CD15, CD21, and CD22 samples of Table 1,
respectively]) (left panel) and in NPs from humans (n 3) (middle panel) and mice (n 8) (right panel). F, Effect of a 4- and 24-hour treatment with
desmopressin on POMC and AVPR1b mRNA levels (n 2). Values in E and F are expressed as percentages of vehicle-treated controls (Ctrl; set at 100%)
within experiments. ACTH release was determined by a commercial ELISA. mRNA expression levels were measured by qrtRT-PCR, and mRNA copy
numbers were normalized with -actin mRNA copy number expression. Values represent means SEM. Significant differences between NPs and
corticotropinomas in A to D and desmopressin and vehicle-treated controls in E and F: *, P .05; **, P .01; ***, P .001.
Table 2. Demographic Data and Copy Number of POMC and Vasopressin Receptors Subtype (ABPR1a, AVPR1b,
and AVPR2) mRNA Content Corrected by -Actin in Normal Human Pituitary Glands
NP S A
Absolute mRNA Copy Number/50 ng of Total RNA
mRNA Copy Number/-Actin
mRNA Copy Number
BACT POMC AVPR1a AVPR1b AVPR2 POMC AVPR1a AVPR1b AVPR2
1a F 21 78 400 277 659 507 24 159 2557 3.542 0.00647 0.308 0.033
2a F 29 ND ND ND ND ND ND ND ND ND
3a F 19 4 179 468 5626 189 14 237 44,220 0.001 0.00005 0.003 0.011
4a F 41 261 866 48 015 2736 14 939 23,444 0.183 0.01045 0.057 0.090
5 F 41 493 624 40 230 3648 13 891 4776 0.081 0.00739 0.028 0.010
6a F 69 101 462 89 888 699 35 520 472 0.886 0.00689 0.350 0.005
7a F 67 1 603 691 4 916 564 18 382 1 753 491 ND 3.066 0.01146 1.093 ND
8 820 636 255 947 592 116 600 5755 0.312 0.00072 0.142 0.007
9 575 538 356 835 608 101 800 5356 0.620 0.00106 0.177 0.009
Median 41 748 846 3420 259 330 12 368 1.086 0.006 0.270 0.023
Abbreviations: A, age; BACT, -actin; F, female; ND, not determined; M, male; S, sex.
a Patients in whom normal pieces were available for cell culturing experiments.
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ticotropinomas than in NPs (P  .002) (Figure 1B),
whereas a similar relationshipwas found forAVPR1a and
AVPR2 expression, although these latter comparisons did
not reach statistical significance (Figure 1B). This quan-
titative overexpression of all AVPRs in corticotropinomas
vs NPs could provide an explanation for the well-known
secretory hyperresponsiveness of pituitary corticotrope
adenoma cells to vasopressin (20). Interestingly, we found
a positive and strong correlation between the expression
levels of POMC and AVPR1b in corticotropinoma sam-
ples (P  .0059; Supplemental Figure 3), which was not
observed with AVPR1a or AVPR2.
Similarly, we found that AVPR1b expression was sig-
nificantly higher in corticotropinomas than inNFPAs, so-
matotropinomas, or prolactinomas (P .001 in all cases;
Supplemental Figure 2B). This is the first report offering
quantitative measures of the absolute expression levels
(mRNA copy numbers) of all AVPR subtypes in cortico-
tropinomas and comparing their expression levels with
those of NPs and other types of pituitary tumors. To date,
the information available on the presence of AVPR sub-
types in corticotropinomas has been limited, fragmentary,
and somewhat controversial; however, our findings are, in
part, consistent with data reported by early studies that
used techniques providing relativemeasures of expression
(conventional RT-PCR, nuclease protection, immunohis-
tochemistry, Northern blot, or in situ hybridization),
which indicated that expression of AVPR subtypes is gen-
erally found in corticotrope tumor cells, AVPR1b being
highly expressed in these cells (3, 4, 21–23). Interestingly,
our data indicate that AVPRs are expressed in NPs and
other pituitary adenoma cell types, suggesting that the
AVP/AVPRs system might exert a role in those cell types.
Although caution shouldbe exercised in the interpretation
of these data, these results are novel and intriguing and set
the stage for future investigations to elucidate the possible
physiological role(s) on the AVP/AVPR system in normal
and tumoral noncorticotrope cells. At this point, it should
be mentioned that the expression levels of AVPR1b in
patient CD7 are remarkably higher than those in the rest
of CD samples included in this study (Table 1); however,
when we compared all the analyses included in the article
with and without sample CD7, no significant statistical
differences were found between the mean values of the
groups with sample CD7 and the mean values without
sample CD7. These results indicate that the inclusion of
sampleCD7does not alter (overestimate) the analyses and
conclusions reached in the article and, therefore, we de-
cided not to exclude the sample from the analyses.
2. Desmopressin directly stimulates ACTH release,
POMC expression, and [Ca2]i kinetics in corticotropi-
noma cells. We observed that corticotropinoma cells se-
creted higher levels of basal ACTH in the culture medium
than normal corticotrope cells in vitro (24-hour incuba-
tion, P .001) (Figure 1C). This result, together with the
cell-blotting data showing that each corticotropinoma cell
individually secretesmore basalACTHand containsmore
basal ACTH inside the cell (Figure 1D), also serves as a
positive control for our study, by indicating that the cul-
ture system used allows for the maintenance of correct
pituitary cell function.
Of note, we observed that desmopressin markedly in-
creased ACTH release in all (100%; 4 and 24 hours) cell
cultures derived from human corticotropinomas (Figure
1E) but not inNP cell cultures (human andmouse) (Figure
1E). Furthermore, we found that the stimulatory effect of
desmopressin on ACTH release was prolonged in time,
because it was still evident after 24 hours of incubation
(Figure 1E) and was also reflected by a modest, but sig-
nificant, increase in POMC mRNA (132% vs control)
(Figure 1F). Because of the limited available number of
cells derived from the culture experiments, we were not
able to study the effects of vasopressin in depth, in parallel
with those of desmopressin, on corticotropinoma cells;
however, it should be mentioned that we had the oppor-
tunity to observe that vasopressin was able to stimulate
ACTH release at the same level as desmopressin in one of
the CD samples included in the study (145% vs 140%
increase with respect to the control, set at 100%; 24-hour
incubation; sample CD22 of Table 1). Taken together,
these results are partially in agreementwith those reported
previously using different approaches (3, 12, 24), which
indicated that desmopressin stimulated ACTH release in
most of the cell culture preparations derived from CD
samples (positive response observed between 65% [12] to
100% [3, 24] of the samples analyzed). It should also be
noted that the lack of response reported by Pecori Giraldi
et al (12) in some of their cell preparationsmight be due to
the fact that AVPR1b expressionwas not detected in some
of those unresponsive cell culture samples, despite the
clear positive response to desmopressin observed in vivo
in those patients, which, as clearly indicated by these
authors, suggested that there might be a problem related
with those specific cell culture preparations (ie, cell dam-
age) and/or to the experimental conditions used.
The facts that desmopressin-induced ACTH increase is
exclusive of corticotrope adenomas but not normal cor-
ticotrope cells (Figure 1E) and that AVPR1b is markedly
overexpressed in corticotropinomas (results of this [Figure
1B and Supplemental Figure 2] and other studies [23])
suggest the existence of a selective constitutive activation
of the level of specific receptors and/or secondmessengers
imparting higher sensitivity to desmopressin (andpossibly
to endogenous vasopressin in vivo) in patientswithCD. In
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line with this idea, we demonstrate that desmopressin di-
rectly and selectively increases the levels of [Ca2]i (a sec-
ond messenger tightly coupled to and required for hor-
mone secretory vesicle release [25]) in cell cultures from
patients with CD but not in those from NP or other pitu-
itary adenoma cell cultures (Figure 2, A and B). Specifi-
cally, desmopressin treatment evoked a rapid and pro-
nounced stimulatory effect in the kinetics of [Ca2]i in
85% of corticotropinoma cells but did not alter these
kinetics in cell cultures from NPs or other types of pi-
tuitary tumors (NFPAs, prolactinomas, somatotropi-
nomas,mixedprolactin/GH-secretingadenomas, and thy-
rotropinomas) (Figure 2, A and B), which is consistent
with the lack of effect on hormone release in NPs (Figure
1E, right panel). Therefore, these results might explain in
part the rapid and sustained stimulatory activity of des-
mopressin in corticotropinomas.
3. Selective antagonists identify AVPR1b as the most
likelymediator of desmopressin stimulatory effects in cor-
ticotropinoma cells. Use of selective antagonists for each
AVPR subtype revealed that the stimulatory effect of des-
mopressin on [Ca2]i kinetics andACTHrelease ismainly
Tumor # in 
Table 1 % cells % Max ± SEM Time ± SEM 
04 61 252.9 ± 5.4 8.0 ± 1.7
05 100 215.7 ± 14.0 17.2 ± 5.3
06 100 127.0 ± 4.1 16.3 ± 0.5
07 97 169.3 ± 6.0 15.8 ± 0.2
14 70 170.8 ± 22.8 20.0 ± 6.5
15 98 240.6 ± 48.9 20.1 ± 9.1
17 76 206.3 ± 9.5 13.2 ± 1.8
Median 85 197.3 ± 16.8 15.8 ± 1.6
% cells % Max ± SEM Time ± SEM 
Dm 85 197.3 ± 16.8 15.8 ± 1.6
1a/1b/2-Ant 0
1a-Ant+Dm 51 201.3 ± 76.9 26.1 ± 7.8
1b-Ant+Dm 28 147.7 ± 14.0 45.8 ± 13.1
2-Ant+Dm 70 191.8 ± 21.4 20.3 ± 8.2
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Figure 2. Effect of desmopressin on ACTH release and free cytosolic calcium kinetics in the presence and absence of selective AVPR-antagonists.
A, Percentage of corticotropinoma cells (% cells) showing changes in [Ca2]i in response to desmopressin. Percentage of maximum response (%
Max) and time of response to desmopressin administration are also indicated. The corticotropinoma cell preparations number used in these
experiments corresponding to the specific samples included in Table 1 are also indicated. B, Representative profiles of changes in [Ca2]i in
corticotropinomas (n  7) and in NPs (n  6), NFPAs (n  6), somatotropinomas (n  5), prolactinomas (n  2), mixed prolactin/GH-secreting
adenomas (GH-PRLoma; n  1), and thyrotropinomas (n  1) cell cultures in response to desmopressin administration (Dm; 100 nM; arrow). C,
Percentage of corticotropinoma cells (% cells) showing changes in [Ca2]i in response to selective AVPR antagonists for AVPR1a (1a-Ant), AVPR1b
(1b-Ant), or AVPR2 (2-Ant), and desmopressin in the absence or presence of antagonists (n  3). Percentage of maximum response (% Max) and
time of response to desmopressin administration are also indicated. D, Effect of 24-hour treatment with desmopressin (100 nM) on ACTH release
in the absence or presence of specific AVPR antagonists in human CD cell cultures. E, Representative profiles of changes in [Ca2]i in human CD
cell cultures in response to desmopressin (Dm; 100 nM; arrow) in the absence or presence of specific AVPR antagonists. Values are expressed as a
percentage of vehicle-treated controls (set at 100%; n  3; 3–5 wells/treatment). Significantly different from control: **, P  .01; ***, P  .001.
Statistically different from desmopressin-treatment: a, P  .01.
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exerted via AVPR1b (Figure 2, C and D, respectively),
which is found to be overexpressed in CD samples (Figure
1B and Supplemental Figure 2B), and its expression is pos-
itively correlated with POMC mRNA levels in cortico-
tropinomas (Supplemental Figure 3). Specifically, the
AVPR1b antagonist nelivaptan, which had no effect on
basal ACTH release or [Ca2]i kinetics, fully blocked the
desmopressin-stimulated ACTH secretion (Figure 2D)
and [Ca2]i increase (Figure 2, C and E) in corticotropi-
noma cell cultures. The ability of the AVPR1b antagonist
to counteract the increase in [Ca2]i kinetics evoked by
desmopressin is clearly indicated by a severely delayed
response (3-fold; from 15.8 to 45.8 s after treatment) and
by the significantly reduced proportion of cells responsive
to desmopressin (85% vs 28%) and the reduced percent
maximal response of the cells (197.3 vs 147.7%) (Figure
2C). On the other hand, coincubation of desmopressin
with the antagonists forAVPR1a (relcovaptan) orAVPR2
(tolvaptan) did not block the desmopressin-stimulated
ACTH secretion on corticotropinomas (Figure 2D). In
terms of [Ca2]i kinetics, the presence of AVPR1a and
AVPR2 antagonists reduced the proportion of cells re-
sponsive to desmopressin (85% vs 51% for AVPR1a an-
tagonist and vs 70% for AVPR2 antagonist) (Figure 2C)
and slightly delayed their responses (from 15.8 to 26.1
seconds for the AVPR1a antagonist and to 20.3 seconds
for the AVPR2 antagonist) (Figure 2C) but to a lower
extent than the AVPR1b antagonists did. In fact, the per-
cent maximal response of the cells was similar in the pres-
ence or the absence of these antagonists (197.3% vs
201.3%for theAVPR1aantagonist andvs191.8%for the
AVPR2antagonist) (Figure 2C). These results suggest that
AVPR1a and AVPR2 might also be involved in the stim-
ulatory response of corticotropinoma cells from patients
with CD to desmopressin, although clearly to a lesser ex-
tent than AVPR1b. Indeed, in support of this notion, pre-
vious reports have shown that AVPR1b antagonists can
reduce stress-induced ACTH secretion from rodents in
vitro (26) and in vivo (26–29), and studies have indicated
thatAVPR1bandAVPR2antagonists canblunt (although
not block) desmopressin-induced ACTH release from hu-
man corticotropinoma cell cultures (12). Moreover, in a
different model system, the pancreatic hamster In-R1-G9
cell line, stimulation of free cytosolic calcium concentra-
tions by vasopressin was fully blocked by an AVPR1b
antagonist, whereas AVPR1a and AVPR2 antagonists
were much less efficient in counteracting this stimulatory
effect (30).Therefore, although it has not beenproven that
AVP antagonists can reduce ACTH levels in patients with
CD, these and our results, when viewed together, suggest
that further studies should be conducted to explore the
potential that specific AVPR1b antagonists may have for
the development of therapeutic approaches to disorders of
ACTH-dependent cortisol excess, such as CD, and per-
haps other stress-related disorders, as has been previously
postulated by others (26–29).
4. Desmopressin also exerts homologous regulation of
AVPR1b gene expression in vitro. An additional mecha-
nism to control the response of normal and tumoral cells
to their ligands, either endogenous/natural or synthetic, is
exertedat the level of the expressionofmembrane receptor
availability, as has been shown in other ligand receptor
systems (31, 32). However, in contrast to the information
gathered regarding the stimulatory role played by desmo-
pressin on pituitary ACTH release, to our knowledge, no
studies have been conducted to date to examine the direct
homologous regulationofdesmopressinon its receptors at
the level of the human pituitary. As mentioned above, our
study shows that desmopressin treatment significantly in-
creased POMC mRNA levels (Figure 1F, left panel). In-
terestingly, ourdata reveal that the effects of desmopressin
on human corticotropinoma cells are not only confined to
the stimulation of ACTH expression and release but also
include a down-regulation of AVPR1b expression that is
exerted after a short (4-hour) exposure and is sustained in
prolonged (24-hour) incubations (Figure 1F, right panel).
This reduction in AVPR1b expression might represent a
compensatory mechanism, in line with that typically ob-
served in this family of receptors (32) to reduce the re-
sponsiveness of corticotropinoma cells to ligands. In keep-
ing with these data, it has been reported that pituitary
AVPR1b mRNA levels (Northern blot analysis) decrease
in response to acute or prolonged osmotic stress stimula-
tion (ip hypertonic saline injection) in rats and that this
down-regulation was prevented by pretreatment with an
AVPR1b antagonist (33).
5. Expression levels of AVPR1b are correlated to re-
sponses to the desmopressin test (plasma ACTH levels)
before surgery of patients with CD.
In the present series, a clear positive response to des-
mopressin was observed in all patients for whom results
from invivodesmopressin testswere available (100%;n
8) (Figure 3A; patients indicated in Table 1). This result is
consistent with the rates (80%–100%) observed in other
studies (3–6, 9, 10). Specifically,mean plasmaACTHand
cortisol levels started rising shortly after desmopressin ad-
ministration, reaching a peak at 15 and 60 minutes, re-
spectively (Figure 3A). Interestingly, a clear positive cor-
relation was only found between AVPR1b but not
AVPR1a or AVPR2 mRNA levels and basal plasma
ACTH levels (Figure 3B). These results support our in
vitro (Figure 2, D–E) and in vivo (Supplemental Figure 3)
data and reinforce the notion that the desmopressin stim-
ulatory effect on ACTH release is mainly mediated via
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AVPR1b. At variance with our results, a comparable pos-
itive correlation was recently described (4) between the
ACTH increase in response to desmopressin in patients
with CD and the degree of AVPR2 expression (as mea-
sured by a relative quantification assay using immunohis-
tochemistry, which has been described previously that has
serious limitations as a true quantitative assay [34]). Nev-
ertheless, it should be emphasized that our novel findings
are fully supported by previous studies that used either
AVPR1b knockout mice, which demonstrated that
AVPR1b is required for the NP and adrenal response
(ACTH and corticosterone levels, respectively) to acute
stressful stimuli (35), or transgenic mice overexpressing
AVPR1b in the pituitary, which indicated that ACTH se-
cretions in response to AVP and hypothalamic-pituitary-
adrenal axis activity (basal corticosterone levels) are sig-
nificantly increased compared with wild-type controls
(36). Thus, it seems plausible that AVPR expression levels
in pituitary andmore specifically those of AVPR1b in cor-
ticotropinomas would relate to the in vivo response of
patients with CD to desmopressin.
6. Desmopressin increased cell proliferation in cortico-
tropinomas in vitro. We also had the opportunity to ob-
serve that desmopressin was able to exclusively stimulate
other functional parameters in human corticotropinoma
cells. Specifically, desmopressin moderately, but signifi-
cantly, increased cell proliferation in
2 corticotropinomas (24, 48, and 72
hours of incubation being the maxi-
mum increase observed at 72 hours
[132% vs control]; Supplemental
Figure 4) but not in cell cultures from
NFPAs, somatotropinomas, or pro-
lactinomas (data not shown). This
observation is, in part, supported by
a previous report indicating that
AVP was also able to stimulate cell
proliferation in corticotropinoma
AtT20cells (37) aswell as in cell lines
(CHO-K1and In-R1-G9) expressing
high levels of human or rodent
AVPR1b (30). Further studies, using
larger numbers of CD culture sam-
ples and different types of assays,
which are beyond our current ca-
pabilities, will be required to un-
equivocally establish whether des-
mopressin and AVP do increase
proliferation rate.
In summary, our study indicates
that the effect of desmopressin on
corticotropinomacells is (1)marked,
because it strongly stimulates ACTH
release and [Ca2]i levels, (2) prolonged, because it en-
hances both ACTH expression and/or release at short (4-
hour) and long (24-hour) periodsof time, and (3) exclusive
of corticotropinoma cells, because it was only observed in
cell cultures from patients with CD but not in NP cells or
in other human pituitary tumor cell types. Although it has
been reported that mutations of AVPR1b are not found in
the pituitary tumors of patients with CD and, therefore,
are not likely to be involved in the pathogenesis of this
disease (21), the results of the present study and those of
other laboratories (4, 21, 23) indicate that AVPR1b is
overexpressed and is directly involved in the desmopres-
sin-stimulated ACTH secretion and [Ca2]i signaling ob-
served in human pituitary corticotropinomas, which
might account, together with the additional effects that
desmopressin may have at suprapituitary levels (38), for
the well-known endogenous hyperresponsiveness of pa-
tients with CD to vasopressin (and to desmopressin).
Thus, our results invite to suggest that the potential use of
AVPR1b antagonists in therapeutic approaches for pa-
tients with CD (ie, improving clinical outcome) and per-
haps with other stress-related disorders should be ex-
plored further. Because it has not been proven that AVP
antagonist can reduce ACTH levels in patients with CD,
further studies are required to formally prove this hypoth-
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Figure 3. Expression levels of AVPR subtypes are correlated to the response to the desmopressin
test (plasma ACTH levels) in patients with corticotropinomas (n  8). A, Plasma cortisol (left
panel) and ACTH (right panel) responses to desmopressin tests in patients with
corticotropinomas. ACTH/cortisol levels were measured before an iv injection of desmopressin
(10 g; time 0) and 15, 30, 60, 90, and 120 minutes after the iv injection. Significantly different
from basal ACTH/cortisol levels (time 0): *, P  .05; **, P  .01; ***, P  .001. B, Correlations
between AVPR1b expression adjusted by -actin in corticotropinomas and plasma levels of ACTH
in response to desmopressin tests in CD patients (n  8).
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esis. However, this notion is supported by previous ob-
servations demonstrating that treatmentwith SSR149415
or Org (AVPR1b antagonists that have no effect on basal
pituitary adrenal activity and arewell tolerated in animals
and humans) in vivo in rodents can completely reduce
arginine/vasopressin-stimulated and stress-induced
ACTH secretion (26, 28, 29).
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SUPPLEMENTAL MATERIAL AND METHODS 
 
Cortisol and ACTH assays: We used electrochemiluminescence assays in the Seville´s 
hospital [E170 Modular Analytics (Roche Diagnostic, Manheim Germany)] and 
immunoradiometric assays in the Cordoba’s hospital [ACTH IRMA (DRG Diagnostics, Marburg, 
Germany) for ACTH and Architect System (Abbott, Illinois, USA) for cortisol]. Details of the 
different assays are as follow: 1) ACTH levels in E170 Modular Analytics were within-run 
precision between 0.6% to 2.7% and intermediate imprecision between 1.8% to 5.4% for values 
between 4.9-1205 pg/mL. The normal range values were 7.2-63.3 pg/mL and the lower detection 
limit was 1 pg/ml; 2) sensitivity of the ACTH IRMA assay was between 4 and 994 pg/mL with an 
intraassay and interassay coefficients of variation of 3 and 4.8%. The normal range value was 5-45 
pg/mL; 3) Serum cortisol and UFC levels in E170 Modular Analytics were within-run precision 
between 1,0-1.3% and 2,2-2,9% and intermediate imprecision between 1.4-1.6% and 1,8-2,5% for 
concentration levels between 208 nmol/L-1268 nmol/L and 617-1683 nmol/L, respectively. The 
normal range values for serum cortisol and UFC were 171-536 nmol/L and 100-379 nmol/24 h 
respectively, and the lower detections limit was 0,5 nmol/L and; 4) sensitivity of the Architect assay 
was 22.08 nmol/L with an intraassay and interassay coefficients of variation of 2.9 and 3.9%. The 
normal range values for serum cortisol and UFC were 101.2-535.7 nmol/L/24h and 171-536 
nmol/L, respectively. 
RNA isolation, reverse-transcription, qrtRT-PCR of human transcripts from normal 
pituitaries and tumor samples: Details of RNA extraction, quantification, reverse-transcription as 
well as of the development, validation and application of qrtRT-PCR to measure the expression 
levels of different human transcripts have been previously reported elsewhere by our group (14-16). 
To control for variations in the amount of RNA used in the reverse-transcription reaction and the 
efficiency of the RT reaction, the expression level (copy-number) of each transcript was adjusted by 
beta-actin expression. It should be noted that, as previously reported (14, 15) and based on the 
stringent criteria to maximize specificity and efficiency, the qrtRT-PCR technique, as applied, can 
be used to accurately quantify copy numbers for all human transcripts included in this study.  
Primary pituitary cell culture and analysis of ACTH concentrations and gene-expression 
modulation in response to desmopressin: Human and mouse pituitary samples were dispersed into 
single cells by enzymatic and mechanical disruption and cultured. After a 36-48h of incubation 
(37C), medium was removed and cells were pre-incubated for 1h in fresh, warm, serum-free 
medium to stabilize basal hormone secretion. After this pre-incubation step, the medium was 
replaced with serum-free medium containing the different treatments.  
Selective AVPRs antagonists (Relcovaptan, Nelivaptan and Tolvaptan: antagonists for 
AVPR1a, AVPR1b and AVPR2, respectively; Axon Medchem BV, Groningen, The Netherlands) 
were used in the presence or absence of desmopressin in order to elucidate the specific receptor(s) 
mediating the ACTH-stimulated response to desmopressin in corticotropinoma cells. Specifically, 
medium containing the different antagonists was added following the 1h pre-incubation period 
(medium alone was used in the vehicle-treated controls) for a 90 min period and then, the medium 
was replaced with medium alone (vehicle) or containing the selected antagonist combined with 
desmopressin and the cells were incubated for an additional 24-h period.  
After treatments, the medium was recovered and frozen for subsequent analysis of ACTH 
concentrations using commercial immunoassays (DRG International, NJ, USA). Total cellular RNA 
was extracted, quantified and reverse transcribed (RT) for subsequent analysis of gene expression of 
POMC and AVPR-subtypes by qrtRT-PCR following methods previously reported by our group 
(17, 18, 31).  
Measurements of free cytosolic calcium concentration ([Ca2+]i) and cell proliferation in 
response to desmopressin: As previously reported, these functional parameters were measured 
using fura-2AM (50,000 cells/coverslip; Molecular Probes, Eugene, OR) (16) and alamar-blue 
(10,000 cells/well-plate; Biosource International, Camarillo, CA) reagents (19). 
 Briefly, for the measurement of [Ca2+]i, cells were grown onto glass coverslips for 36-48h 
(35-mm plates) and incubated for 30 min at 37C with fura-2AM in phenol red-free DMEM 
containing 20mM NaHCO3 (pH 7.4). Coverslips were washed with DMEM and cells examined for 
changes in [Ca2+]i after the corresponding treatment [desmopressin alone or combined with an 
specific AVPR-antagonist (preincubated 15 min before adding desmopressin) at the indicated 
concentrations] using MetaFluor Software (Imaging Corp., West Chester, PA). 
Statistical analysis: Raw data were evaluated for heterogeneity of variance and, where 
found, values were log transformed. Statistical differences were assessed by Student’s t-tests to 
compare the effect of desmopressin vs. vehicle-treated control in vitro or by one-way ANOVA 
followed by Fisher’s test for multiple comparisons to determine the effect of AVPR antagonists on 
desmopressin-stimulated ACTH secretion in vitro. Correlations between in vivo parameters were 
studied using Pearson's correlation test. Differences in the in vivo desmopressin test were assayed 
by one-way ANOVA. All data are expressed as means ± S.E.M. P<0.05 was considered significant. 
When P values ranged between <0.1 and >0.05, a trend for significance was indicated where 
appropriate. All statistical analyses were performed using the GraphPad Prism5 (GraphPad 
Software; La Jolla, CA). 
 
Supplemental table 1: Human-specific primers for POMC, AVPR1a, AVPR1b, AVPR2 and beta-actin 
(ACTB) used for quantitative real-time RT-PCR. 
 
Gene 
GenBank 
accession no. 
Primer Sequence 
Nucleotide 
position 
Product 
size (bp) 
POMC BC065832 
Sn: CCCTACAGGATGGAGCACTT 
As: CGTTCTTGATGATGGCGTTT 
Sn: 744 
As: 870 
127 
AVPR1a NM_000706.3 
Sn: GACGGCTTACATCGTCTGCT 
As: TGGTGATGGTAGGGTTTTCC 
Sn: 2865 
As: 2968 
104 
AVPR1b NM_000707.3 
Sn: ACAAGAATGCCCCTGATGAA 
As: GGCTGTTGAAGCCCATGTAG 
Sn: 1078 
As: 1188 
111 
AVPR2 AY242131.1 
Sn: CTGCCCCAGCTCTTCATCTT 
As: TAGGTGCCACGAACACCATC 
Sn: 585  
As:723 
139 
ACTB NM_001101.3 
Sn: ACTCTTCCAGCCTTCCTTCCT 
As:CAGTGATCTCCTTCTGCATCCT 
Sn: 864 
As: 1039 
176 
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Melatonin regulates somatotrope and lactotrope
function through common and distinct signaling
pathways in cultured primary pituitary cells from
female primates
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Melatonin is secreted by the pineal gland and exhibits a striking circadian rhythm in its release.
Dependingon the species studied somepituitary hormones also displaymarked circadian/seasonal
patterns and rhythms of secretion. However, the precise relationship between melatonin and
pituitary function remains controversial, and studies focusing on the direct role of melatonin in
normal pituitary cells are limited to non-primate species. Here, adult normal primate (baboons)
primary pituitary cell cultures were used to determine the direct impact of melatonin on the
functioning of all pituitary cell types from the pars distalis. Melatonin increased GH and PRL
expression/release in a dose- and time-dependent fashion, a response that was blocked by soma-
tostatin. However, melatonin did not significantly affect ACTH, FSH, LH or TSH expression/release.
Melatonin did not alter GHRH- or ghrelin-induced GH and/or PRL secretions, suggesting that
melatonin may activate similar signaling-pathways as ghrelin/GHRH. The effects of melatonin on
GH/PRL release, which are likely mediated throughMT1 receptor, involve both common (AC/PKA/
extracellular calcium-channels) and distinct (PLC/intracellular calcium-channels) signaling-path-
ways.Actionsofmelatoninonpituitary cells also included regulationof theexpressionofother key
components for the control of somatotrope/lactotrope function (GHRH-, ghrelin- and somatosta-
tin-receptors). These results show, for the first time in a primate model, that melatonin directly
regulates somatotrope/lactotrope function, thereby lending support to thenotion that theactions
of melatonin on these cells might substantially contribute to the define daily patterns of GH and
PRL observed in primates, and perhaps in humans.
Melatonin (MT) is an ancientmolecule, widely spreadin nature (ie, plants and animals), whose chemical
structure has been unchanged over billions of years of
evolution (1). The presence of MT very early in evolution
supports its importance for the physiology of many cel-
lular systems that express MT binding sites. In mammals,
MT is synthesized in several cells, tissues, and organs for
local utilization (autocrine or paracrine actions) (2); how-
ever, circulating MT is mainly provided by the pineal
gland wherein it is produced and directly released to the
blood and cerebrospinal fluid (CSF), a process that is un-
der the precise control of the master circadian clock, the
suprachiasmatic nucleus (SCN) of the hypothalamus (3,
4).CirculatingMT exhibits a striking circadian rhythm in
its release and has a well-established role in a number of
physiological processes and behaviors involving both cen-
ISSN Print 0013-7227 ISSN Online 1945-7170
Printed in U.S.A.
Copyright © 2014 by the Endocrine Society
Received October 6, 2014. Accepted December 22, 2014.
Abbreviations:
N E U R O E N D O C R I N O L O G Y
doi: 10.1210/en.2014-1819 Endocrinology endo.endojournals.org 1
The Endocrine Society. Downloaded from press.endocrine.org by [${individualUser.displayName}] on 29 January 2015. at 04:27 For personal use only. No other uses without permission. . All rights reserved.
tral and peripheral systems in humans and seasonally
breeding animals (ie, transducer of light/dark informa-
tion) (5). In fact, nowadays MT is being used therapeuti-
cally in the alleviation of some disorders (ie, jet-lag and
sleep disorders, neuroprotection, etc.,) (6, 7). These main
physiological actions of MT in MT-responsive cells de-
pend upon the expression of three proteins to which MT
binds with strong affinity, the two well-characterized G-
protein coupled seven transmembrane domain receptors
(GPCRs; MT1 and MT2) (8), and the less-characterized
cytosolic enzyme quinone reductase 2 (QR2) (9).
Although the actions ofMT in a member of physiolog-
ical systems of various species are now well established
(mostly nonprimate species), the importance ofMT in the
function of some key neuroendocrine organs/tissues has
not been clearly defined in mammals, specially in humans
and nonhuman primates. Therefore, and in view of the
therapeutic applications of MT in humans mentioned
above (6, 7), it would be important to evaluate the direct
actionsofMT in someof thesekeyneuroendocrine tissues,
as is the case of the pituitary gland, often referred to as the
‘master endocrine gland’. Indeed, the pituitary is consid-
ered themost important organ of the endocrine system for
its capacity to produce several hormones that control
many of themost important functions of the body, such as
growth, metabolism, reproduction, and stress (10). The
anterior pituitary is composed of five hormone-secreting
cell types, including those expressing prolactin (PRL) and
growth hormone (GH), which account for most of the
gland, adrenocorticotropin (ACTH)-secreting and thyro-
tropin (TSH)-secreting cells, and gonadotropin [follicle-
stimulating hormone (FSH) and luteinizing hormone
(LH)] cells (11). The cells of the anterior pituitary gland
are subjected to the stimulatory and inhibitory actions of
multiple central and peripheral regulators which result in
the synthesis and release of these hormones according to
a precise pattern in terms of amount and time (12). In fact,
similar to MT, anterior pituitary hormones also show
marked circadian patterns and rhythms of secretion.
However, quite surprisingly the precise relationship be-
tween MT and anterior pituitary function remains con-
troversial. Specifically, most the data available regarding
the direct role that MT exerts on pituitary cell function,
which have been derived from laboratory rodent species
(largely rat), suggest that MT may contribute to the con-
trol of some pituitary hormone secretions (13). However,
these data are quite limited and in many instances is con-
troversial since they indicate thatMT can either stimulate,
inhibit or have no effect on the secretionof a given anterior
pituitaryhormone (14–20). In addition, rodent species are
basically nocturnal and, consequently, the information
obtained in these species should not be extrapolated di-
rectly to diurnal species, and especially to humans or non-
human primates.
To the best of our knowledge, the exact direct role(s)
that MT plays in regulating the function of all anterior
pituitary cell types in humanor primates remain to be fully
elucidated. For that reason, themain goal of this studywas
aimed at determining, for the first time,what are the direct
effects of MT on the pituitary hormonal expression and
release in normal primates (baboons,Papio anubis), a spe-
cies that more closely models human physiology (21, 22).
In addition, the pituitary cell types found to be directly
controlled by MT were further studied to determine the
precise contribution of intracellular signaling pathways,
including adenylyl cyclase (AC), protein kinase A (PKA),
phospholipaseC (PLC), proteinkinaseC (PKC)and extra-
and intra-cellular Ca2, to the effects of MT using stan-
dard pharmacological (inhibitory) approaches. Our re-
sults unveil a clear, selective action of MT only on soma-
totropes and lactotropes, which seems to involve both
common and distinct signaling mechanisms and may en-
tail physiological relevant action of MT on the circadian
regulation of GH/PRL release in primates.
Materials and Methods
Reagents. All reagents, peptides and inhibitors of signaling
pathways used in this studywere purchased from Sigma-Aldrich
(St. Louis, MO) unless otherwise specified. Somatostatin was
purchased from Phoenix Pharmaceuticals (Burlingame, CA).
-Minimum essential media, HEPES, horse serum, and penicil-
lin-streptomycin were obtained from Invitrogen (Grand Island,
NY). U73122 was purchased from Cayman Chemical (Ann Ar-
bor, MI).
Animals and tissue collection. Primate (Olive Baboon;Papio
anubis; n 6, 7–10 years of age; 15.3–18.3 Kg of weight) pitu-
itaries were obtained from randomly cyclic control females from
a breeding colony at the University of Illinois at Chicago within
15 minutes after sodium pentobarbital overdose as previously
reported (23, 24). Pituitaries were immediately excised and
placed in sterile cold (4°C) media (-MEMwith: 0.15% BSA, 6
nMHEPES, 10 IU/ml penicillin and 10g/ml streptomycin) and
transported to the laboratory. Then, under sterile conditions,
pars distalis of the pituitary was isolated, washed twice in fresh
media and cut into small pieces (20–40 mg) with surgical
blades. Two small fragments of the pars distalis were rapidly
frozen in liquid nitrogen and stored at –80 C until extraction for
total RNA (see below), whereas the remaining fragments were
dispersed into single cells for culture (see below). Cell cultures
were used to determine the effect of MT (alone or, in combina-
tionwith other regulators of pituitary function) on pituitary hor-
monal synthesis and secretion. Therefore, it should be noted that
the effect of MT was determined exclusively on cells located in
the pars distalis. At the end of the corresponding incubation
periods with the different treatments, media were recovered for
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hormone analysis and, cells recovered for RNA analysis (see
below). All these samples (media and cells) were sent to the Uni-
versity of Cordoba where all the measurements and analyses
were carried out. Accordingly, all the studies included in this
manuscript were approved by Ethics Committees of the two in-
stitutions participating in this research: University of Illinois at
Chicago and University of Córdoba Institutional Animal Care
and Use Committees.
Primary pituitary cell cultures. anterior pituitaries from ba-
boonswere dispersed into single cells by enzymatic andmechan-
ical disruptionandcellswere cultured following themethodsand
reagents previously reported (25). Briefly, cells (200.000 cells/
well) were plated onto 24-well plates in media containing 10%
fetal horse serum. After 36h incubation (37°C), media was re-
moved and cells preincubated for 1h with fresh, warm, serum-
free media alone to stabilize basal hormone secretion. After the
preincubation period with serum-free media, cells were incu-
bated with serum-free media containing the following treat-
ments: 1)MT alone (10-14 to 10-6M; dose-response experiment;
4h incubation); 2) MT alone (10 nM) for 4-, 12- and 24-hour
(time course experiment); 3) MT alone (10 nM) or in combina-
tion with GH-releasing hormone (GHRH, 10 nM), acylated-
ghrelin (10 nM) or somatostatin (100 nM) for 4h. In addition, in
order to study the intracellular signaling pathways involved in
the MT-mediated actions on GH and PRL release, serum-free
media containing inhibitors of different intracellular signaling
pathways [AC (MDL-12,330A; 10 M), PKA (H89; 15 M),
PLC (U73122; 50M), extracellular Ca2 channels (nifedipine;
1 M) or intracellular Ca2 channels (thapsigargin; 10 M)]
was incubated for 90 minutes after the 1h preincubation period
with serum-free media, and then, the media were replaced with
mediawith the specific inhibitor alone (vehicle) ormediawith the
inhibitor containing MT (10 nM) and incubated for an addi-
tional 4h. Additional controls consisted of serum-free media
alone or media with MT (both cases without inhibitors). Doses
for GHRH, ghrelin, SST or inhibitors of intracellular signaling
pathways were selected based on previous studies (23, 26, 27).
After the corresponding treatments and incubations periods,
media were collected for hormone analysis using commercial
ELISAS (see below) and, in selected cases, cells were processed
for totalRNArecovery and assessment ofmRNA levels by quan-
titative real-time PCR (qrtPCR; see below).
Hormone release analysis. GH, PRL, ACTH, LH, FSH and
TSH hormone concentrations in the culture media were mea-
sured using human commercial ELISAs [Human: GH, LH, FSH,
PRL,ACTHandTSH(reference numbers: EIA-1787,EIA-1289,
EIA-1288, EIA-1291, EIA-3647 and EIA-1790, respectively;
DRG, Mountainside, NJ)]. All the assays were performed fol-
lowing the manufacturer’s instructions where the information
regarding specificity, detectability and reproducibility for each
of the assays can be accessed at the websites of the indicated
company.
RNA isolation, reverse-transcription and qrtPCR of ba-
boon transcripts.Whole tissues (pituitary and hypothalamus)
and pituitary cell cultures from baboons were processed for re-
covery of total RNA and the subsequent quantification of the
amount of RNA recovered using kits and methods previously
described (23, 24, 27). Total RNA (0.15 g for pituitary cell
cultures and 1 g for whole tissues) was reversed transcribed in
a 20l volume using random-hexamer primers and the cDNA
First Strand Synthesis kit (MRI Fermentas, Hannover,MD). cD-
NAs were amplified by qrtPCR using a Stratagene Mx3000p
real-time PCR machine and the brilliant SYBR Green QPCR
MasterMix (Stratagene, La Jolla, CA). To estimatemRNA copy
number, samples were run against specific synthetic standards
(1, 101, 102, 103, 104, 105, and 106 copies of synthetic cDNA
template for each transcript of interest) run on the same plate.
Details regarding the development, validation, and application
of a qrtPCR to measure expression levels of baboon transcripts,
including cyclophilin-A (usedas ahousekeepinggene), havebeen
reported previously (23, 25, 28). Specific sets of primer se-
quencesused in this studyhavebeenpreviously reported (23,24).
New baboon primer sequences were used in the present study to
amplify baboonMT1 (Sense: GCGTCCTCATCTTCACCATC;
Antisense: CACCAACGGGTACGGATAAA; Accession num-
ber: XM_003899434.1; product size: 158bp) and MT2 (Sense:
GTGCTCAGGAACCGCAAG; Antisense: AGAAGATGGC-
CACGAGGATT; Accession number: XM_003910543.1; prod-
uct size: 115bp). To control for variations in the amount of RNA
used in the RT reaction and the efficiency of the RT reaction,
mRNA copy numbers of the baboon transcripts analyzed were
adjusted by cyclophilin-A expression, where baboon cyclophi-
lin-A mRNA levels did not significantly vary between experi-
mental groups (data not shown).
Statistical analysis. To normalize values within each treat-
ment and minimize intragroup variations in the different exper-
iments (ie, different stage of the estrus cycle and/or to the met-
abolic environment, age of the tissue donor, etc.,), the values
obtained were compared with vehicle-treated controls (set at
100%), where this style of data presentation does not alter the
relative differences between MT-treated and vehicle-treated
groups. Each study was tested in a minimum of three separate
independent pituitary cultures carried out on different days and
with different cell preparations (3–4 replicated/treatment/exper-
iment). Differences between groups were assessed by one-way
ANOVA [or two way ANOVA when the intracellular signaling
pathways, with treatments with and without (controls) specific
inhibitors, were studied] followed by a Newman-Keuls test for
multiple comparisons. P  .05 was considered significant. All
data are expressed as means  SE. All statistical analyses were
performed using the GB-STAT software package (Dynamic Mi-
crosystems, Silver Spring, MD) and GraphPad Prism 6.0 (La
Jolla, CA).
Results and Discussion
The release of MT by the pineal gland as well as the se-
cretion of various hormones by the pituitary gland, in-
cluding GH and PRL, display clear circadian patterns
and/or rhythms of secretion over a 24h period (eg, noc-
turnal increase in MT as well as in plasma GH and PRL
(29–31)). However, the potential direct relationship be-
tween MT and the control of anterior pituitary cell func-
tion remains unclear, and the information available is
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somewhat controversial. In fact, most the data available
derives from early studies conducted in nonprimate spe-
cies (largely from in vitro studies in rodent species, espe-
cially rat) which have shown thatMT can have inhibitory
(14, 15, 18, 19), stimulatory (18) or no effects (14, 16–19)
on basal or stimulated hormonal release from the anterior
pituitary. However, a caveat should be introduced at this
point, because, although this early data undoubtedly has
great interest and value for the scientific community,most
of this information was generated from nocturnal species,
which are active at night, and consequently, caution
should be exercised before extrapolating this information
to diurnal species and especially to humans or nonhuman
primates.
To the best of our knowledge, the precise direct role
thatMTmayplay in regulating the functionof the anterior
pituitary cell types in human or nonhuman primates re-
mains to be fully elucidated. Actually, the only available
data in these species was generated in in vivo studies, and,
again, appear controversial, in that they indicate that MT
can exert either stimulatory (31–43), inhibitory (44, 45),
ornoeffects (36,40,42,43,45–49)onpituitaryhormonal
secretions, where some of these divergent, even opposite
results, were generated from the same laboratories, which
suggested that these discrepancies could be explained by
differences on the age, sex and/or reproductive status, etc.,
of the animal models used, or on the time of the day when
the experiments were performed. Consequently, and with
the aim of clarifying these conflicting results observed in
humans and primates in vivo, the main goal of this study
was to determine the direct (in vitro) effects of MT on the
expression and release of all anterior pituitary hormones
using primary pituitary cell cultures from an appropriate,
validated, primatemodel system. Specifically, we used the
baboon as a working animal model, based on the many
similarities that exist at the physiological and genomic
levels between this primate species and the human, and
because this model has been previously used by different
laboratories to test a variety of hypotheses that cannot be
directly tested in human subjects (21–24, 26, 27).
Direct effect of melatonin on the function of all
anterior pituitary cell types in a nonhuman
primate model
As shown in figure-1A, a 4h-incubation withMT stim-
ulated GH and PRL release in a concentration-dependent
manner, starting at a 10-10M dose. Conversely, FSH or
TSHreleasewas not altered by anyof theMTdoses tested,
and MT tended to inhibit LH secretion at a 10-8 M dose,
although this latter effect did not reach statistical signifi-
cance (P  .09). The lowest MT dose that caused a max-
imal stimulatory effect onbothGHandPRL secretionwas
10-8M, which is on the range of physiological concentra-
tions of this hormone in the human circulation (50, 51).
Hence, this concentration was chosen to further explore
direct MT actions on somatotrope and lactotrope
function.
Treatment with MT for increasing incubation times
demonstrated that the stimulatory effect of MT on GH
and PRL secretion was held over time (Figure-1B). Yet,
interestingly, our data revealed that maximal hormone
release was already achieved, for both GH and PRL, after
4h of incubation, and although the stimulatory effect was
still observed after long-term (12–24h) incubation, no fur-
ther quantitative increase was appreciable above the ini-
tial stimulation seen at 4 hours (Figure-1B). These obser-
vations in primary pituitary cell cultures from baboon are
consistent with early reports showing that MT can en-
hance GH (31–35) and PRL (36–41, 43) secretion in hu-
mans in vivo. Thus, results of our study, coupled to those
from previous reports, support the possibility that MT
exerts a direct, stimulatory effect on GH and PRL release,
which could potentially contribute to the nocturnal rise of
these hormones observed in humans in vivo (29–31). In
favor of this idea are also previous reports showing that:
1) the nocturnal rise in PRL release is preceded by an in-
crease in MT (41), 2) exogenous administration of MT
enhanced the nocturnal pulsatile secretion of PRL in nor-
mally cycling women (48), and 3) the rise in MT concen-
tration during the night closely parallels, and may likely
favor the nocturnal rise observed inGH release in humans
and animal models (32, 52, 53). Moreover, some studies
have shown that exposure to a regular light/dark cycle
which favors an increase inMTduring thenocturnal cycle,
as opposed to the more common constant light environ-
ment disturbing the natural increase of MT over a 24h
period, promotes body growth in human infants (54) or
neonatal rats (55). Nevertheless, whether this latter effect
on body growth is unequivocally caused by aMT-induced
increase inGH levels remains to be elucidated. In linewith
this, it should be mentioned that although the available
evidence support the contention that therapeutic admin-
istration of MT (eg, used to alleviate symptoms of mood,
sleep or other disorders) is relatively safe in adult human
subjects and animal models at various dose ranges (5),
most of these effects have not been demonstrated at clin-
ically relevant concentrations in humans. Therefore,
based on our data, and taking into account that GH and
PRL are two closely related hormones involved in the con-
trol of numerous physiological functions (eg, growth, glu-
cose and lipid metabolism, immune system etc.,) (56, 57),
future studies exploring effects of MT dose, treatment re-
gime, safety, formulation, time of the day at administra-
tion, etc., are warranted in order to precisely delineate
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whether the increase in GH and PRL levels observed in
humans in response to treatment with pure MT [or its
agonists; (31–41, 43)], could cause some side effects on
some of the physiological functions associated to the
GH/PRL-axes.
Direct effect of melatonin on hormone expression
of all anterior pituitary cell types in a nonhuman
primate model
We next studied whether MT administration can also
control synthesis of pituitary hormones (Figure-2). To our
knowledge, no studies have reported hitherto the direct
effects of MT on expression of pituitary hormones in hu-
mans or nonhuman primates. Interestingly, and as ob-
served previously for hormonal secretions (figure-1A), at
doses evoking maximal GH and PRL release, MT also
acted directly to augment GH expression after long-term
exposure (24h) and, PRL expression after both short- and
long-term exposure (4h and 24h). On the opposite, this
same experimental paradigm failed to significantly alter
expression of LH, FSH, TSH or the ACTH precursor
POMC (Figure-2). However, it should be mentioned that
since the pars tuberalis of the pituitary contain a popula-
tion of thyrotrope and gonadotropes cells (58), we cannot
discard the possibility that MT could also exert relevant
direct effects on the function of cells (ie, expression and/or
secretion) located in the pars tuberalis (which was not
collected in our cell culture preparations). In addition, our
data are in contrast with a recent publication (59) dem-
onstrating that MT suppresses ACTH production in the
mouse pituitary corticotrope tumor cell line AtT20.
Hence, we cannot discard the possibility that MT might
differentially regulate ACTH production in cultured nor-
mal vs. tumoral corticotrope cells and/or in corticotrope
cells of different species (primate vs. mouse). In any case,
definitely, it is clear that further studies should be per-
formed in order to elucidate this differential effect exerted
by MT on ACTH production in normal corticotrope cell
vs. corticotropinoma cells. Altogether, our results clearly
demonstrate that, under the experimental conditions used
in this study, direct actions of MT on cultured primary
pituitary cells from baboons include the selective regula-
tionofhormonal synthesis and release inonly twoanterior
pituitary cell types, somatotropes and lactotropes, with-
out appreciably altering the function of other pituitary cell
types. As such, our results support the possibility thatMT
could act as an additional regulatory component to help
themajor governing factors (ie,GHRH, somatostatin, do-
pamine) in, finely tuning the complex regulation of the
somatotropic and lactotropic axes.
Interaction of MT with key regulators of GH/PRL
secretion: GHRH, ghrelin and somatostatin in a
nonhuman primate model
It iswell known that a number of factors producedboth
at the central and peripheral level can directly act at the
pituitary gland to modulate hormonal synthesis and/or
release independently of, or cooperatively with, the pri-
mary regulatory factors (60). Therefore, and based on the
previous results (figures 1 and 2), we next tested the in-
teraction between MT and some primary regulators of
somatotrope and lactotrope function (ie, GHRH, ghrelin
and somatostatin (23, 26, 61)) using a 4h-incubation time
and a 10-8 M concentration.
As previously shown (Figure-1 and (23, 26)), treat-
ments with MT, GHRH and/or ghrelin alone stimulated
GH and PRL release (figure-3A and -3B, respectively).
However, comparison of the stimulatory effects of MT,
GHRH and ghrelin revealed that the effect of MT on GH
secretion was slightly, but significantly less marked than
that exerted by GHRH and ghrelin (figure-3A), whereas
MT and ghrelin induced comparable increases on PRL
secretion (Figure-3B). As expected, somatostatin (the clas-
sical inhibitory factor of pituitary hormone secretions)
was able to fully block the stimulatory actions of MT on
both GH and PRL secretion (figure-3A and -3B, respec-
tively). Interestingly, GHRH and ghrelin stimulatory ac-
tions on GH or PRL release were not altered by coadmin-
istrationofMT, suggesting thatMTmight activate similar
intracellular signaling pathways as ghrelin or GHRH to
induce GH and PRL secretion, respectively (see below).
It isworth noting that this is the first report studying the
direct interaction betweenMT,GHRHand ghrelin in pri-
mary pituitary cell cultures. Previous in vivo results indi-
cated that MT could increase GH responsiveness to
GHRH in humans (62) and in animal models (32, 62);
however, as inour current in vitro study, other reports also
found thatMT does not alter GHRH-induced GH release
in vivo (53). On the other hand, to our knowledge, no
information has been published to date on the interaction
between MT and ghrelin.
Overall, the results presented herein are novel and re-
inforce the contention that MT could represent an addi-
tional modulatory component contributing, in concert
with other primary regulators, to the direct control of the
GH- and PRL-axes in the pituitary of primates, and pos-
sibly also in humans. Obviously, our data cannot discard
the possibility that the actions of MT at other levels (cen-
tral or peripheral) might mediate its regulatory actions of
pituitary hormones. In fact, previous results indicated that
the primary action of MT in the control of pituitary hor-
mones could be exerted at the hypothalamic level (32, 62,
63). However, there are also some reports in favor of a
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directpituitaryactionofMTinvivo, independent fromthe
hypothalamus (ie,modelswith an hypothalamic-pituitary
disconnection), to regulate hormone release (64, 65). Fur-
ther support for a direct action ofMT at the pituitary level
is provided by data showing that MT receptors (specifi-
cally MT1) are expressed in the pituitary of humans and
various animal models (66, 67), and the clear evidence
provided by binding studies showing thatMTbinds to the
membranes of pituitaries fromvarious animalmodels (52,
68–71), and by pharmacological studies indicating that
the pituitary concentrate peripherally administrated MT
(72).
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MT-receptors expression in the pituitary of
baboons
Similar to that previously shown in human pituitaries
(66), in the present study we found that MT1, but not
MT2, was highly expressed in baboon pituitaries and, this
expression was higher than that found in the hypothala-
mus (whereMT2 was also expressed at similar levels than
MT1; Figure-4). These results suggest that the actions of
MT at the pituitary level in primates (and possibly in hu-
mans) might be exclusively mediated through MT1.
Intracellular signaling pathways for MT-mediated
GH and PRL release in a nonhuman primate model
There is solid evidence indicating that MT can activate
a wide variety of signals via MT receptors; however, the
particular transduction pathways directly associated to
these receptors remain an unsolved and complex issue in
most the cells regulated by MT. Specifically, it has been
reported that modification of a repertoire of signaling
pathways (ie, activities of AC, PLC, certain PKC subtypes,
calcium and potassium channels, etc.,) are associated to
MT1 and MT2 in specific cells/tissues (4, 73). However,
very limited studies have focused on the signaling path-
ways activated by MT at the anterior pituitary, and all of
them have been performed in nonprimate species. Thus, it
has been shown that MT alone had no effect on basal
[Ca2]i (74) but was able to inhibit forskolin-induced
cAMP levels in anterior pituitary of neonatal rats in vitro
(75). However, the precise contribution of major intra-
cellular signaling pathways (including AC, PKA, PLC,
PKC, extra and intracellular Ca2, etc.,) to the effects of
MT on anterior pituitary hormonal secretions has not
been determined to date. Accordingly, we next aimed at
elucidating theprecise intracellular signalingpathwaysac-
tivated by MT to induce GH and PRL secretion in the
baboon pituitary.
The use of a standard pharmacological (inhibitory) ap-
proach revealed that MT stimulates GH and PRL release
through similar but not identical signaling pathways (Fig-
ure-5). Specifically, given the limited source of baboon cell
preparations and of the number of cells obtained after
dispersion of the pituitary gland, we were able to study
only some selected signaling pathways based on previous
reports indicating the putative signaling routes activated
by MT in other cellular systems (4, 73). Thus, inhibition
of AC and PKA completely blockedMT-induced GH and
PRL release (Figure-5A), while PLC inhibition only inhib-
ited GH but not PRL secretion (Figure-5B). Furthermore,
inhibition of extracellular Ca2 influx effectively blocked
MT-mediatedGHandPRLrelease; however, inhibitionof
intracellularCa2mobilization only blockedGH, andnot
PRL release (Figure-5C). It should be noted that the con-
centration of inhibitors were selected according to previ-
ous studies (23, 24, 27) where administration of all these
inhibitors didnotmodifybasalGHorPRLrelease (Figure-
5).Altogether, these results provide the first evidencedem-
onstrating that the stimulatory effects of MT on GH re-
lease requires AC/PKA and extra-/intra-cellular Ca2,
whereas AC/PKA/PLC activation and extracellular Ca2
influx are necessary for the stimulatory actions of MT on
PRL secretion in primary pituitary cell cultures from
baboons.
Additional factors involved in MT-induced
regulation on somatotrope and lactotrope
function
Our results also revealed that the direct actions of MT
in the baboon pituitary are not confined exclusively to the
stimulation of GH and PRL synthesis and release but also
include regulation of key components governing somato-
tropeand lactotrope function (eg,GHRH,ghrelin andSST
+ MT 
PR
L 
re
le
as
e 
(%
 o
f c
on
tr
ol
) 
G
hr
el
in
 
SS
T 
G
hr
el
in
 
SS
T 
Co
nt
ro
l 
M
T 
0 
50 
100 
150 
200 
250 
a 
b 
b 
a 
a 
b 
G
H
R
H
 
G
hr
el
in
 
SS
T 
Co
nt
ro
l 
M
T 0 
50 
100 
150 
200 
250 
c 
c 
c c 
a a a 
b 
G
H
 r
el
ea
se
 
(%
 o
f c
on
tr
ol
) 
G
H
R
H
 
G
hr
el
in
 
SS
T 
+ MT 
A B 
Figure 3. Interaction of melatonin (10n; MT) with common regulators
of somatotrope and lactotrope function [GH-releasing hormone
(GHRH, 10 nM), ghrelin (10 nM) and/or somatostatin (SST, 100 nM)]
on GH (A) or PRL (B) secretion in primary pituitary cells cultures from
baboons. Data are expressed as percent of control (set at 100%; white
columns) and represent the mean  SEM (n  3–4 individual
experiments, 3–4 wells/experiment). Values that do not share a
common letter (a, b) are statistically different (*,P  .05).
0 
200 
400 
600 
800 
m
RN
A
 c
op
y 
 
nu
m
be
r /
 5
0 
ng
 
Pituitary Hypothalamus 
** 
MT1 MT2 MT1 MT2 
Figure 4. Presence of melatonin receptors [MT1 (white columns) and
MT2 (black columns)] in the baboon pituitary and hypothalamus (n 
12). Data are expressed as absolute mRNA copy number of MT1 and
MT2 and represent the mean  SEM (n  3–4 individual experiments,
3–4 wells/experiment). Asterisks indicate values that significantly differ
from MT1 (**,P  .01).
doi: 10.1210/en.2014-1819 endo.endojournals.org 7
The Endocrine Society. Downloaded from press.endocrine.org by [${individualUser.displayName}] on 29 January 2015. at 04:27 For personal use only. No other uses without permission. . All rights reserved.
receptors) (Figure-6). In particular, MT treatment did not
alter the expression levels of GHRH-R, GHS-R, soma-
tostatin receptor subtypes (sst1, sst2, sst5) or dopamine
receptor subtype-2 (D2) at 4h of incubation (Figure-6A),
whereas it provoked an increase in the expression of re-
ceptors associated to primary stimulation of GH and/or
PRL secretion (GHRH-R and GHS-R), and a down-reg-
ulation in the expression of some key inhibitory receptors
[sst2 and sst5;while sst1 orD2 expressionwas not altered;
Figure-6] at 24h of incubation (Figure-6B), which, in con-
junction, might be serving to enhance the stimulatory ef-
fect ofMTon somatotrope and lactotrope function.These
results thus unveil additional points of regulation of MT
at the pituitary (GHRH-R, GHS-R and sst2/sst5), which
could also contribute to the ability ofMT tomodulate the
regulatory axes of these two cell types in the baboon
pituitary.
Overall, the results of this report unveil the existence of
two regulatory layers for MT at the secretory and gene
expression levels in the GH-axis; however, there is a tem-
poral dissociation between them. Specifically, secretory
actions are rapid (4h) and can be sustained over time
(12–24h; Figure-1B),whereas gene expression effects (GH
and regulatory receptors) necessarily require longer peri-
ods to be effective [24h, but not at 4h; Figure 2 (top panel)
and Figure-6)], and might represent an additional regula-
tory mechanism to enhance the responsiveness of soma-
totrope cells to specific ligands as MT. Therefore, we
might speculate that the likely influence of changes in re-
ceptor expression (ie, GHRH-R, GHS-R or sst-subtypes)
in modulating the response of somatotropes to their hy-
pothalamic regulators (GHRH, ghrelin and somatostatin)
as a consequence of MT actions on pituitary cells would
require longer incubation times (at least 24h), which
would impart changes in responsiveness of pituitary cells
as compared to the initial actions of these peptides at
shorter period of incubation (ie, 4h; figure-3). Addition-
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ally, we have previously reported that 4h treatment with
GHRH or ghrelin inhibited GHRH-R or GHS-R expres-
sion, respectively (76, 77), while 4h-treatment with SST
increased sst1, sst2 and sst5 expression levels (77) in pri-
mary baboon pituitary cell cultures. All these data could,
in part, also help to explain the lack of significant differ-
ences observed in terms of GH release after 4h incubation
with GHRH or ghrelin (Figure-3) in the absence or in the
presence ofMT, since the sensitivity toGHRHandghrelin
is diminished (ie, GHRH-R and GHS-R levels are de-
creased in response to GHRH and ghrelin treatment at
4h), as well as, why somatostatin was able to completely
abolish the stimulatory effect of MT on GH release, since
the sensitivity to SST is augmented (ie, sst1, sst2 and sst5
are increased in response to SST treatment at 4h). Obvi-
ously, further work will be required to complete our un-
derstanding of this complex process and to fully elucidate
the molecular mechanisms underlying the effect of MT
alone or in combination with GHRH, ghrelin and SST on
GH release on baboon primary pituitary cell cultures at 4-
and 24-hour.
Interestingly, although it has been reported that puta-
tive response-elements for the transcription factor Pit-1 (a
critical factor for the development and function of soma-
totrope and lactotrope cells) have been found in the pro-
moters of GH, PRL, GHRH-R, GHS-R and MT1 of sev-
eral species (78–81), the stimulatory effect of MT on
somatotrope and lactotrope cell function does not seem to
be mediated by an increase in expression of the transcrip-
tion factor Pit-1 (Figure-6B).However,we cannot exclude
the possibility that Pit-1 protein levels may be altered in
response to MT but unfortunately, we could not investi-
gate this possibility at this time due to the limited source
of baboon cell preparations and of the number of cells
obtained after dispersion of the pituitary gland.
Summary
The present study provide the first evidence indicating
that: 1) MT treatment directly stimulates GH and PRL
secretion and expression in a dose- and time-dependent
manner in primary pituitary cell cultures from baboons,
and that these effects are probably exerted through MT1;
2) Direct actions of MT on somatotrope and lactotrope
function are not confined to the stimulation of GH and
PRL expression/release butmay also include regulation of
the expression of other key regulatory components of so-
matotrope and lactotrope cell function (ie, the receptors
for GHRH, ghrelin and somatostatin); 3) The effects of
MT on GH and PRL release are mediated through com-
mon (AC/PKA and extracellular calcium influx) and dis-
tinct (PLC and intracellular calcium mobilization) signal-
ing pathways. The direct actions of MT on somatotrope
and lactotrope function shown herein lend credence to the
possibility that this hormone can contribute to finely tune
the precise daily patterns of secretion of these cell types in
primates and, open the possibility that MT, together with
GHRH, ghrelin and somatostatin, might be an additional
key factor involved in the regulation of somatotrope and
lactotrope function in primates and, possibly also in
humans.
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